Page last updated: 2024-08-01 09:36:58
entacapone
Description
entacapone: structure given in first source [MeSH]
entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group. [CHeBI]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 5281081 |
| CHEMBL ID | 953 |
| SCHEMBL ID | 34504 |
| SCHEMBL ID | 34505 |
| SCHEMBL ID | 13596593 |
| CHEBI ID | 4798 |
| MeSH ID | M0193491 |
Synonyms (117)
| Synonym |
|---|
| AC-393 |
| BIDD:GT0026 |
| com-998 |
| entacaponum |
| comtess |
| entacaponum [inn-latin] |
| comtan |
| (e)-alpha-cyano-n,n-diethyl-3,4-dihydroxy-5-nitrocinnamamide |
| or-611 |
| 2-propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-, (2e)- |
| or 611 |
| entacapona [inn-spanish] |
| (e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-2-propenamide |
| 130929-57-6 |
| C07943 |
| entacapone |
| n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide |
| DB00494 |
| D00781 |
| comtan (tn) |
| entacapone (jp17/usp/inn) |
| NCGC00164555-01 |
| 2-cyano-n,n-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide |
| 2-propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl- |
| (e)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-n,n-diethyl-prop-2-enamide |
| 116314-67-1 |
| CHEBI:4798 , |
| entacapona |
| (2e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethylprop-2-enamide |
| HMS2089O16 |
| CHEMBL953 , |
| entacapone orion |
| entacapone teva |
| bdbm50108879 |
| (e)-2-cyano-n,n-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide |
| A806167 |
| NCGC00164555-02 |
| (e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethylprop-2-enamide |
| (e)-entacapone |
| entacapone [usan:usp:inn:ban] |
| unii-4975g9nm6t |
| 4975g9nm6t , |
| hsdb 8251 |
| entacom |
| cas-130929-57-6 |
| tox21_112184 |
| dtxsid5046439 , |
| dtxcid3026439 |
| BCP9000645 |
| AKOS015965009 |
| HY-14280 |
| CS-1266 |
| AKOS015907685 |
| S3147 |
| gtpl6647 |
| BRD-K83636919-001-01-4 |
| entacapone [ema epar] |
| entacapone component of levodopa/carbidopa/entacapone orion |
| entacapone [mart.] |
| entacapone [jan] |
| entacapone component of stalevo |
| levodopa/carbidopa/entacapone orion component entacapone |
| entacapone [usp monograph] |
| entacapone [ep monograph] |
| (e)-.alpha.-cyano-n,n-diethyl-3,4-dihydroxy-5-nitrocinnamamide |
| entacapone component of corbilta |
| entacapone [vandf] |
| entacapone [mi] |
| corbilta component entacapone |
| entacapone [inn] |
| entacapone [orange book] |
| entacapone [usp-rs] |
| entacapone [usan] |
| entacapone [who-dd] |
| stalevo component entacapone |
| CCG-213064 |
| SCHEMBL34504 |
| SCHEMBL34505 |
| NCGC00164555-03 |
| tox21_112184_1 |
| (2e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-2-propenamide |
| JRURYQJSLYLRLN-BJMVGYQFSA-N |
| (e)-n, n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide |
| (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide |
| AB01275450-01 |
| SCHEMBL13596593 |
| (e)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethylacrylamide |
| AB01275450_02 |
| AB01275450_03 |
| J-005902 |
| EX-A1130 |
| sr-05000001452 |
| SR-05000001452-3 |
| SR-05000001452-1 |
| SR-05000001452-2 |
| J-008069 |
| mfcd00866580 |
| HMS3713B20 |
| SW199035-2 |
| Q416444 |
| 2-propenamide,2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-,(2e)- |
| (~{e})-2-cyano-~{n},~{n}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide |
| PD9 , |
| or611 |
| HMS3885K09 |
| A922031 |
| NCGC00164555-10 |
| entacaponum (latin) |
| entacapone (mart.) |
| entacapona (inn-spanish) |
| entacaponum (inn-latin) |
| entacapone (ep monograph) |
| entacapone (usp monograph) |
| entacapone (usan:usp:inn:ban) |
| n04bx02 |
| entacapone (usp-rs) |
| E0961 |
Roles (4)
Drug Classes (4)
| Class | Description |
|---|
| monocarboxylic acid amide | A carboxamide derived from a monocarboxylic acid. |
| nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
| catechols | Any compound containing an o-diphenol component. |
| 2-nitrophenols | A mononitrophenol that is 2-nitrophenol and its derivatives resulting from substitution of one or more of the hydrogens attached to the benzene ring by a non-nitro group. |
Pathways (1)
entacapone is involved in 1 pathway(s), involving a total of 83 unique proteins and 30 unique compounds
Protein Targets (47)
Potency Measurements
Inhibition Measurements
Other Measurements
Bioassays (198)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
ISSN: 1095-9203 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1220257 | Ratio of drug level in blood to plasma in human | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID588209 | Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset | 2010 | Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
ISSN: 1520-5010 | Developing structure-activity relationships for the prediction of hepatotoxicity. |
| AID50090 | Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 1 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID1308089 | Binding affinity to human recombinant HIBCH after 1 hr in presence of active Tcp-CC-13 by Western blot analysis | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1220242 | Unbound intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID11951 | Half life period in rabbit liver homogenate | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
ISSN: 0960-894X | Synthesis of a water-soluble prodrug of entacapone. |
| AID473642 | Cytotoxicity against mouse Neuro2a cells assessed as cell viability at 30 uM after 24 hrs | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
ISSN: 1520-4804 | Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID281572 | Inhibition of peripheral COMT in mouse liver at 30 mg/kg, po by gastric tube after 6 hrs | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
ISSN: 0022-2623 | Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID50078 | Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 0.5 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID1632019 | Inhibition of MB-COMT in Wistar rat brain assessed as metanephrine formation preincubated for 20 mins followed by addition of adrenaline as substrate and SAM measured after 15 mins by chromatographic analysis | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1632021 | Permeability of the compound in PBS:EtOH (70:30) measured after 2 hrs and 30 mins by PAMPA-BBB assay | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID256804 | Percentage inhibitory activity against COMT for 9h in homogenates of rat liver administered with 30mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID49923 | Inhibition of Catechol O-methyltransferase activity in rat liver | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID1808092 | Drug metabolism in human gut microbes assessed as metabolite formation by LC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
ISSN: 1520-4804 | Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach. |
| AID281573 | Inhibition of central COMT in mouse brain at 30 mg/kg, po by gastric tube after 6 hrs | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
ISSN: 0022-2623 | Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID1308078 | Inhibition of human recombinant His-tagged soluble COMT expressed in Escherichia coli BL21 using aesculetin as substrate after 60 mins by microplate assay in presence of SAM | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1473982 | Ratio of drug concentration at steady state in human at 200 mg, po Q3h measured after 3 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID473640 | Inhibition of COMT in Wistar rat liver homogenates assessed as metanephrine formation at 3 mg/kg, po measured after 3 hrs relative to control | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
ISSN: 1520-4804 | Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID50093 | percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 6 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1308083 | Binding affinity to PDXK in human HepG2 assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of inactive Tcp-CC 14 by differential competition capture compoun | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1632018 | Inhibition of S-COMT in Wistar rat liver assessed as metanephrine formation preincubated for 20 mins followed by addition of adrenaline as substrate and SAM measured after 5 mins by chromatographic analysis | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1220256 | Total clearance in human | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID1308082 | Binding affinity to GCDH in human HepG2 assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of active Tcp-CC-13 by differential competition capture compound | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID256794 | Inhibitory activity against COMT in rat brain | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID281571 | Inhibition of central COMT in mouse brain at 30 mg/kg, po by gastric tube after 1 hr | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
ISSN: 0022-2623 | Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1308093 | Mitochondrial toxicity in human HepG2 cells assessed as mitochondrial membrane potential levels at 50 uM by TMRE-based mitochondria membrane potential assay relative to control | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID634973 | Inhibition of human thrombin using Boc-VPR-AMC as substrate at 25 uM preincubated for 15 mins before substrate addition measured up to 10 mins by spectrofluorimetry | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
ISSN: 1464-3391 | Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. |
| AID1220240 | Unbound fraction during CYP4500-mediated metabolism in human intestinal microsomes | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID473641 | Inhibition of COMT in NMRI mouse liver homogenates assessed as metanephrine formation at 3 mg/kg, po measured after 3 hrs relative to control | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
ISSN: 1520-4804 | Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID256796 | Percentage inhibitory activity against COMT for 1h in homogenates of rat brain administered with 30mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID256799 | Percentage inhibitory activity against COMT for 9h in homogenates of rat brain administered with 30 mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1632020 | Selectivity ratio, ratio of IC50 for S-COMT in Wistar rat liver to IC50 for MB-COMT in Wistar rat brain | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1220557 | Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Species independence in brain tissue binding using brain homogenates. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID21714 | Solubility at pH 1.2 | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
ISSN: 0960-894X | Synthesis of a water-soluble prodrug of entacapone. |
| AID1473979 | AUC in human at 200 mg, po Q3h measured after 3 hrs | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1542227 | Inhibition of synthetic AcPHF6 peptide aggregation in pH 7.4 phosphate buffer assessed as reduction in fluorescence intensity at 50 uM and measured every minute over 2 hrs with 5 secs shaking prior to each reading by ThT fluorescence assay | 2019 | European journal of medicinal chemistry, Apr-01, Volume: 167ISSN: 1768-3254 | Repurposing nitrocatechols: 5-Nitro-α-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6. |
| AID1307962 | Inhibition of Mycobacterium tuberculosis InhA at 80 uM using DD-CoA and NADH | 2016 | Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
ISSN: 1520-4804 | Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design. |
| AID1220558 | Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Species independence in brain tissue binding using brain homogenates. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID256803 | Percentage inhibitory activity against COMT for 3h in homogenates of rat liver administered with 30 mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID256800 | Percentage inhibitory activity against COMT for 1h in homogenates of rat liver administered with 30 mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID1308079 | Binding affinity to COMT in human HepG2 assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of active Tcp-CC-13 by differential competition capture compound | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1308080 | Binding affinity to ADL1 in human HepG2 assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of active Tcp-CC-13 by differential competition capture compound | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1308090 | Binding affinity to His-tagged human recombinant soluble COMT after 1 hr in presence of active Tcp-CC-13 by Western blot analysis | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1632028 | Irreversible electrochemical behavior of compound assessed as single oxidation peak at 0.1 mM and pH 7.4 using Ag/AgCl reference electrode measured over 0 to 0.6 V by cyclic voltammetry | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID624638 | Drug glucuronidation reaction catalyzed by human recombinant UGT2B15 | 2005 | Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
ISSN: 0163-7258 | UDP-glucuronosyltransferases and clinical drug-drug interactions. |
| AID256798 | Percentage inhibitory activity against COMT for 6h in homogenates of rat brain administered with 30 mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1808089 | Stability of compound in mini gut model assessed as half life by LC-MS analysis | 2021 | Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
ISSN: 1520-4804 | Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach. |
| AID256793 | Inhibitory activity against COMT in rat liver | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID473638 | Inhibition of COMT in NMRI mouse liver homogenates assessed as metanephrine formation at 30 mg/kg, po measured after 6 hrs relative to control | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
ISSN: 1520-4804 | Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4
ISSN: 1878-5832 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1308091 | Binding affinity to His-tagged human recombinant soluble COMT after 1 hr in presence of active Tcp-CC-13 by streptavidin based Western blot analysis | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1632026 | Electrochemical behavior of compound assessed as anodic peak for oxidation of catechol group at 0.1 mM and pH 7.4 using Ag/AgCl reference electrode measured over 0 to 0.6 V by differential pulse voltammetry | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1308087 | Binding affinity to human recombinant HIBCH assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of active Tcp-CC-13 by differential competition capture compo | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1220241 | Intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID634971 | Inhibition of Dengue virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-NleKRRS-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
ISSN: 1464-3391 | Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. |
| AID624637 | Drug glucuronidation reaction catalyzed by human recombinant UGT1A9 | 2005 | Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
ISSN: 0163-7258 | UDP-glucuronosyltransferases and clinical drug-drug interactions. |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4
ISSN: 1878-5832 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1220259 | Oral absorption in human | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID50082 | Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 9 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID256792 | Percentage inhibitory activity against COMT at 100 nM in human neuroblastoma SK-N-SH cells | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1632025 | Cytotoxicity in Wistar Han rat primary hepatocytes assessed as neutral red uptake at 50 uM measured after 24 hrs relative to untreated control | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID1308084 | Binding affinity to AKR1B10 in human HepG2 assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of inactive Tcp-CC 14 by differential competition capture comp | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID21722 | Solubility at pH 7.4 | 2000 | Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
ISSN: 0960-894X | Synthesis of a water-soluble prodrug of entacapone. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1220560 | Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Species independence in brain tissue binding using brain homogenates. |
| AID1659943 | Inhibition of rat liver COMT using esculetin as substrate by fluorescence based spectrophotometry | 2020 | Bioorganic & medicinal chemistry letters, 06-15, Volume: 30, Issue:12
ISSN: 1464-3405 | Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1632035 | Irreversible electrochemical behavior of compound assessed as single cathodic peak at 0.1 mM and pH 7.4 using Ag/AgCl reference electrode by cyclic voltammetry | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID50084 | Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 1 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
ISSN: 1520-4804 | Physicochemical determinants of human renal clearance. |
| AID1220239 | Unbound intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID50083 | Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 0.5 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID1473983 | Ratio of drug concentration at steady state in human at 200 mg, po Q3h measured after 3 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID49912 | Inhibition of Catechol O-methyltransferase activity in SK-N-SH cells at a concentration of 100 nM | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID256795 | Percentage inhibitory activity against COMT for 0.5h in homogenates of rat brain administered with 30mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1220258 | Renal clearance in human | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1632022 | Cytotoxicity in Wistar Han rat primary hepatocytes assessed as viable cells at 50 uM measured after 24 hrs by MTT reduction assay relative to untreated control | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1918193 | Dissociation constant, pKa of the compound | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
ISSN: 1520-4804 | Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID256797 | Percentage inhibitory activity against COMT for 3h in homogenates of rat brain administered with 30mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID281570 | Inhibition of peripheral COMT in mouse liver at 30 mg/kg, po by gastric tube after 1 hr | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
ISSN: 0022-2623 | Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID256801 | Percentage inhibitory activity against COMT for 6h in homogenates of rat liver administered with 30 mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID50086 | Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 6 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1308094 | Mitochondrial toxicity in human HepG2 cells assessed as mitochondrial membrane potential levels at 100 uM by TMRE-based mitochondria membrane potential assay relative to control | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1220556 | Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Species independence in brain tissue binding using brain homogenates. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1918194 | Lipophilicity, log D of the compound | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
ISSN: 1520-4804 | Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment. |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1918192 | Inhibition of human OAT2 tv.1 variant expressed in HEK293 cells assessed as inhibition of [3H]cGMP uptake by scintillation analysis | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
ISSN: 1520-4804 | Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment. |
| AID1220554 | Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Species independence in brain tissue binding using brain homogenates. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1308081 | Binding affinity to CCBL2 in human HepG2 assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of active Tcp-CC-13 by differential competition capture compound | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1220555 | Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Species independence in brain tissue binding using brain homogenates. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID49922 | Inhibition of Catechol O-methyltransferase activity in rat brain | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID588210 | Human drug-induced liver injury (DILI) modelling dataset from Ekins et al | 2010 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
ISSN: 1521-009X | A predictive ligand-based Bayesian model for human drug-induced liver injury. |
| AID256802 | Percentage inhibitory activity against COMT for 0.5h in homogenates of rat liver administered with 30mg/kg by Gastric tube | 2005 | Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25
ISSN: 0022-2623 | Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. |
| AID634972 | Inhibition of West Nile virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-GLKRGG-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
ISSN: 1464-3391 | Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
ISSN: 1521-009X | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1632032 | Electrochemical behavior of the compound assessed as reduction potential for hydroxylamine derivative formation at 0.1 mM and pH 7.4 using Ag/AgCl reference electrode measured over 0.25 to -1 V by differential pulse voltammetry | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID1473980 | Drug concentration at steady state in human at 200 mg, po Q3h measured after 3 hrs | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID50080 | Percent inhibition of Catechol O-methyltransferase activity in rat brain at dose of 30 mg/kg determined at 3 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID50088 | Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 9 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID1220559 | Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Species independence in brain tissue binding using brain homogenates. |
| AID1473981 | Ratio of drug concentration at steady state in human at 200 mg, po Q3h measured after 3 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID50085 | Percent inhibition of Catechol O-methyltransferase activity in rat liver at dose of 30 mg/kg determined at 3 hr after its administration | 2002 | Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3
ISSN: 0022-2623 | Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. |
| AID1307961 | Antimicrobial activity against Mycobacterium tuberculosis str. Erdman assessed as complete inhibition of growth incubated for 14 days by microplate assay | 2016 | Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
ISSN: 1520-4804 | Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design. |
| AID1808090 | Stability in human gut microbes assessed as half life by LC-MS analysis | 2021 | Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
ISSN: 1520-4804 | Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach. |
| AID1808091 | Drug metabolism in mini gut model assessed as metabolite formation by LC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
ISSN: 1520-4804 | Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
ISSN: 1520-4804 | Physicochemical determinants of human renal clearance. |
| AID1632030 | Irreversible electrochemical behavior of compound assessed as oxidation potential at 0.1 mM and pH 7.4 using Ag/AgCl reference electrode measured over 0 to 0.6 V by differential pulse voltammetry | 2016 | Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
ISSN: 1520-4804 | Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. |
| AID1308085 | Binding affinity to NIPSNAP3A in human HepG2 assessed as intensity fold change of cumulated normalized intensity of protein between capture and competition assay at 100 uM after 1 hr in presence of inactive Tcp-CC 14 by differential competition capture co | 2016 | Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
ISSN: 1520-4804 | Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry. |
| AID1220255 | Apparent permeability by PAMPA method | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
ISSN: 1520-4804 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1220237 | Unbound fraction during UGT-mediated glucuronidation in human intestinal microsomes | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID281569 | Inhibition of COMT in human SK-N-SH cells at 100 nM | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
ISSN: 0022-2623 | Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. |
| AID1220238 | Intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
ISSN: 1521-009X | Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1745854 | NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3
ISSN: 1754-8411 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1745855 | NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3
ISSN: 1754-8411 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
Research
Studies (466)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 78 (16.74) | 18.2507 |
| 2000's | 189 (40.56) | 29.6817 |
| 2010's | 148 (31.76) | 24.3611 |
| 2020's | 51 (10.94) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 112 (22.27%) | 5.53% |
| Reviews | 81 (16.10%) | 6.00% |
| Case Studies | 24 (4.77%) | 4.05% |
| Observational | 2 (0.40%) | 0.25% |
| Other | 284 (56.46%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| acetamide | | acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indoleacetamide | | indoles;
monocarboxylic acid amide;
N-acylammonia | bacterial metabolite;
fungal metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dihydrolipoamide | | dithiol;
monocarboxylic acid amide | cofactor;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| formamide | | carboximidic acid;
formamides;
monocarboxylic acid amide;
one-carbon compound | solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lipoamide | | dithiolanes;
monocarboxylic acid amide | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrazinamide | | monocarboxylic acid amide;
N-acylammonia;
pyrazines | antitubercular agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pk 11195 | | aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(n,n-hexamethylene)amiloride | | aromatic amine;
azepanes;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines | antineoplastic agent;
apoptosis inducer;
odorant receptor antagonist;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethylisopropylamiloride | | aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound | anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acebutolol | | aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acetazolamide | | monocarboxylic acid amide;
sulfonamide;
thiadiazoles | anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acetochlor | | aromatic amide;
monocarboxylic acid amide;
organochlorine compound | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alachlor | | aromatic amide;
monocarboxylic acid amide;
organochlorine compound | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ampiroxicam | | acetal;
aminopyridine;
benzothiazine;
etabonate ester;
monocarboxylic acid amide;
sulfonamide | analgesic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| atenolol | | ethanolamines;
monocarboxylic acid amide;
propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzquinamide | | monocarboxylic acid amide | antiemetic;
antipsychotic agent;
H1-receptor antagonist;
muscarinic antagonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carcinine | | beta-alanine derivative;
imidazoles;
monocarboxylic acid amide;
organonitrogen compound;
organooxygen compound | antioxidant;
crustacean metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dacarbazine | | imidazoles;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
carcinogenic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dibucaine | | aromatic ether;
monocarboxylic acid amide;
tertiary amino compound | topical anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimethoate | | monocarboxylic acid amide;
organic thiophosphate | acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| disopyramide | | monocarboxylic acid amide;
pyridines;
tertiary amino compound | anti-arrhythmia drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etanidazole | | C-nitro compound;
imidazoles;
monocarboxylic acid amide | alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flecainide | | aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines | anti-arrhythmia drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide | androgen antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glipizide | | aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines | EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leflunomide | | (trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide | antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| qx-314 | | monocarboxylic acid amide | local anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| modafinil | | monocarboxylic acid amide;
sulfoxide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deet | | benzamides;
monocarboxylic acid amide | environmental contaminant;
insect repellent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipamperone | | aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prilocaine | | amino acid amide;
monocarboxylic acid amide | anticonvulsant;
local anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propachlor | | anilide;
monocarboxylic acid amide;
organochlorine compound | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbamylhydrazine | | carbohydrazide;
monocarboxylic acid amide;
one-carbon compound;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lysergic acid diethylamide | | ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound | dopamine agonist;
hallucinogen;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propionamide | | monocarboxylic acid amide;
primary fatty amide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-methylacetamide | | acetamides;
monocarboxylic acid amide | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenylacetamide | | monocarboxylic acid amide | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-aminonicotinamide | | aminopyridine;
monocarboxylic acid amide;
primary amino compound | antimetabolite;
EC 1.1.1.44 (NADP(+)-dependent decarboxylating phosphogluconate dehydrogenase) inhibitor;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminoimidazole carboxamide | | aminoimidazole;
monocarboxylic acid amide | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| valeramide | | monocarboxylic acid amide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| devrinol | | aromatic ether;
monocarboxylic acid amide;
naphthalenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiamphenicol | | monocarboxylic acid amide;
sulfone | antimicrobial agent;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lisuride | | monocarboxylic acid amide | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimethylacetamide | | acetamides;
monocarboxylic acid amide | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzonidazole | | C-nitro compound;
imidazoles;
monocarboxylic acid amide | antiprotozoal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-methyl-n-(trimethylsilyl)trifluoroacetamide | | monocarboxylic acid amide;
N-silyl compound;
trifluoroacetamide | chromatographic reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ribavirin | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide | anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tocainide | | monocarboxylic acid amide | anti-arrhythmia drug;
local anaesthetic;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| closantel | | aromatic amide;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile;
organoiodine compound;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alfentanil | | monocarboxylic acid amide;
piperidines | central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ranolazine | | aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| remifentanil | | alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester | intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| valsartan | | biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methylfentanyl | | monocarboxylic acid amide;
piperidines | mu-opioid receptor agonist;
opioid analgesic;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-fluorofentanyl | | monocarboxylic acid amide;
organofluorine compound;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,2,4-triazole-3-carboxamide | | aromatic amide;
monocarboxylic acid amide;
primary carboxamide;
triazoles | drug metabolite;
human urinary metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aloxistatin | | epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide | anticoronaviral agent;
cathepsin B inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenylacetylglycine | | monocarboxylic acid amide;
monocarboxylic acid;
N-acylglycine | human metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mandelamide | | benzyl alcohols;
monocarboxylic acid amide;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(3-methyl-1-triazeno)imidazole-4-carboxamide | | imidazoles;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biocytin | | azabicycloalkane;
L-alpha-amino acid zwitterion;
L-lysine derivative;
monocarboxylic acid amide;
non-proteinogenic L-alpha-amino acid;
thiabicycloalkane;
ureas | mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biotinamide | | biotins;
monocarboxylic acid amide | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lactamide | | monocarboxylic acid amide;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ribavirin 5'-diphosphate | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide;
ribose monophosphate | antiviral agent;
drug metabolite;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
human blood serum metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| difenpiramide | | biphenyls;
monocarboxylic acid amide;
pyridines | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| u 69593 | | monocarboxylic acid amide;
N-alkylpyrrolidine;
organic heterobicyclic compound;
oxaspiro compound | anti-inflammatory agent;
diuretic;
kappa-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenazine-1-carboxamide | | aromatic amide;
monocarboxylic acid amide;
phenazines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ribavirin 5'-triphosphate | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide;
ribose triphosphate | antiviral agent;
drug metabolite;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
eukaryotic initiation factor 4F inhibitor;
human blood serum metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | | adenosines;
monocarboxylic acid amide;
organoiodine compound | adenosine A3 receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-carbamoylimidazolium 5-olate | | hydroxyimidazole;
monocarboxylic acid amide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ribavirin 5'-diphosphate | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide;
ribose diphosphate | antiviral agent;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dexpanthenol | | amino alcohol;
monocarboxylic acid amide | cholinergic drug;
provitamin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cercosporamide | | dibenzofurans;
methyl ketone;
monocarboxylic acid amide;
polyphenol | antifungal agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite;
phytotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclazosin | | aromatic amide;
aromatic ether;
furans;
monocarboxylic acid amide;
quinazolines;
quinoxaline derivative | adenosine A2A receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nepafenac | | monocarboxylic acid amide | cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rp 73401 | | aromatic ether;
benzamides;
chloropyridine;
monocarboxylic acid amide | anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide | | anilide fungicide;
aromatic amide;
dichlorobenzene;
monocarboxylic acid amide;
phenols | antifungal agrochemical;
EC 1.14.13.72 (methylsterol monooxygenase) inhibitor;
sterol biosynthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norfentanyl | | anilide;
monocarboxylic acid amide;
piperidines | drug metabolite;
opioid analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rocaglamide | | monocarboxylic acid amide;
monomethoxybenzene;
organic heterotricyclic compound | antileishmanial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| taurolithocholic acid | | bile acid taurine conjugate;
monocarboxylic acid amide | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ochratoxin a | | isochromanes;
monocarboxylic acid amide;
N-acyl-L-phenylalanine;
organochlorine compound;
phenylalanine derivative | Aspergillus metabolite;
calcium channel blocker;
carcinogenic agent;
mycotoxin;
nephrotoxin;
Penicillium metabolite;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ergonovine | | ergot alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | diagnostic agent;
fungal metabolite;
oxytocic;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| darifenacin | | 1-benzofurans;
monocarboxylic acid amide;
pyrrolidines | antispasmodic drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adenosine-5'-(n-ethylcarboxamide) | | adenosines;
monocarboxylic acid amide | adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glucuronamide | | monocarboxylic acid amide;
monosaccharide derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-methyl-n-(tert-butyldimethylsilyl)trifluoroacetamide | | monocarboxylic acid amide;
N-silyl compound;
trifluoroacetamide | chromatographic reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(3-chloro-4-methylphenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide | | anilide fungicide;
monocarboxylic acid amide;
monochlorobenzenes;
organosulfur compound;
thiadiazoles | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lincomycin | | carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound | antimicrobial agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| u-50488 | | dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine | analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-octylhomovanillamide | | guaiacols;
monocarboxylic acid amide | protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adenosine-5'-(N-propyl)carboxamide | | adenosines;
monocarboxylic acid amide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ex 527 | | carbazoles;
monocarboxylic acid amide;
organochlorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cerulenin | | epoxide;
monocarboxylic acid amide | antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fortimicin a | | amino cyclitol glycoside;
aminoglycoside antibiotic;
diol;
monocarboxylic acid amide;
primary amino compound | antibacterial agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenretinide | | monocarboxylic acid amide;
retinoid | antineoplastic agent;
antioxidant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bimatoprost | | monocarboxylic acid amide | antiglaucoma drug;
antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ag-490 | | catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide | anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monocrotophos | | alkenyl phosphate;
dialkyl phosphate;
monocarboxylic acid amide;
organophosphate insecticide | acaricide;
agrochemical;
avicide;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 685458 | | carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aliskiren | | monocarboxylic acid amide;
monomethoxybenzene | antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| su 1498 | | enamide;
monocarboxylic acid amide;
nitrile;
phenols;
secondary carboxamide | vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n(3)-(4-methoxyfumaroyl)-2,3-diaminopropionic acid | | enoate ester;
methyl ester;
monocarboxylic acid amide | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ekb 569 | | aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile | protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| netupitant | | aminopyridine;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
toluenes | antiemetic;
neurokinin-1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-fluoro-3-(trifluoromethyl)phenoxy)-n-(phenylmethyl)butanamide | | (trifluoromethyl)benzenes;
aromatic ether;
monocarboxylic acid amide;
monofluorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-methyl-d-lysergic acid butanolamide | | ergot alkaloid;
monocarboxylic acid amide | serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| platensimycin | | aromatic amide;
cyclic ether;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage | antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vilazodone | | 1-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile | antidepressant;
serotonergic agonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-demethylloperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| avibactam | | azabicycloalkane;
hydroxylamine O-sulfonic acid;
monocarboxylic acid amide;
ureas | antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mirabegron | | 1,3-thiazoles;
aromatic amide;
ethanolamines;
monocarboxylic acid amide | beta-adrenergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| avanafil | | aromatic amide;
monocarboxylic acid amide;
organochlorine compound;
prolinols;
pyrimidines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rivaroxaban | | aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| selexipag | | aromatic amine;
ether;
monocarboxylic acid amide;
N-sulfonylcarboxamide;
pyrazines;
tertiary amino compound | orphan drug;
platelet aggregation inhibitor;
prodrug;
prostacyclin receptor agonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine | | adenosines;
monocarboxylic acid amide;
organoiodine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly-2157299 | | aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines | antineoplastic agent;
TGFbeta receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SIS3 free base | | aromatic ether;
enamide;
isoquinolines;
monocarboxylic acid amide;
pyrrolopyridine;
tertiary carboxamide | Smad3 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bl1521 | | enamide;
hydroxamic acid;
monocarboxylic acid amide | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tasimelteon | | 1-benzofurans;
cyclopropanes;
monocarboxylic acid amide | melatonin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| edoxaban | | chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fr 901464 | | acetate ester;
cyclic hemiketal;
monocarboxylic acid amide;
pyrans;
spiro-epoxide | antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 477118 | | adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mandipropamid | | aromatic ether;
monocarboxylic acid amide;
monochlorobenzenes;
terminal acetylenic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 60-6583 | | aminopyridine;
aromatic ether;
aryl sulfide;
cyanopyridine;
cyclopropanes;
monocarboxylic acid amide | adenosine A2B receptor agonist;
anti-inflammatory agent;
cardioprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vx-770 | | aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone | CFTR potentiator;
orphan drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| platencin | | aromatic amide;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage | antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tenovin-6 | | monocarboxylic acid amide;
tertiary amino compound;
thioureas | antineoplastic agent;
p53 activator;
Sir2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bacillaene | | enamine;
monocarboxylic acid amide;
polyene antibiotic;
polyketide;
secondary alcohol | antibacterial agent;
antimicrobial agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluazaindolizine | | aromatic amide;
imidazopyridine;
monocarboxylic acid amide;
monochlorobenzenes;
monomethoxybenzene;
N-sulfonylcarboxamide;
organofluorine pesticide | agrochemical;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crambescidin 800 | | alkaloid;
carboxylic ester;
guanidines;
monocarboxylic acid amide;
organic heteropentacyclic compound;
primary amino compound;
secondary alcohol;
spiro compound | anti-HIV-1 agent;
anti-HSV-1 agent;
antimalarial;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| novobiocin | | carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols | antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piroxicam | | benzothiazine;
monocarboxylic acid amide;
pyridines | analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mobic | | 1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide | analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mobiflex | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoxicam | | benzothiazine;
isoxazoles;
monocarboxylic acid amide | antirheumatic drug;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lornoxicam | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| streptolydigin | | bridged compound;
cyclic ketal;
enol;
monocarboxylic acid amide;
N-glycosyl compound;
organic heterobicyclic compound;
pyrrolidinone;
spiro-epoxide | antimicrobial agent;
bacterial metabolite;
EC 2.7.7.6 (RNA polymerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk1265744 | | difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide | HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dolutegravir | | difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide | HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]pyrazole-4-carboxamide | | aromatic amide;
monocarboxylic acid amide;
organofluorine compound;
pyrazoles;
trichlorobenzene | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| HG-10-102-01 | | aminopyrimidine;
aromatic ether;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
secondary amino compound | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bictegravir | | monocarboxylic acid amide;
organic heterotetracyclic compound;
secondary carboxamide;
trifluorobenzene | HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ver 52296 | | aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols | angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyanopyridine | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenyl-3-furoxancarbonitrile | | 1,2,5-oxadiazole;
benzenes;
N-oxide;
nitrile | geroprotector;
nitric oxide donor;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anastrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbonyl cyanide m-chlorophenyl hydrazone | | hydrazone;
monochlorobenzenes;
nitrile | antibacterial agent;
geroprotector;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cimaterol | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cimetidine | | aliphatic sulfide;
guanidines;
imidazoles;
nitrile | adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cypermethrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound | agrochemical;
molluscicide;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dichlobanil | | dichlorobenzene;
nitrile | agrochemical;
cellulose synthesis inhibitor;
environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbonyl cyanide p-trifluoromethoxyphenylhydrazone | | aromatic ether;
hydrazone;
nitrile;
organofluorine compound | ATP synthase inhibitor;
geroprotector;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fipronil | | (trifluoromethyl)benzenes;
dichlorobenzene;
nitrile;
primary amino compound;
pyrazoles;
sulfoxide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| letrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| milrinone | | bipyridines;
nitrile;
pyridone | cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nilvadipine | | dihydropyridine;
isopropyl ester;
methyl ester;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| periciazine | | hydroxypiperidine;
nitrile;
phenothiazines | adrenergic antagonist;
first generation antipsychotic;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zaleplon | | nitrile;
pyrazolopyrimidine | anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| systhane | | monochlorobenzenes;
nitrile;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chloroacetonitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzyl cyanide | | benzenes;
nitrile | animal metabolite;
pheromone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pirinitramide | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyanamide | | nitrile;
one-carbon compound | EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dicyandiamido | | guanidines;
nitrile | curing agent;
explosive;
fertilizer;
flame retardant;
nitrification inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ricinine | | nitrile;
pyridine alkaloid;
pyridone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toyocamycin | | antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside | antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-cyanophenol | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-dicyanobenzene | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenoxylate | | ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine | antidiarrhoeal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ioxynil | | iodophenol;
nitrile | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enbucrilate | | alpha,beta-unsaturated monocarboxylic acid;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyanophenphos | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| difenoxin | | nitrile;
piperidinemonocarboxylic acid;
tertiary amine | antidiarrhoeal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| decamethrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organobromine compound | agrochemical;
antifeedant;
calcium channel agonist;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluvalinate | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bezitramide | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| d 888 | | aromatic ether;
nitrile;
tertiary amino compound | anti-arrhythmia drug;
calcium channel blocker;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyanopyrazine | | nitrile;
pyrazines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetracyanoquinodimethane | | alicyclic compound;
nitrile;
quinodimethane | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-chlorophenyl)-2-phenyl-2-(1,2,4-triazol-1-ylmethyl)butanenitrile | | monochlorobenzenes;
nitrile;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludioxonil | | benzodioxoles;
nitrile;
organofluorine compound;
pyrroles | androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenpiclonil | | dichlorobenzene;
nitrile;
pyrroles | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorfenapyr | | hemiaminal ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles | proacaricide;
proinsecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile | | dimethoxybenzene;
nitrile;
secondary amino compound | drug metabolite;
marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-bis(4-hydroxyphenyl)-propionitrile | | nitrile;
phenols | estrogen receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyfluthrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound | agrochemical;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norverapamil | | aromatic ether;
nitrile;
polyether;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| taxiphyllin | | beta-D-glucoside;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiacloprid | | monochloropyridine;
nitrile;
thiazolidines | environmental contaminant;
neonicotinoid insectide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-epithiobutanenitrile | | epithionitrile;
nitrile;
thiirane | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyc 682 | | nitrile;
nucleoside analogue;
secondary carboxamide | antimetabolite;
antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dhurrin | | beta-D-glucoside;
cyanogenic glycoside;
monosaccharide derivative;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminopotentidine | | aromatic ether;
benzamides;
guanidines;
nitrile;
piperidines;
substituted aniline | H2-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile | | monochlorobenzenes;
nitrile;
organobromine compound;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles | acaricide;
antifouling biocide;
insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prizes | | carboxamidine;
monochloropyridine;
nitrile | environmental contaminant;
neonicotinoid insectide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 778,123 | | imidazoles;
monochlorobenzenes;
nitrile;
piperazinone;
tertiary amino compound | antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indole-3-acetonitrile | | indoles;
nitrile | auxin;
human xenobiotic metabolite;
plant hormone;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Girgensonine | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 214662 | | benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diclazuril | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ravuconazole | | 1,3-thiazoles;
fluorobenzenes;
nitrile;
tertiary alcohol;
triazoles | antifungal drug;
antileishmanial agent;
EC 1.14.14.154 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mesoxalonitrile | | alpha-ketonitrile;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[di(propan-2-yl)phosphorylmethyl]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crotononitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,6-diamino-4-(1-phenylethyl)-4H-thiopyran-3,5-dicarbonitrile | | nitrile;
organosulfur heterocyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-hydroxy-1-(3-hydroxypropyl)-4-methyl-2-oxo-5-(1-piperidinylmethyl)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trilostane | | 17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile | abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-ethyl-4,6-dimethyl-2-sulfanylidene-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-3-(methoxymethyl)-5-spiro[2H-pyrano[2,3-c]pyrazole-4,4'-thiane]carbonitrile | | nitrile;
organic sulfide;
organosulfur heterocyclic compound;
oxaspiro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iFSP1 | | aromatic amine;
nitrile;
primary amino compound;
pyridobenzimidazole;
toluenes | antineoplastic agent;
ferroptosis inducer;
ferroptosis suppressor protein 1 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(4-chloro-5-dithiazolylidene)amino]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone | | bromophenol;
nitrile;
pyridone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1H-imidazol-1-ylmethyl)benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-1-(4-chlorophenyl)-2-oxo-4-(1,2,4-triazol-1-ylmethyl)-5-pyrimidinecarbonitrile | | monochlorobenzenes;
nitrile;
pyrimidone;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-tert-butyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,6-dimethyl-2-[3-(4-morpholinyl)propylamino]-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(methylamino)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1-piperidinyl)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-fluorophenyl)-2-[4-[(4-fluorophenyl)-oxomethyl]phenyl]acetonitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-Chloro-2-hydroxy-4,6-dimethylnicotinonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-oxo-4,6-dithiophen-2-yl-1H-pyridine-3-carbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(4-chlorophenyl)methoxy]-6-methoxybenzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[[4-(2-furanylmethyl)-5-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]thio]methyl]benzonitrile | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| or 1259 | | hydrazone;
nitrile;
pyridazinone | anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azoxystrobin | | aryloxypyrimidine;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
methyl ester;
nitrile | antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
quinone outside inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fipronil sulfone | | (trifluoromethyl)benzenes;
dichlorobenzene;
nitrile;
pyrazoles;
sulfone | marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-[2-hydroxy-3-(4-morpholinyl)propoxy]phenyl]benzonitrile | | biphenyls;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nafadotride | | aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyhalothrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[3-(diethylamino)propylamino]-4-(methoxymethyl)-6-methyl-3-pyridinecarbonitrile | | nitrile;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-cyano-4-hydroxycinnamic acid | | monohydroxycinnamic acid;
nitrile;
phenols | MALDI matrix material | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 11-7082 | | nitrile;
sulfone | apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 11-7085 | | benzenes;
nitrile;
sulfone | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tyrphostin ag825 | | aromatic ether;
benzothiazoles;
enamide;
nitrile;
organic sulfide;
phenols;
primary carboxamide | epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-(p-Methoxyphenyl)-2-pyridineacrylonitrile | | nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rilpivirine | | aminopyrimidine;
nitrile | EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isavuconazole | | 1,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug | EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flonicamid | | nitrile;
organofluorine compound;
pyridinecarboxamide | environmental contaminant;
insecticide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyazofamid | | imidazole fungicide;
imidazoles;
nitrile;
organochlorine compound;
sulfamides;
sulfonamide fungicide | antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perampanel | | bipyridines;
nitrile;
pyridone | AMPA receptor antagonist;
anticonvulsant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tofacitinib | | N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound | antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide | | 1,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethaboxam | | 1,3-thiazoles;
aromatic amide;
aromatic amine;
nitrile;
secondary amino compound;
thiophenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alogliptin | | nitrile;
piperidines;
primary amino compound;
pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyflumetofen | | (trifluoromethyl)benzenes;
2-methoxyethyl ester;
beta-ketoester;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| finafloxacin | | cyclopropanes;
monocarboxylic acid;
nitrile;
organofluorine compound;
quinolone;
secondary amino compound;
tertiary amino compound | antibacterial drug;
antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyantraniliprole | | nitrile;
organobromine compound;
organochlorine compound;
pyrazole insecticide;
pyridines;
secondary carboxamide | ryanodine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha(-(cyclopropylcarbonyl)-2-(methyvlsulfonyl)-beta-oxo-4-(trifluromethyl)benzenepropanenitrile) | | (trifluoromethyl)benzenes;
aromatic ketone;
beta-diketone;
cyclopropanes;
nitrile;
sulfone | agrochemical;
EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mdv 3100 | | (trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound | androgen antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trelagliptin | | benzenes;
nitrile | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulfoxaflor | | nitrile;
organofluorine compound;
pyridines;
sulfoximide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyenopyrafen | | nitrile;
pivalate ester;
pyrazoles | agrochemical;
proacaricide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SL-327 | | (trifluoromethyl)benzenes;
enamine;
nitrile;
organic sulfide;
primary amino compound;
substituted aniline | EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | | aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound | anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| incb-018424 | | nitrile;
pyrazoles;
pyrrolopyrimidine | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glasdegib | | benzimidazoles;
nitrile;
phenylureas;
piperidines | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baricitinib | | azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide | anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monepantel | | (trifluoromethyl)benzenes;
aromatic ether;
aryl sulfide;
nitrile;
secondary carboxamide | anthelminthic drug;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GS-441524 | | aromatic amine;
C-nucleoside;
nitrile;
pyrrolotriazine | anticoronaviral agent;
antiviral agent;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| an2728 | | aromatic ether;
benzoxaborole;
nitrile | antipsoriatic;
non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tak-632 | | (trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alectinib | | aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| delgocitinib | | azaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide | anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lfm a13 | | aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| teriflunomide | | (trifluoromethyl)benzenes;
aromatic amide;
enamide;
enol;
nitrile;
secondary carboxamide | drug metabolite;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GS-443902 | | aromatic amine;
C-nucleoside;
nitrile;
organic triphosphate;
pyrrolotriazine | anticoronaviral agent;
antiviral drug;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf-06463922 | | aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 8932 | | aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine | anticoronaviral agent;
antiviral drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AZ3451 | | benzimidazoles;
benzodioxoles;
nitrile;
organobromine compound;
secondary carboxamide | anti-inflammatory agent;
autophagy inducer;
PAR2 negative allosteric modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile | | hydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nirmatrelvir | | azabicyclohexane;
nitrile;
organofluorine compound;
pyrrolidin-2-ones;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide | anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| protocatechuic acid | | catechols;
dihydroxybenzoic acid | antineoplastic agent;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-dihydroxybiphenyl | | catechols;
hydroxybiphenyls | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| catechol | | catechols | allelochemical;
genotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyphenylacetic acid | | catechols;
dihydroxyphenylacetic acid | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sk&f 77434 | | benzazepine;
catechols;
tertiary amino compound | dopamine agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sk&f-38393 | | benzazepine;
catechols;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-fluoronorepinephrine | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tyrphostin a23 | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benserazide | | carbohydrazide;
catechols;
primary alcohol;
primary amino compound | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| caffeic acid | | catechols;
hydroxycinnamic acid | antioxidant;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| masoprocol | | catechols;
lignan;
tetrol | antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoproterenol hydrochloride | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(1S)-1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methoxycatechol | | aromatic ether;
catechols | G-protein-coupled receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyacetophenone | | acetophenones;
catechols;
dihydroxyacetophenone | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethylnorepinephrine | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-o-methylgallic acid | | benzoic acids;
catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| colterol | | catechols;
ethanolamines;
secondary alcohol;
secondary amino compound;
triol | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromocatechol | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enterobactin | | catechols;
crown compound;
macrotriolide;
polyphenol | bacterial metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbidopa | | catechols;
hydrazines;
monocarboxylic acid | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbidopa | | catechols;
hydrate;
hydrazines;
monocarboxylic acid | antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvin | | abietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid | angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-pentadecacatechol | | catechols | allergen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-ethylcatechol | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brazilin | | catechols;
organic heterotetracyclic compound;
tertiary alcohol | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
biological pigment;
hepatoprotective agent;
histological dye;
NF-kappaB inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl protocatechuate | | catechols;
ethyl ester | antibacterial agent;
antioxidant;
apoptosis inducer;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lanosol | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyphenylethanol | | catechols;
primary alcohol | antineoplastic agent;
antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxymandelic acid | | 2-hydroxy monocarboxylic acid;
catechols | antioxidant;
drug metabolite;
human metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyphenylglycol | | catechols;
tetrol | metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxybenzylamine | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| droxidopa | | catechols;
L-tyrosine derivative | antihypertensive agent;
prodrug;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-acetyldopamine | | acetamides;
catechols;
N-(fatty acyl)-dopamine;
secondary carboxamide | human urinary metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyphenylacetaldehyde | | alpha-CH2-containing aldehyde;
catechols;
phenylacetaldehydes | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-heptadecylcatechol | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-lipotropin, gln(9)- | | catechols;
crown compound;
macrocyclic lactone | bacterial metabolite;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| protosappanin a | | catechols | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chrysobactin | | catechols;
dipeptide;
monocarboxylic acid;
primary alcohol;
primary amino compound | bacterial metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sk&f 83959 | | benzazepine;
catechols;
organochlorine compound;
tertiary amino compound | dopamine agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyphenylglycolaldehyde | | catechols;
hydroxyaldehyde | human metabolite;
mouse metabolite;
neurotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| a 3253 | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-s-cysteinyldopa | | amino dicarboxylic acid;
aryl sulfide;
catechols;
diamine;
L-tyrosine derivative;
S-conjugate;
S-organyl-L-cysteine | human urinary metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-fluorocatechol | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n(beta)-alanyldopamine | | catechols;
primary amino compound;
secondary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxyterphenyllin | | catechols;
dimethoxybenzene;
para-terphenyl | Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 3,4-dihydroxybenzoate | | catechols;
methyl ester | antioxidant;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norbelladine | | catechols;
phenethylamine alkaloid;
polyphenol;
secondary amino compound | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rimiterol | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyphenyllactic acid | | 2-hydroxy monocarboxylic acid;
catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxyestrone | | 2-hydroxy steroid;
catechols | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3',4,5'-tetrahydroxystilbene | | catechols;
polyphenol;
resorcinols;
stilbenol | antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capsazepine | | benzazepine;
catechols;
monochlorobenzenes;
thioureas | capsaicin receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-nitrocatechol | | C-nitro compound;
catechols | human xenobiotic metabolite;
lipoxygenase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tolcapone | | 2-nitrophenols;
benzophenones;
catechols | antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oleuropein | | beta-D-glucoside;
catechols;
diester;
methyl ester;
pyrans;
secoiridoid glycoside | anti-inflammatory agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
NF-kappaB inhibitor;
nutraceutical;
plant metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-o-caffeoylshikimic acid | | alpha,beta-unsaturated monocarboxylic acid;
carboxylic ester;
catechols;
cyclohexenecarboxylic acid | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acteoside | | catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol | anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ellagic acid | | catechols;
cyclic ketone;
lactone;
organic heterotetracyclic compound;
polyphenol | antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor;
EC 2.4.1.1 (glycogen phosphorylase) inhibitor;
EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor;
EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor;
EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
food additive;
fungal metabolite;
geroprotector;
plant metabolite;
skin lightening agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| arachidonyl dopamine | | catechols;
fatty amide;
N-(fatty acyl)-dopamine;
secondary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-oleoyldopamine | | catechols;
fatty amide;
N-(fatty acyl)-dopamine;
secondary carboxamide | TRPV1 agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sappanchalcone | | catechols;
chalcones;
monomethoxybenzene | anti-allergic agent;
anti-inflammatory agent;
antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetrahydroxycurcumin | | beta-diketone;
catechols;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2',3,4-trihydroxychalcone | | catechols;
chalcones | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3',4'-dihydroxyaurone | | catechols;
hydroxyaurone | EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thunberginol f | | catechols;
gamma-lactone;
isobenzofuranone | metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvianolic acid B | | 1-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol | anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| a 77636 | | adamantanes;
catechols;
isochromenes;
primary amino compound | antiparkinson drug;
dopamine agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| altenusin | | aromatic ether;
carboxybiphenyl;
catechols;
hydroxybiphenyls;
polyphenol | antifungal agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-hydroxyestrone | | 17-oxo steroid;
3-hydroxy steroid;
4-hydroxy steroid;
catechols;
phenolic steroid | carcinogenic agent;
estrogen;
human urinary metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-caffeoyltyramine | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 11-hydroxysugiol | | abietane diterpenoid;
carbotricyclic compound;
catechols;
cyclic terpene ketone;
meroterpenoid | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myxochelin b | | benzamides;
catechols | bacterial metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aspalathin | | C-glycosyl compound;
catechols;
dihydrochalcones;
polyketide;
polyphenol | antioxidant;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
hypoglycemic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dihydro-n-caffeoyltyramine | | catechols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| violaceol II | | aromatic ether;
catechols;
resorcinols | mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dihydroxyphenyl)-2-thiocyanate-ethanone | | aromatic ketone;
catechols;
thiocyanates | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vanchrobactin | | catechols;
dipeptide;
guanidines;
monocarboxylic acid;
primary alcohol;
triol | bacterial metabolite;
marine metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hispidin | | 2-pyranones;
catechols | antioxidant;
EC 2.7.11.13 (protein kinase C) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oleuropein aglycone | | catechols;
diester;
lactol;
methyl ester;
pyrans;
secoiridoid | anti-inflammatory agent;
antioxidant;
mTOR inhibitor;
neuroprotective agent;
plant metabolite;
TRPA1 channel agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide | | catechols;
hydrazide;
hydrazone;
naphthols | EC 3.6.5.5 (dynamin GTPase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| roxarsone | | 2-nitrophenols;
organoarsonic acid | agrochemical;
animal growth promotant;
antibacterial drug;
coccidiostat | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-nitrophenol | | 2-nitrophenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nitrohydroxyiodophenylacetate | | 2-nitrophenols;
organoiodine compound;
phenylacetic acids | antigen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-hydroxy-3-nitrophenylacetyl-o-succinimide ester | | 2-nitrophenols;
N-hydroxysuccinimide ester | hapten | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-nitrotyrosine | | 2-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-amino-2-nitrophenol | | 2-nitrophenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| ethylene dichloride | | chloroethanes | hepatotoxic agent;
mutagen;
non-polar solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| protocatechuic acid | | catechols;
dihydroxybenzoic acid | antineoplastic agent;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aminolevulinic acid | | 4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid | antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ethylene glycol | | ethanediol;
glycol | metabolite;
mouse metabolite;
solvent;
toxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| acetic acid | | monocarboxylic acid | antimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetamide | | acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| allantoin | | imidazolidine-2,4-dione;
ureas | Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinacrine | | acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound | antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| betaine | | amino-acid betaine;
glycine derivative | fundamental metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carnitine | | amino-acid betaine | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| citric acid, anhydrous | | tricarboxylic acid | antimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| coumarin | | coumarins | fluorescent dye;
human metabolite;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| salicylic acid | | monohydroxybenzoic acid | algal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite | 2010 | 2023 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| gallic acid | | trihydroxybenzoic acid | antineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-aminophenol | | aminophenol | allergen;
metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bupropion | | aromatic ketone;
monochlorobenzenes;
secondary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| aminocaproic acid | | amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid | antifibrinolytic drug;
hematologic agent;
metabolite | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| creatine | | glycine derivative;
guanidines;
zwitterion | geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| formaldehyde | | aldehyde;
one-carbon compound | allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexachlorocyclohexane | | chlorocyclohexane | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| glycine | | alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroquinone | | benzenediol;
hydroquinones | antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thioctic acid | | dithiolanes;
heterocyclic fatty acid;
thia fatty acid | fundamental metabolite;
geroprotector | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| inositol | | cyclitol;
hexol | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| melatonin | | acetamides;
tryptamines | anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niacin | | pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3 | antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| orotic acid | | pyrimidinemonocarboxylic acid | Escherichia coli metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-aminobenzoic acid | | aminobenzoic acid;
aromatic amino-acid zwitterion | allergen;
Escherichia coli metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenol | | phenols | antiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylacetic acid | | benzenes;
monocarboxylic acid;
phenylacetic acids | allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| picolinic acid | | pyridinemonocarboxylic acid | human metabolite;
MALDI matrix material | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pyrazinamide | | monocarboxylic acid amide;
N-acylammonia;
pyrazines | antitubercular agent;
prodrug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| pyridoxal phosphate | | methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate | coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridoxine | | hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6 | cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| thiamine | | primary alcohol;
vitamin B1 | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2023 | 10.2 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| uracil | | pyrimidine nucleobase;
pyrimidone | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| catechin | | hydroxyflavan | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| menthol | | p-menthane monoterpenoid;
secondary alcohol | volatile oil component | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-(3-chlorophenyl)piperazine | | monochlorobenzenes;
N-arylpiperazine | drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2,4-dinitrophenol | | dinitrophenol | allergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 3-aminobenzamide | | benzamides;
substituted aniline | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3-methylcholanthrene | | ortho- and peri-fused polycyclic arene | aryl hydrocarbon receptor agonist;
carcinogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enprofylline | | oxopurine | anti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| pleconaril | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 4-(2-aminoethyl)benzenesulfonylfluoride | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 2010 | 2023 | 11.1 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| tacrine | | acridines;
aromatic amine | EC 3.1.1.7 (acetylcholinesterase) inhibitor | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| acebutolol | | aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2005 | 2016 | 13.3 | low | 0 | 0 | 0 | 7 | 3 | 0 |
| acetazolamide | | monocarboxylic acid amide;
sulfonamide;
thiadiazoles | anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| acetohexamide | | acetophenones;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| acetohydroxamic acid | | acetohydroxamic acids;
carbohydroximic acid | algal metabolite;
EC 3.5.1.5 (urease) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alaproclate | | alpha-amino acid ester | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| albendazole | | aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester | anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| albuterol | | phenols;
phenylethanolamines;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| alendronate | | 1,1-bis(phosphonic acid);
primary amino compound | bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| alosetron | | imidazoles;
pyridoindole | antiemetic;
gastrointestinal drug;
serotonergic antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alprazolam | | organochlorine compound;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| alprenolol | | secondary alcohol;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2008 | 2023 | 11.4 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| altretamine | | triamino-1,3,5-triazine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amantadine | | adamantanes;
primary aliphatic amine | analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| ambenonium | | quaternary ammonium ion | EC 3.1.1.8 (cholinesterase) inhibitor | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ambroxol | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diatrizoic acid | | acetamides;
benzoic acids;
organoiodine compound | environmental contaminant;
radioopaque medium;
xenobiotic | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| amifostine anhydrous | | diamine;
organic thiophosphate | antioxidant;
prodrug;
radiation protective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aminoglutethimide | | dicarboximide;
piperidones;
substituted aniline | adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2010 | 2013 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| pimagedine | | guanidines;
one-carbon compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| p-aminohippuric acid | | N-acylglycine | Daphnia magna metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| theophylline | | dimethylxanthine | adenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| 2-aminothiazole | | 1,3-thiazoles;
primary amino compound | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amiodarone | | 1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound | cardiovascular drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| dan 2163 | | aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone | environmental contaminant;
second generation antipsychotic;
xenobiotic | 2009 | 2013 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 2005 | 2016 | 13.9 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| amlexanox | | monocarboxylic acid;
pyridochromene | anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amlodipine | | dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| amobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amodiaquine | | aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amoxapine | | dibenzooxazepine | adrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| anastrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| anethole trithione | | methoxybenzenes | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anthralin | | anthracenes | antipsoriatic | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| antipyrine | | pyrazolone | antipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| astemizole | | benzimidazoles;
piperidines | anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| atenolol | | ethanolamines;
monocarboxylic acid amide;
propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| azathioprine | | aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine | antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| azelastine | | monochlorobenzenes;
phthalazines;
tertiary amino compound | anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor | 2008 | 2011 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 2010 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| barbital | | barbiturates | drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bendazac | | indazoles;
monocarboxylic acid | non-steroidal anti-inflammatory drug;
radical scavenger | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bendroflumethiazide | | benzothiadiazine;
sulfonamide | antihypertensive agent;
diuretic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzamide | | benzamides | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| benzbromarone | | 1-benzofurans;
aromatic ketone | uricosuric drug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| benzocaine | | benzoate ester;
substituted aniline | allergen;
antipruritic drug;
sensitiser;
topical anaesthetic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| betaxolol | | propanolamine | antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| bethanechol | | carbamate ester;
quaternary ammonium ion | muscarinic agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bevantolol | | propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| bay h 4502 | | biphenyls;
imidazoles | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| biperiden | | piperidines;
tertiary alcohol;
tertiary amino compound | antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| bisacodyl | | diarylmethane | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| bithionol | | aryl sulfide;
bridged diphenyl antifungal drug;
bridged diphenyl fungicide;
dichlorobenzene;
organochlorine pesticide;
polyphenol | antifungal agrochemical;
antiplatyhelmintic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bromazepam | | organic molecular entity | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| bromopride | | benzamides | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| bromisovalum | | N-acylurea;
organobromine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bronopol | | nitro compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brotizolam | | organic molecular entity | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| buflomedil | | aromatic ketone | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| bumetanide | | amino acid;
benzoic acids;
sulfonamide | diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| bunazosin | | quinazolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bupivacaine | | aromatic amide;
piperidinecarboxamide;
tertiary amino compound | | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 2010 | 2016 | 12.6 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| busulfan | | methanesulfonate ester | alkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| secbutabarbital | | barbiturates | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| butalbital | | barbiturates | analgesic;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| metrizoate | | monocarboxylic acid | radioopaque medium | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| camostat | | benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide | anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| camphor, (+-)-isomer | | bornane monoterpenoid;
cyclic monoterpene ketone | plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| candesartan cilexetil | | biphenyls | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| candesartan | | benzimidazolecarboxylic acid;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2010 | 2023 | 9.2 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 2005 | 2016 | 13.3 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| carbinoxamine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carisoprodol | | carbamate ester | muscle relaxant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carmustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| carprofen | | carbazoles;
organochlorine compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cetirizine | | ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines | anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cetylpyridinium | | pyridinium ion | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| chloral hydrate | | aldehyde hydrate;
ethanediol;
organochlorine compound | general anaesthetic;
mouse metabolite;
sedative;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorambucil | | aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| chlorcyclizine | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlordiazepoxide | | benzodiazepine | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| chlormezanone | | 1,3-thiazine;
lactam;
monochlorobenzenes;
sulfone | antipsychotic agent;
anxiolytic drug;
muscle relaxant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| chlorothiazide | | benzothiadiazine | antihypertensive agent;
diuretic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chloroxylenol | | monochlorobenzenes;
phenols | antiseptic drug;
disinfectant;
molluscicide | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 2008 | 2023 | 12.0 | low | 0 | 0 | 0 | 6 | 3 | 1 |
| chlorpropamide | | monochlorobenzenes;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 3 | 0 |
| chlorthalidone | | isoindoles;
monochlorobenzenes;
sulfonamide | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| chlorzoxazone | | 1,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound | muscle relaxant;
sedative | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| cifenline | | diarylmethane | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ciclopirox | | cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone | antibacterial agent;
antiseborrheic | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ciglitazone | | aromatic ether;
thiazolidinone | antineoplastic agent;
insulin-sensitizing drug | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cilostazol | | lactam;
tetrazoles | anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cimetidine | | aliphatic sulfide;
guanidines;
imidazoles;
nitrile | adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2005 | 2016 | 13.9 | low | 0 | 0 | 0 | 7 | 2 | 0 |
| cinoxacin | | cinnolines;
oxacycle;
oxo carboxylic acid | antibacterial drug;
antiinfective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ciprofibrate | | cyclopropanes;
monocarboxylic acid;
organochlorine compound | antilipemic drug | 2010 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| cisapride | | benzamides | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 3 | 0 |
| clioquinol | | monohydroxyquinoline;
organochlorine compound;
organoiodine compound | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clobazam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clofazimine | | monochlorobenzenes;
phenazines | dye;
leprostatic drug;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clofibrate | | aromatic ether;
ethyl ester;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| clofibric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clomiphene | | tertiary amine | estrogen antagonist;
estrogen receptor modulator | 2010 | 2016 | 11.8 | medium | 0 | 0 | 0 | 2 | 2 | 0 |
| clomipramine | | dibenzoazepine | anticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor | 2005 | 2023 | 12.0 | low | 0 | 0 | 0 | 4 | 3 | 1 |
| clonazepam | | 1,4-benzodiazepinone;
monochlorobenzenes | anticonvulsant;
anxiolytic drug;
GABA modulator | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| clonidine | | clonidine;
imidazoline | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| 4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide | | sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorazepate | | 1,4-benzodiazepinone | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 2008 | 2016 | 12.0 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| clotiazepam | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| cromolyn | | chromones;
dicarboxylic acid | anti-asthmatic drug;
calcium channel blocker | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| cyclandelate | | carboxylic ester;
secondary alcohol | vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclobenzaprine | | carbotricyclic compound | antidepressant;
muscle relaxant;
tranquilizing drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclofenil | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 2005 | 2016 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| danthron | | dihydroxyanthraquinone | apoptosis inducer;
plant metabolite | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| dapsone | | substituted aniline;
sulfone | anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug | 2005 | 2016 | 13.9 | low | 0 | 0 | 0 | 7 | 2 | 0 |
| deferiprone | | 4-pyridones | iron chelator;
protective agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| deferoxamine | | acyclic desferrioxamine | bacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 3 | 0 |
| nordazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amphetamine | | primary amine | | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| eflornithine | | alpha-amino acid;
fluoroamino acid | trypanocidal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic | 2005 | 2016 | 13.9 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| diazoxide | | benzothiadiazine;
organochlorine compound;
sulfone | antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| diclofenac | | amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2005 | 2016 | 14.0 | low | 0 | 0 | 0 | 7 | 2 | 0 |
| ddt | | benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide | bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dichlorphenamide | | dichlorobenzene;
sulfonamide | antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dicyclomine | | carboxylic ester;
tertiary amine | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diethylcarbamazine | | N-carbamoylpiperazine;
N-methylpiperazine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| pentetic acid | | pentacarboxylic acid | copper chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diflunisal | | monohydroxybenzoic acid;
organofluorine compound | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2005 | 2016 | 14.2 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| dimercaprol | | dithiol;
primary alcohol | chelator | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| dipyridamole | | piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol | adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2010 | 2023 | 10.3 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| disopyramide | | monocarboxylic acid amide;
pyridines;
tertiary amino compound | anti-arrhythmia drug | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| disulfiram | | organic disulfide;
organosulfur acaricide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor | 2010 | 2023 | 9.6 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 2005 | 2023 | 12.8 | low | 0 | 0 | 0 | 7 | 1 | 1 |
| domperidone | | benzimidazoles;
heteroarylpiperidine | antiemetic;
dopaminergic antagonist | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| donepezil | | aromatic ether;
indanones;
piperidines;
racemate | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| doxapram | | morpholines;
pyrrolidin-2-ones | central nervous system stimulant | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 2008 | 2023 | 8.3 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| doxepin | | dibenzooxepine;
tertiary amino compound | antidepressant | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| doxylamine | | pyridines;
tertiary amine | anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dyphylline | | oxopurine;
propane-1,2-diols | bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ebastine | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ebselen | | benzoselenazole | anti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| econazole | | dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| edrophonium | | phenols;
quaternary ammonium ion | antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enflurane | | ether;
organochlorine compound;
organofluorine compound | anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enoxacin | | 1,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| estazolam | | triazoles;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA modulator | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ethacrynic acid | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ethosuximide | | dicarboximide;
pyrrolidinone | anticonvulsant;
geroprotector;
T-type calcium channel blocker | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ethotoin | | imidazolidine-2,4-dione | anticonvulsant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethoxzolamide | | aromatic ether;
benzothiazoles;
sulfonamide | antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etidronate | | 1,1-bis(phosphonic acid) | antineoplastic agent;
bone density conservation agent;
chelator | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| etilefrine | | phenols | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| etodolac | | monocarboxylic acid;
organic heterotricyclic compound | antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 2-hexyloxybenzamide | | aromatic ether;
benzamides | antifungal agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| brl 42810 | | 2-aminopurines;
acetate ester | antiviral drug;
prodrug | 2010 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| carbonyl cyanide p-trifluoromethoxyphenylhydrazone | | aromatic ether;
hydrazone;
nitrile;
organofluorine compound | ATP synthase inhibitor;
geroprotector;
ionophore | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| felbamate | | carbamate ester | anticonvulsant;
neuroprotective agent | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| 4-biphenylylacetic acid | | biphenyls;
monocarboxylic acid | non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| felodipine | | dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| fenoldopam | | benzazepine | alpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenoprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2005 | 2016 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| berotek | | resorcinols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenspiride | | azaspiro compound | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| fexofenadine | | piperidines;
tertiary amine | anti-allergic agent;
H1-receptor antagonist | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| fipexide | | benzodioxoles | | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| flavoxate | | carboxylic ester;
flavones;
piperidines;
tertiary amino compound | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flecainide | | aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines | anti-arrhythmia drug | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| fleroxacin | | difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines | antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| fluconazole | | conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug | environmental contaminant;
P450 inhibitor;
xenobiotic | 2005 | 2016 | 13.9 | low | 0 | 0 | 0 | 7 | 2 | 0 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| flufenamic acid | | aromatic amino acid;
organofluorine compound | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2005 | 2010 | 15.2 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| fluphenazine | | N-alkylpiperazine;
organofluorine compound;
phenothiazines | anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| flumazenil | | ethyl ester;
imidazobenzodiazepine;
organofluorine compound | antidote to benzodiazepine poisoning;
GABA antagonist | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| flunitrazepam | | 1,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes | anxiolytic drug;
GABAA receptor agonist;
sedative | 2005 | 2010 | 16.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| fluorescite | | benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye | fluorescent dye;
radioopaque medium | 2008 | 2016 | 11.7 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| flurazepam | | 1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound | anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flurbiprofen | | fluorobiphenyl;
monocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2005 | 2016 | 13.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| fluspirilene | | diarylmethane | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| flutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide | androgen antagonist;
antineoplastic agent | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| fomepizole | | pyrazoles | antidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| foscarnet | | carboxylic acid;
one-carbon compound;
phosphonic acids | antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor | 2008 | 2016 | 13.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| furosemide | | chlorobenzoic acid;
furans;
sulfonamide | environmental contaminant;
loop diuretic;
xenobiotic | 2005 | 2016 | 13.9 | low | 0 | 0 | 0 | 7 | 2 | 0 |
| gabapentin | | gamma-amino acid | anticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic | 2008 | 2016 | 13.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| gabexate | | benzoate ester | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gemfibrozil | | aromatic ether | antilipemic drug | 2010 | 2016 | 11.6 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| glafenine | | aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound | inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| gliclazide | | N-sulfonylurea | hypoglycemic agent;
insulin secretagogue;
radical scavenger | 2010 | 2013 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| glimepiride | | sulfonamide | | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| glipizide | | aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines | EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| glutaral | | dialdehyde | cross-linking reagent;
disinfectant;
fixative | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| glutethimide | | piperidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 2008 | 2022 | 11.4 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester | | benzenes | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gossypol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| granisetron | | aromatic amide;
indazoles | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| guaiazulene | | sesquiterpene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guaifenesin | | methoxybenzenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanethidine | | azocanes;
guanidines | adrenergic antagonist;
antihypertensive agent;
sympatholytic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanfacine | | acetamides | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| guanidine | | carboxamidine;
guanidines;
one-carbon compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fasudil | | isoquinolines;
N-sulfonyldiazepane | antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| halothane | | haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound | inhalation anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexachlorophene | | bridged diphenyl fungicide;
polyphenol;
trichlorobenzene | acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| miltefosine | | phosphocholines;
phospholipid | anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| hexestrol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexetidine | | organic heteromonocyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexobarbital | | barbiturates | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| hexylresorcinol | | resorcinols | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| beta-thujaplicin | | cyclic ketone;
enol;
monoterpenoid | antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hycanthone | | thioxanthenes | mutagen;
schistosomicide drug | 2010 | 2023 | 9.7 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| hydralazine | | azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines | antihypertensive agent;
vasodilator agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| hydrochlorothiazide | | benzothiadiazine;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2010 | 2023 | 9.3 | low | 0 | 0 | 0 | 3 | 2 | 2 |
| hydroflumethiazide | | benzothiadiazine;
thiazide | antihypertensive agent;
diuretic | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| hydroxychloroquine | | aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| hydroxyurea | | one-carbon compound;
ureas | antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| hydroxyzine | | hydroxyether;
monochlorobenzenes;
N-alkylpiperazine | anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| hypericin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ibuprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic | 2005 | 2023 | 12.8 | low | 0 | 0 | 0 | 7 | 1 | 1 |
| phenelzine | | primary amine | | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 3 | 0 |
| alverine | | tertiary amine | antispasmodic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| idebenone | | 1,4-benzoquinones;
primary alcohol | antioxidant;
ferroptosis inhibitor | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| ifosfamide | | ifosfamides | alkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2005 | 2022 | 12.1 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| amrinone | | bipyridines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| indapamide | | indoles;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2005 | 2023 | 11.8 | low | 0 | 0 | 0 | 7 | 4 | 2 |
| iohexol | | benzenedicarboxamide;
organoiodine compound | environmental contaminant;
radioopaque medium;
xenobiotic | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| iopromide | | dicarboxylic acid diamide;
organoiodine compound | environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| iothalamic acid | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iodipamide | | benzoic acids;
organoiodine compound;
secondary carboxamide | radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ioversol | | amidobenzoic acid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| iproniazid | | carbohydrazide;
pyridines | | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| avapro | | azaspiro compound;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2008 | 2023 | 11.1 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| isocarboxazid | | benzenes | | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| isoflurane | | organofluorine compound | inhalation anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoniazid | | carbohydrazide | antitubercular agent;
drug allergen | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| isoxsuprine | | alkylbenzene | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isradipine | | benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| itraconazole | | piperazines | | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| ketamine | | cyclohexanones;
monochlorobenzenes;
secondary amino compound | analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| ketoprofen | | benzophenones;
oxo monocarboxylic acid | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2005 | 2022 | 12.9 | low | 0 | 0 | 0 | 7 | 1 | 1 |
| ketorolac | | amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate | analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ketotifen | | cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound | anti-asthmatic drug;
H1-receptor antagonist | 2005 | 2010 | 15.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| khellin | | furanochromone;
organic heterotricyclic compound;
oxacycle | anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| kojic acid | | 4-pyranones;
enol;
primary alcohol | Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| labetalol | | benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound | | 2008 | 2016 | 13.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| lamotrigine | | 1,2,4-triazines;
dichlorobenzene;
primary arylamine | anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| lansoprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| lapachol | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| beta-lapachone | | benzochromenone;
orthoquinones | anti-inflammatory agent;
antineoplastic agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| leflunomide | | (trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide | antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| letrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| lofepramine | | aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound | antidepressant | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lomefloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antimicrobial agent;
antitubercular agent;
photosensitizing agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lomustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 2010 | 2023 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| loratadine | | benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide | anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist | 2013 | 2023 | 6.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| lorazepam | | benzodiazepine | | 2005 | 2016 | 14.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2008 | 2023 | 12.0 | low | 0 | 0 | 0 | 6 | 1 | 1 |
| loxapine | | dibenzooxazepine | antipsychotic agent;
dopaminergic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide | | benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mafenide | | aromatic amine | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| malathion | | diester;
ethyl ester;
organic thiophosphate | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diisopropyl 1,3-dithiol-2-ylidenemalonate | | isopropyl ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| maprotiline | | anthracenes | | 2008 | 2016 | 12.6 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| mazindol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mebendazole | | aromatic ketone;
benzimidazoles;
carbamate ester | antinematodal drug;
microtubule-destabilising agent;
tubulin modulator | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| mecamylamine | | primary aliphatic amine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mechlorethamine | | nitrogen mustard;
organochlorine compound | alkylating agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meclizine | | diarylmethane | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| meclofenamic acid | | aminobenzoic acid;
organochlorine compound;
secondary amino compound | analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meclofenamate sodium anhydrous | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| meclofenoxate | | monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefenamic acid | | aminobenzoic acid;
secondary amino compound | analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2005 | 2016 | 13.3 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| memantine | | adamantanes;
primary aliphatic amine | antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| vitamin k 3 | | 1,4-naphthoquinones;
vitamin K | angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| mepenzolate | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meperidine | | ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound | antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| mephenytoin | | imidazolidine-2,4-dione | anticonvulsant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mepivacaine | | piperidinecarboxamide | drug allergen;
local anaesthetic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| meprobamate | | organic molecular entity | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| mesalamine | | amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols | non-steroidal anti-inflammatory drug | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mesoridazine | | phenothiazines;
sulfoxide;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metaproterenol | | aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| methadone | | benzenes;
diarylmethane;
ketone;
tertiary amino compound | | 2005 | 2016 | 14.3 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| methapyrilene | | ethylenediamine derivative | anti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative | 2008 | 2010 | 14.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| methazolamide | | sulfonamide;
thiadiazoles | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| methenamine | | polyazaalkane;
polycyclic cage;
tetramine | antibacterial drug | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| methocarbamol | | aromatic ether;
carbamate ester;
secondary alcohol | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| methoxsalen | | aromatic ether;
psoralens | antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methoxyflurane | | ether;
organochlorine compound;
organofluorine compound | hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyclothiazide | | benzothiadiazine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nocodazole | | aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes | antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methyl salicylate | | benzoate ester;
methyl ester;
salicylates | flavouring agent;
insect attractant;
metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylphenidate | | beta-amino acid ester;
methyl ester;
piperidines | | 2008 | 2016 | 13.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| methyprylon | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metoclopramide | | benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound | antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| metolazone | | organochlorine compound;
quinazolines;
sulfonamide | antihypertensive agent;
diuretic;
ion transport inhibitor | 2008 | 2016 | 13.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| metronidazole | | C-nitro compound;
imidazoles;
primary alcohol | antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| metyrapone | | aromatic ketone | antimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mexiletine | | aromatic ether;
primary amino compound | anti-arrhythmia drug | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mianserin | | dibenzoazepine | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| miconazole | | dichlorobenzene;
ether;
imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 2008 | 2016 | 12.9 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| midodrine | | amino acid amide;
aromatic ether;
secondary alcohol | alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| milrinone | | bipyridines;
nitrile;
pyridone | cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| minoxidil | | dialkylarylamine;
tertiary amino compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| mitotane | | diarylmethane | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mitoxantrone | | dihydroxyanthraquinone | analgesic;
antineoplastic agent | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| modafinil | | monocarboxylic acid amide;
sulfoxide | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| moxisylyte | | monoterpenoid | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| entinostat | | benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| deet | | benzamides;
monocarboxylic acid amide | environmental contaminant;
insect repellent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acecainide | | acetamides;
benzamides | anti-arrhythmia drug | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ethylmaleimide | | maleimides | anticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nabumetone | | methoxynaphthalene;
methyl ketone | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2010 | 2023 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| nadolol | | tetralins | | 2013 | 2022 | 7.0 | medium | 0 | 0 | 0 | 0 | 2 | 1 |
| nafamostat | | benzoic acids;
guanidines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nalidixic acid | | 1,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| naratriptan | | heteroarylpiperidine;
sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| nefopam | | benzoxazocine;
tertiary amino compound | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| neostigmine | | quaternary ammonium ion | antidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nevirapine | | cyclopropanes;
dipyridodiazepine | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| nialamide | | organonitrogen compound;
organooxygen compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nicardipine | | benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| niceritrol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 2008 | 2022 | 12.0 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| niflumic acid | | aromatic carboxylic acid;
pyridines | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nilutamide | | (trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone | androgen antagonist;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nimesulide | | aromatic ether;
C-nitro compound;
sulfonamide | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| nimodipine | | 2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester | antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 3 | 0 |
| nisoldipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| nitrazepam | | 1,4-benzodiazepinone;
C-nitro compound | anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| nitroglycerin | | nitroglycerol | explosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nizatidine | | 1,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist | 2008 | 2016 | 13.4 | high | 0 | 0 | 0 | 4 | 1 | 0 |
| nomifensine | | isoquinolines | dopamine uptake inhibitor | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| masoprocol | | catechols;
lignan;
tetrol | antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 2005 | 2016 | 13.8 | low | 0 | 0 | 0 | 5 | 3 | 0 |
| ofloxacin | | 3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| ondansetron | | carbazoles | | 2008 | 2016 | 12.6 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| orphenadrine | | ether;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| osalmide | | organic molecular entity | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| oxamniquine | | aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxaprozin | | 1,3-oxazoles;
monocarboxylic acid | analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| oxazepam | | 1,4-benzodiazepinone;
organochlorine compound | anxiolytic drug;
environmental contaminant;
xenobiotic | 2005 | 2016 | 14.3 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| oxethazaine | | amino acid amide | | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| oxibendazole | | benzimidazoles;
carbamate ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxiracetam | | organonitrogen compound;
organooxygen compound | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxprenolol | | aromatic ether | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxybenzone | | hydroxybenzophenone;
monomethoxybenzene | dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxybutynin | | acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound | antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| oxyphenbutazone | | phenols;
pyrazolidines | antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminosalicylic acid | | aminobenzoic acid;
phenols | antitubercular agent | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| palmidrol | | endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine | anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pamidronate | | phosphonoacetic acid | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| pantoprazole | | aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| papaverine | | benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines | antispasmodic drug;
vasodilator agent | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| 4-dichlorobenzene | | dichlorobenzene | insecticide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| pargyline | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| pemoline | | 1,3-oxazoles | central nervous system stimulant | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| pentamidine | | aromatic ether;
carboxamidine;
diether | anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pentobarbital | | barbiturates | GABAA receptor agonist | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| pentoxifylline | | oxopurine | | 2008 | 2023 | 10.0 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| perazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perhexiline | | piperidines | cardiovascular drug | 2010 | 2023 | 9.2 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| perphenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| phenacetin | | acetamides;
aromatic ether | cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug | 2008 | 2013 | 13.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| phenazopyridine | | diaminopyridine;
monoazo compound | anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| phenobarbital | | barbiturates | anticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| phenolphthalein | | phenols | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenoxybenzamine | | aromatic amine | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phentermine | | primary amine | adrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| phenylbutazone | | pyrazolidines | antirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2005 | 2010 | 15.2 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| phenylmethylsulfonyl fluoride | | acyl fluoride | serine proteinase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| moxonidine | | organohalogen compound;
pyrimidines | | 2008 | 2010 | 14.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| pimobendan | | benzimidazoles;
pyridazinone | cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 2008 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| pinacidil | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| pindolol | | indoles;
secondary amine | antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pipemidic acid | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperazine | | azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent | anthelminthic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piracetam | | organonitrogen compound;
organooxygen compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piretanide | | aromatic ether | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| piribedil | | N-arylpiperazine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pj-34 | | phenanthridines;
secondary carboxamide;
tertiary amino compound | angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| polythiazide | | benzothiadiazine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| practolol | | acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug;
beta-adrenergic antagonist | 2009 | 2010 | 14.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| duodote | | pyridinium ion | antidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ono 1078 | | chromones | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyranoprofen | | pyridochromene | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| praziquantel | | isoquinolines | | 2010 | 2023 | 10.3 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| prilocaine | | amino acid amide;
monocarboxylic acid amide | anticonvulsant;
local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| primaquine | | aminoquinoline;
aromatic ether;
N-substituted diamine | antimalarial | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| primidone | | pyrimidone | anticonvulsant;
environmental contaminant;
xenobiotic | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| probenecid | | benzoic acids;
sulfonamide | uricosuric drug | 2005 | 2023 | 12.6 | low | 0 | 0 | 0 | 7 | 2 | 1 |
| probucol | | dithioketal;
polyphenol | anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug | 2010 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 0 | 1 |
| procainamide | | benzamides | anti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| procarbazine | | benzamides;
hydrazines | antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| prochlorperazine | | N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines | alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| procyclidine | | pyrrolidines;
tertiary alcohol | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| promazine | | phenothiazines;
tertiary amine | antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist | 2008 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| promethazine | | phenothiazines;
tertiary amine | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| propafenone | | aromatic ketone;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| propantheline | | xanthenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| propofol | | phenols | anticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative | 2005 | 2016 | 14.2 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| protriptyline | | carbotricyclic compound | antidepressant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyridinolcarbamate | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridostigmine | | pyridinium ion | | 2008 | 2016 | 13.2 | medium | 0 | 0 | 0 | 3 | 1 | 0 |
| pyrimethamine | | aminopyrimidine;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| sch 16134 | | benzodiazepine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quetiapine | | dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rabeprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| raloxifene | | 1-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols | bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ranitidine | | aralkylamine | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| opc 12759 | | secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| riluzole | | benzothiazoles | | 2010 | 2016 | 12.3 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| rimantadine | | alkylamine | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| rizatriptan | | tryptamines | anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| rofecoxib | | butenolide;
sulfone | analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rolipram | | pyrrolidin-2-ones | antidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ropinirole | | indolones;
tertiary amine | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| salicylamide | | phenols;
salicylamides | antirheumatic drug;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| salicylsalicylic acid | | benzoate ester;
benzoic acids;
phenols;
salicylates | antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| scriptaid | | isoquinolines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sebacic acid | | alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid | human metabolite;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| secobarbital | | barbiturates | anaesthesia adjuvant;
GABA modulator;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sevoflurane | | ether;
organofluorine compound | central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sibutramine | | organochlorine compound;
tertiary amino compound | anti-obesity agent;
serotonin uptake inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfadiazine | | pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| risedronic acid | | pyridines | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| sotalol | | ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide | anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| 4-phenylbutyric acid, sodium salt | | organic sodium salt | EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenofibrate | | benzochromenone;
delta-lactone;
naphtho-alpha-pyrone | platelet aggregation inhibitor;
Sir2 inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| imatinib | | aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines | antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2008 | 2023 | 10.2 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| succinylcholine | | quaternary ammonium ion;
succinate ester | drug allergen;
muscle relaxant;
neuromuscular agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfabenzamide | | benzenes;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
antimicrobial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sulfadimethoxine | | aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamerazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfameter | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
leprostatic drug;
renal agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamethazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamethizole | | sulfonamide antibiotic;
sulfonamide;
thiadiazoles | antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| sulfamethoxazole | | isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| sulfanilamide | | substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| sulfanitran | | sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfaphenazole | | primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfapyridine | | pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfasalazine | | | | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| sulfathiazole | | 1,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 2005 | 2016 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfinpyrazone | | pyrazolidines;
sulfoxide | uricosuric drug | 2005 | 2010 | 15.1 | low | 0 | 0 | 0 | 7 | 0 | 0 |
| sulfisoxazole | | isoxazoles;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
drug allergen | 2005 | 2022 | 12.8 | low | 0 | 0 | 0 | 4 | 1 | 1 |
| sulfobromophthalein | | 2-benzofurans;
organobromine compound;
organosulfonic acid;
phenols | dye | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol | | alkylbenzene | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| sulpiride | | benzamides;
N-alkylpyrrolidine;
sulfonamide | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 2009 | 2010 | 14.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| sumatriptan | | sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 2008 | 2022 | 11.8 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| suprofen | | aromatic ketone;
monocarboxylic acid;
thiophenes | antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2008 | 2023 | 12.0 | low | 0 | 0 | 0 | 4 | 0 | 1 |
| suramin | | naphthalenesulfonic acid;
phenylureas;
secondary carboxamide | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 2008 | 2010 | 14.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| gatifloxacin | | N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| tazarotene | | acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane | keratolytic drug;
prodrug;
teratogenic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tegafur | | organohalogen compound;
pyrimidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| telenzepine | | benzodiazepine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| temazepam | | benzodiazepine | | 2005 | 2016 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 2008 | 2016 | 12.6 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| terazosin | | furans;
piperazines;
primary amino compound;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| terbutaline | | phenylethanolamines;
resorcinols | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| terfenadine | | diarylmethane | | 2010 | 2013 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| tetracaine | | benzoate ester;
tertiary amino compound | local anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thalidomide | | phthalimides;
piperidones | | 2008 | 2023 | 9.8 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| thiabendazole | | 1,3-thiazoles;
benzimidazole fungicide;
benzimidazoles | antifungal agrochemical;
antinematodal drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thiotepa | | aziridines | | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tiapride | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tiaprofenic acid | | aromatic ketone;
monocarboxylic acid;
thiophenes | drug allergen;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ticlopidine | | monochlorobenzenes;
thienopyridine | anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2010 | 2023 | 10.2 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| tilorone | | aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound | anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tinidazole | | imidazoles | antiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| tiopronin | | N-acyl-amino acid | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tizanidine | | benzothiadiazole;
imidazoles | alpha-adrenergic agonist;
muscle relaxant | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| nikethamide | | pyridinecarboxamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tolazamide | | N-sulfonylurea | hypoglycemic agent;
potassium channel blocker | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| tolbutamide | | N-sulfonylurea | human metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| tolmetin | | aromatic ketone;
monocarboxylic acid;
pyrroles | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tolnaftate | | monothiocarbamic ester | antifungal drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tolperisone | | aromatic ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ultram | | aromatic ether;
tertiary alcohol;
tertiary amino compound | | 2008 | 2016 | 13.4 | medium | 0 | 0 | 0 | 4 | 1 | 0 |
| tranexamic acid | | amino acid | | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| triamterene | | pteridines | diuretic;
sodium channel blocker | 2008 | 2023 | 10.2 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| triazolam | | triazolobenzodiazepine | sedative | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| triclosan | | aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols | antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 2010 | 2023 | 9.2 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| triflupromazine | | organofluorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| trigonelline | | alkaloid;
iminium betaine | food component;
human urinary metabolite;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| trihexyphenidyl | | amine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trimethadione | | oxazolidinone | anticonvulsant;
geroprotector | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| trimethobenzamide | | benzamides;
tertiary amino compound | antiemetic | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| trimethoprim | | aminopyrimidine;
methoxybenzenes | antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| trimetrexate | | | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| trimipramine | | dibenzoazepine;
tertiary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 2005 | 2016 | 13.3 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| thenoyltrifluoroacetone | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tyramine | | monoamine molecular messenger;
primary amino compound;
tyramines | EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tyrphostin a9 | | alkylbenzene | geroprotector | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| delavirdine | | aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| undecylenic acid | | undecenoic acid | antifungal drug;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| urapidil | | piperazines | | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| venlafaxine | | cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound | adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| vesnarinone | | organic molecular entity | | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| vigabatrin | | gamma-amino acid | anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| viloxazine | | aromatic ether | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pirinixic acid | | aryl sulfide;
organochlorine compound;
pyrimidines | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ici 204,219 | | carbamate ester;
indoles;
N-sulfonylcarboxamide | anti-asthmatic agent;
leukotriene antagonist | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| zaleplon | | nitrile;
pyrazolopyrimidine | anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| zolpidem | | imidazopyridine | central nervous system depressant;
GABA agonist;
sedative | 2008 | 2016 | 13.6 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| zomepirac | | aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles | cardiovascular drug;
non-steroidal anti-inflammatory drug | 2005 | 2010 | 15.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| zonisamide | | 1,2-benzoxazoles;
sulfonamide | anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker | 2011 | 2016 | 10.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| zopiclone | | monochloropyridine;
pyrrolopyrazine | central nervous system depressant;
sedative | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| guanidine hydrochloride | | one-carbon compound;
organic chloride salt | protein denaturant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrocortisone acetate | | cortisol ester;
tertiary alpha-hydroxy ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cortisone acetate | | corticosteroid hormone | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mitomycin | | mitomycin | alkylating agent;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxyphenonium | | acylcholine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| estriol | | 16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid | estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cephaloridine | | beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative | antibacterial drug | 2008 | 2010 | 14.5 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| phentolamine | | imidazoles;
phenols;
substituted aniline;
tertiary amino compound | alpha-adrenergic antagonist;
vasodilator agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sorbitol | | glucitol | cathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| floxuridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| piperonyl butoxide | | benzodioxoles | pesticide synergist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromouracil | | nucleobase analogue;
pyrimidines | mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,3',5-triiodothyroacetic acid | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoproterenol hydrochloride | | catechols | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| histamine dihydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thyroxine | | 2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine | antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dextroamphetamine | | 1-phenylpropan-2-amine | adrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethindrone acetate | | 3-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound | progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| spironolactone | | 3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester | aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| cyclobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| allobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillamine | | non-proteinogenic alpha-amino acid;
penicillamine | antirheumatic drug;
chelator;
copper chelator;
drug allergen | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| trichlorfon | | organic phosphonate;
organochlorine compound;
phosphonic ester | agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cysteine | | cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 2008 | 2016 | 13.6 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| estrone | | 17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols | antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| oxandrolone | | 17beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid | anabolic agent;
androgen | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dehydroepiandrosterone | | 17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid | androgen;
human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| promazine hydrochloride | | hydrochloride | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nad | | NAD | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-acetylaminofluorene | | 2-acetamidofluorenes | antimitotic;
carcinogenic agent;
epitope;
mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillin g | | penicillin allergen;
penicillin | antibacterial drug;
drug allergen;
epitope | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| idoxuridine | | organoiodine compound;
pyrimidine 2'-deoxyribonucleoside | antiviral drug;
DNA synthesis inhibitor | 2010 | 2023 | 9.7 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| pilocarpine | | pilocarpine | antiglaucoma drug | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| triiodothyronine | | 2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine | human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| isonicotinic acid | | pyridinemonocarboxylic acid | algal metabolite;
human metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| carbon tetrachloride | | chlorocarbon;
chloromethanes | hepatotoxic agent;
refrigerant | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| chloramphenicol | | C-nitro compound;
carboxamide;
diol;
organochlorine compound | antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor | 2005 | 2023 | 12.2 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| glutamine | | amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lysine | | aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid | algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cetrimonium bromide | | organic bromide salt;
quaternary ammonium salt | detergent;
surfactant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vincristine | | acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| physostigmine | | carbamate ester;
indole alkaloid | antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic | 2010 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethinyl estradiol | | 17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2005 | 2013 | 14.7 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| testosterone propionate | | steroid ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tubocurarine | | bisbenzylisoquinoline alkaloid | drug allergen;
muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apomorphine | | aporphine alkaloid | alpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| aminopyrine | | pyrazolone;
tertiary amino compound | antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyltestosterone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone | anabolic agent;
androgen;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| promethazine hydrochloride | | hydrochloride | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| tetrabenazine | | benzoquinolizine;
cyclic ketone;
tertiary amino compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cephalothin | | azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes | antibacterial drug;
antimicrobial agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| uridine | | uridines | drug metabolite;
fundamental metabolite;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| kanamycin a | | kanamycins | bacterial metabolite | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 2008 | 2021 | 12.4 | low | 0 | 0 | 0 | 5 | 1 | 1 |
| edetic acid | | ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid | anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylethyl alcohol | | benzenes;
primary alcohol | Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cysteamine | | amine;
thiol | geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcholine chloride | | quaternary ammonium salt | | 2010 | 2016 | 12.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| mepazine | | phenothiazines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methoxamine hydrochloride | | dimethoxybenzene | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| methicillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2022 | 11.0 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| niridazole | | 1,3-thiazoles;
C-nitro compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cloxacillin | | penicillin allergen;
penicillin;
semisynthetic derivative | antibacterial agent;
antibacterial drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| zoxazolamine | | benzoxazole | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| calcium acetate | | calcium salt | chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethylnitrosamine | | nitrosamine | geroprotector;
mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| carbaryl | | carbamate ester;
naphthalenes | acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactose | | lactose | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| primaquine phosphate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Mebutamate | | organic molecular entity | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| colchicine | | alkaloid;
colchicine | anti-inflammatory agent;
gout suppressant;
mutagen | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| gallamine triethiodide | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| mebanazine | | benzenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| uracil mustard | | aminouracil;
nitrogen mustard | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxacillin | | penicillin | antibacterial agent;
antibacterial drug | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ficusin | | psoralens | plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| chloroform | | chloromethanes;
one-carbon compound | carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| triamcinolone diacetate | | corticosteroid hormone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethylformamide | | formamides;
volatile organic compound | geroprotector;
hepatotoxic agent;
polar aprotic solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethindrone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol | progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| norethynodrel | | oxo steroid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cycloserine | | 4-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion | antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benziodarone | | aromatic ketone | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tubercidin | | antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside | antimetabolite;
antineoplastic agent;
bacterial metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ampicillin | | beta-lactam antibiotic;
penicillin allergen;
penicillin | antibacterial drug | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| mannitol | | mannitol | allergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| trifluridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| medroxyprogesterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester | adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive | 2010 | 2013 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| mestranol | | 17beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound | prodrug;
xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| methaqualone | | quinazolines | GABA agonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trypan blue | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cordycepin | | 3'-deoxyribonucleoside;
adenosines | antimetabolite;
nucleoside antibiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan | antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| trichloroacetic acid | | monocarboxylic acid;
organochlorine compound | carcinogenic agent;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perflutren | | fluoroalkane;
fluorocarbon | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triamcinolone acetonide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| fluoxymesterone | | 11beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid | anabolic agent;
antineoplastic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| allylpropymal | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| butobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methsuximide | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tromethamine | | primary amino compound;
triol | buffer | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| trichloroethylene | | chloroethenes | inhalation anaesthetic;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| dichloroacetic acid | | monocarboxylic acid;
organochlorine compound | astringent;
marine metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydrocholic acid | | 12-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid | gastrointestinal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclizine | | N-alkylpiperazine | antiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| rotenone | | organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| 9,10-anthraquinone | | anthraquinone | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| diquat | | organic cation | defoliant;
herbicide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| brompheniramine | | organobromine compound;
pyridines | anti-allergic agent;
H1-receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| penicillin v | | penicillin allergen;
penicillin | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| salicylanilide | | benzanilide fungicide;
salicylamides;
salicylanilides | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| isosorbide dinitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| gramine | | aminoalkylindole;
indole alkaloid;
tertiary amino compound | antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hexachlorobutadiene | | organochlorine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminacrine | | aminoacridines;
primary amino compound | acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pseudoephedrine | | phenylethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diethylpropion | | aromatic ketone;
tertiary amine | appetite depressant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenothiazine | | phenothiazine | ferroptosis inhibitor;
plant metabolite;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| synephrine | | ethanolamines;
phenethylamine alkaloid;
phenols | alpha-adrenergic agonist;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzoyl peroxide | | carbonyl compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-bromophenol | | bromophenol | marine metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methyl gallate | | gallate ester | anti-inflammatory agent;
antioxidant;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3-dinitrobenzene | | dinitrobenzene | neurotoxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridostigmine bromide | | pyridinium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 4,4'-diaminodiphenylmethane | | aromatic amine | allergen;
carcinogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| monobenzone | | benzyl ether | allergen;
dermatologic drug;
melanin synthesis inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| phenylisothiocyanate | | isothiocyanate | allergen;
reagent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| benzonatate | | benzoate ester;
secondary amino compound;
substituted aniline | anaesthetic;
antitussive | 2016 | 2021 | 5.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| 4-bromophenol | | bromophenol | human urinary metabolite;
human xenobiotic metabolite;
marine metabolite;
mouse metabolite;
persistent organic pollutant;
rat metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 2-bromoethylamine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| allyl alcohol | | primary allylic alcohol;
propenol | antibacterial agent;
fungicide;
herbicide;
insecticide;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bromobenzene | | bromoarene;
bromobenzenes;
volatile organic compound | hepatotoxic agent;
mouse metabolite;
non-polar solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| n-pentanoic acid | | short-chain fatty acid;
straight-chain saturated fatty acid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| furan | | furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | carcinogenic agent;
hepatotoxic agent;
Maillard reaction product | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ergotamine | | peptide ergot alkaloid | alpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methylergonovine | | ergoline alkaloid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipramine hydrochloride | | hydrochloride | antidepressant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| neostigmine bromide | | bromide salt | | 2008 | 2010 | 14.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| phenformin | | biguanides | antineoplastic agent;
geroprotector;
hypoglycemic agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mephobarbital | | barbiturates | anticonvulsant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| edrophonium chloride | | chloride salt;
quaternary ammonium salt | antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| hexachlorobenzene | | aromatic fungicide;
chlorobenzenes | antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trinitrotoluene | | trinitrotoluene | explosive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| framycetin | | aminoglycoside | allergen;
antibacterial drug;
Escherichia coli metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrazolanthrone | | anthrapyrazole;
aromatic ketone;
cyclic ketone | antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| di-n-pentyl phthalate | | diester;
phthalate ester | plasticiser | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| meglumine | | hexosamine;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cinchophen | | quinolines | | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| phenazopyridine hydrochloride | | hydrochloride | carcinogenic agent;
local anaesthetic;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tetrracaine hydrochloride | | benzoate ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diphenhydramine hydrochloride | | hydrochloride;
organoammonium salt | anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nafcillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ditiocarb | | dithiocarbamic acids | chelator;
copper chelator | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mequinol | | methoxybenzenes;
phenols | metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methohexital | | acetylenic compound;
barbiturates | drug allergen;
intravenous anaesthetic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quinestrol | | 17-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dydrogesterone | | 20-oxo steroid;
3-oxo-Delta(4) steroid | progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| catechin | | catechin | antioxidant;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tripelennamine hydrochloride | | | | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| ethynodiol diacetate | | steroid ester;
terminal acetylenic compound | contraceptive drug;
estrogen receptor modulator;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ephedrine | | phenethylamine alkaloid;
phenylethanolamines | bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| hydrazine | | azane;
hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| chlormadinone acetate | | corticosteroid hormone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pirinitramide | | nitrile | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| edrophonium bromide | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,3-dimercaptosuccinic acid | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| evans blue | | organic sodium salt | fluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| monocrotaline | | pyrrolizidine alkaloid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| testosterone enanthate | | heptanoate ester;
sterol ester | androgen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminophylline | | mixture | bronchodilator agent;
cardiotonic drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| azacitidine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 2008 | 2023 | 11.2 | low | 0 | 0 | 0 | 4 | 1 | 1 |
| phenyramidol | | aminopyridine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbutamide | | benzenes;
sulfonamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pseudoephedrine hydrochloride | | hydrochloride | plant metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| galantamine | | benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound | antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nandrolone decanoate | | steroid ester | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bucladesine | | 3',5'-cyclic purine nucleotide;
butanamides;
butyrate ester | agonist;
cardiotonic drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| procarbazine hydrochloride | | hydrochloride | antineoplastic agent | 2010 | 2013 | 13.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| betamethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| perflubron | | haloalkane;
organobromine compound;
perfluorinated compound | blood substitute;
radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyproterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester | androgen antagonist;
geroprotector;
progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| lithocholic acid | | bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid | geroprotector;
human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dextropropoxyphene | | 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate | mu-opioid receptor agonist;
opioid analgesic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ketobemidone | | piperidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycyrrhetinic acid | | cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid | immunomodulator;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chenodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| lucanthone | | thioxanthenes | adjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cepharanthine | | bisbenzylisoquinoline alkaloid;
isoquinolines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| aloe emodin | | aromatic primary alcohol;
dihydroxyanthraquinone | antineoplastic agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| chrysophanic acid | | dihydroxyanthraquinone | anti-inflammatory agent;
antiviral agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| emetine | | isoquinoline alkaloid;
pyridoisoquinoline | antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor | 2013 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| osthol | | botanical anti-fungal agent;
coumarins | metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dihydralazine | | phthalazines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flavanone | | flavanones | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| phenylpropanolamine | | amphetamines;
phenethylamine alkaloid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phloretic acid | | hydroxy monocarboxylic acid | plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 4-hydroxybutyric acid | | 4-hydroxy monocarboxylic acid;
hydroxybutyric acid | general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oleanolic acid | | hydroxy monocarboxylic acid;
pentacyclic triterpenoid | plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dihydroergotamine | | ergot alkaloid;
semisynthetic derivative | dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| podophyllotoxin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hesperidin | | 3'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside | mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| medroxyprogesterone | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone | contraceptive drug;
progestin;
synthetic oral contraceptive | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| angelicin | | furanocoumarin | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dimenhydrinate | | diarylmethane | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| chlormethiazole | | thiazoles | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| diperodon | | carbamate ester | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| levocarnitine | | carnitine | antilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role) | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfanilylurea | | benzenes;
sulfonamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gentian violet | | organic chloride salt | anthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amitriptyline hydrochloride | | organic tricyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 1-naphthylisothiocyanate | | isothiocyanate | insecticide | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| hematoporphyrin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lithium carbonate | | carbonate salt;
lithium salt | antimanic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactulose | | glycosylfructose | gastrointestinal drug;
laxative | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isoxsuprine hydrochloride | | alkylbenzene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| betaine hydrochloride | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| megestrol acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2010 | 2023 | 8.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| pamabrom | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2008 | 2023 | 11.2 | low | 0 | 0 | 0 | 4 | 1 | 1 |
| 3-hydroxyacetanilide | | acetamides;
phenols | non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methoxyacetic acid | | ether;
monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
human xenobiotic metabolite;
mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| erythromycin stearate | | aminoglycoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin | | cyclic ketone;
erythromycin | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| hydroxychloroquine sulfate | | | | 2013 | 2023 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 1 |
| levonorgestrel | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound | contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| lormetazepam | | 1,4-benzodiazepinone;
organochlorine compound | sedative | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| vinblastine | | | | 2008 | 2010 | 14.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| diphenoxylate | | ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine | antidiarrhoeal drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyproheptadine hydrochloride (anhydrous) | | hydrochloride | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| estradiol valerate | | steroid ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethambutol hydrochloride | | hydrochloride | antitubercular agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethambutol | | ethanolamines;
ethylenediamine derivative | antitubercular agent;
environmental contaminant;
xenobiotic | 2008 | 2023 | 10.0 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| metformin hydrochloride | | hydrochloride | environmental contaminant;
hypoglycemic agent;
xenobiotic | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| antimycin a | | benzamides;
formamides;
macrodiolide;
phenols | antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide | 2013 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| vancomycin | | glycopeptide | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2008 | 2016 | 13.6 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pregnenolone carbonitrile | | aliphatic nitrile | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ibufenac | | monocarboxylic acid | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| metylperon | | aromatic ketone | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| metaxalone | | aromatic ether | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| spectinomycin | | cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2,3,7,8-tetrachlorodibenzodioxine | | polychlorinated dibenzodioxine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5,5'-dimethyl-2,2'-bipyridyl | | bipyridines | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| dichlorobenzyl alcohol | | benzyl alcohols;
dichlorobenzene | antiseptic drug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| paraquat | | organic cation | geroprotector;
herbicide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| orange g | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dronabinol | | benzochromene;
diterpenoid;
phytocannabinoid;
polyketide | cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| amiloride | | aromatic amine;
guanidines;
organochlorine compound;
pyrazines | diuretic;
sodium channel blocker | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| benperidol | | aromatic ketone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexbrompheniramine | | brompheniramine | anti-allergic agent;
H1-receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfadoxine | | pyrimidines;
sulfonamide | antibacterial drug;
antimalarial | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acadesine | | 1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue | antineoplastic agent;
platelet aggregation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlordesmethyldiazepam | | benzodiazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| stavudine | | dihydrofuran;
nucleoside analogue;
organic molecular entity | antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 2008 | 2010 | 14.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| dicloxacillin | | dichlorobenzene;
penicillin | antibacterial drug | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| iproclozide | | aromatic ether | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| megestrol | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| streptomycin | | antibiotic antifungal drug;
antibiotic fungicide;
streptomycins | antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| dideoxyadenosine | | adenosines;
purine 2',3'-dideoxyribonucleoside | EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| clonidine hydrochloride | | dichlorobenzene | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| cladribine | | organochlorine compound;
purine 2'-deoxyribonucleoside | antineoplastic agent;
immunosuppressive agent | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| ethylene dimethanesulfonate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| carbenicillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| carbenicillin disodium | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydroemetine | | aromatic ether;
isoquinolines;
pyridoisoquinoline | antileishmanial agent;
antimalarial;
antiprotozoal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benorilate | | carbonyl compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimetazidine | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metocurine | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| floxacillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| clomacran | | acridines | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| mexiletine hydrochloride | | hydrochloride | anti-arrhythmia drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| beclomethasone dipropionate | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester | anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug | 2008 | 2010 | 14.7 | medium | 0 | 0 | 0 | 3 | 0 | 0 |
| vidarabine | | beta-D-arabinoside;
purine nucleoside | antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic | 2010 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 0 | 1 |
| methenamine hippurate | | N-acylglycine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| olsalazine | | azobenzenes;
dicarboxylic acid | non-steroidal anti-inflammatory drug;
prodrug | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| 3-deazaadenosine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tiadenol | | aliphatic sulfide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terodiline | | diarylmethane | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| 1-(4-carboxyphenyl)-3,3-dimethyltriazene | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metoclopramide hydrochloride | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| etidronate disodium | | organic sodium salt | antineoplastic agent;
bone density conservation agent;
chelator | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zalcitabine | | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2008 | 2023 | 12.0 | low | 0 | 0 | 0 | 5 | 1 | 1 |
| metocurine iodide | | aromatic ether | | 2008 | 2009 | 15.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sodium thiosulfate | | inorganic sodium salt | antidote to cyanide poisoning;
antifungal drug;
nephroprotective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ancitabine | | diol;
organic heterotricyclic compound | antimetabolite;
antineoplastic agent;
prodrug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| stanozolol | | 17beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol | anabolic agent;
androgen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloropyramine | | aminopyridine | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| clodronic acid | | 1,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound | antineoplastic agent;
bone density conservation agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbendazim | | benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester | antifungal agrochemical;
antinematodal drug;
metabolite;
microtubule-destabilising agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| mafenide acetate | | carboxylic acid | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ethionine | | S-ethylhomocysteine | antimetabolite;
carcinogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| apazone | | benzotriazines | non-steroidal anti-inflammatory drug;
uricosuric drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diacerein | | anthraquinone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xipamide | | benzamides | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| selegiline | | selegiline;
terminal acetylenic compound | geroprotector | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| selegiline hydrochloride, (r)-isomer | | hydrochloride;
terminal acetylenic compound | antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levamisole | | 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole | antinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| clemastine | | monochlorobenzenes;
N-alkylpyrrolidine | anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiamphenicol | | monocarboxylic acid amide;
sulfone | antimicrobial agent;
immunosuppressive agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pancuronium bromide | | bromide salt | cholinergic antagonist;
muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pizotyline | | benzocycloheptathiophene | histamine antagonist;
muscarinic antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephalexin | | beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative | antibacterial drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| isosorbide-5-mononitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2008 | 2010 | 14.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| n'-nitrosonornicotine | | pyridines;
pyrrolidines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ornidazole | | C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol | antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| danazol | | 17beta-hydroxy steroid;
terminal acetylenic compound | anti-estrogen;
estrogen antagonist;
geroprotector | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| clonixin | | aminopyridine;
organochlorine compound;
pyridinemonocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
vasodilator agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenclozic acid | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| laxagetten 4,4'-diacetoxydiphenylpyridylemethane | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| daunorubicin | | aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones | antineoplastic agent;
bacterial metabolite | 2010 | 2023 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| cephapirin | | cephalosporin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fludarabine phosphate | | nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate | antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| disopyramide phosphate | | organoammonium phosphate | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| alclofenac | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbimazole | | 1,3-dihydroimidazole-2-thiones;
carbamate ester | antithyroid drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| triamcinolone | | 11beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxyphenisatin | | indoles | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| tetrachloroethylene | | chlorocarbon;
chloroethenes | nephrotoxic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fludrocortisone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid | adrenergic agent;
anti-inflammatory drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ursodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| pregnanolone | | 3-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid | human metabolite;
intravenous anaesthetic;
sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butylated hydroxytoluene | | phenols | antioxidant;
ferroptosis inhibitor;
food additive;
geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| benzonidazole | | C-nitro compound;
imidazoles;
monocarboxylic acid amide | antiprotozoal drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| butachlor | | aromatic amide;
organochlorine compound;
tertiary carboxamide | environmental contaminant;
herbicide;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| du-21220 | | benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rose bengal b disodium salt | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexchlorpheniramine | | chlorphenamine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ribostamycin | | amino cyclitol glycoside;
aminoglycoside antibiotic | antibacterial drug;
antimicrobial agent;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clometacin | | N-acylindole | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefazolin | | beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles | antibacterial drug | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| amoxicillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| timolol | | timolol | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| indoramin | | tryptamines | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nicergoline | | organic heterotetracyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxcarbazepine | | cyclic ketone;
dibenzoazepine | anticonvulsant;
drug allergen | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| carbidopa | | catechols;
hydrazines;
monocarboxylic acid | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2013 | 2016 | 9.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| toloxatone | | oxazolidinone;
primary alcohol;
toluenes | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| moricizine hydrochloride | | hydrochloride | anti-arrhythmia drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| moricizine | | carbamate ester;
morpholines;
phenothiazines | anti-arrhythmia drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amineptin | | amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound | antidepressant;
dopamine uptake inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| zidovudine | | azide;
pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2005 | 2023 | 12.4 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| feprazone | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pirprofen | | pyrroline | | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| sisomicin | | amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| serentil | | organosulfonate salt | dopaminergic antagonist;
first generation antipsychotic | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| amdinocillin | | penicillin | antibacterial drug;
antiinfective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tobramycin | | amino cyclitol glycoside | antibacterial agent;
antimicrobial agent;
toxin | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 2005 | 2016 | 13.8 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| propafenone hydrochloride | | hydrochloride | anti-arrhythmia drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| dobutamine | | catecholamine;
secondary amine | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ticarcillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| trimazosin | | N-arylpiperazine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penbutolol | | ethanolamines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ribavirin | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide | anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| adinazolam | | triazolobenzodiazepine | anticonvulsant;
antidepressant;
anxiolytic drug;
sedative | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| amikacin | | alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide | antibacterial drug;
antimicrobial agent;
nephrotoxin | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tolamolol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbidopa | | catechols;
hydrate;
hydrazines;
monocarboxylic acid | antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| cephradine | | beta-lactam antibiotic allergen;
cephalosporin | antibacterial drug | 2008 | 2016 | 13.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| ticrynafen | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes | antihypertensive agent;
hepatotoxic agent;
loop diuretic | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| methyldopa | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent | 2008 | 2016 | 13.6 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| pyridoxal phosphate | | pyridinecarbaldehyde | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| tocainide | | monocarboxylic acid amide | anti-arrhythmia drug;
local anaesthetic;
sodium channel blocker | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| sulbenicillin | | penicillin | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| sq-11725 | | | | 2008 | 2010 | 14.5 | low | 0 | 0 | 0 | 6 | 0 | 0 |
| diltiazem | | 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| nonachlazine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vecuronium bromide | | organic bromide salt;
quaternary ammonium salt | muscle relaxant;
neuromuscular agent;
nicotinic antagonist | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vecuronium | | acetate ester;
androstane;
quaternary ammonium ion | drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| benoxaprofen | | 1,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes | antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| permethrin | | cyclopropanecarboxylate ester;
cyclopropanes | agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| exifone | | benzophenones | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pirfenidone | | pyridone | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefloquine | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desogestrel | | 17beta-hydroxy steroid;
terminal acetylenic compound | contraceptive drug;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flecainide acetate | | acetate salt | anti-arrhythmia drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| meptazinol | | azepanes | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nicardipine hydrochloride | | dihydropyridine | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| muzolimine | | dichlorobenzene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitazoxanide | | benzamides;
carboxylic ester | | 2013 | 2023 | 6.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| sufentanil | | anilide;
ether;
piperidines;
thiophenes | anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| acarbose | | tetrasaccharide derivative | EC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| torsemide | | aminopyridine;
N-sulfonylurea;
secondary amino compound | antihypertensive agent;
loop diuretic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| medroxalol | | salicylamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| epirubicin | | aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2005 | 2016 | 14.3 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| cefmetazole | | cephalosporin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| desflurane | | organofluorine compound | inhalation anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| indacrinone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| lorcainide | | acetamides | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| idarubicin | | anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ceforanide | | cephalosporin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperacillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| cefoperazone | | cephalosporin | antibacterial drug | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| staurosporine | | indolocarbazole alkaloid;
organic heterooctacyclic compound | apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| foscarnet sodium | | one-carbon compound;
organic sodium salt | antiviral drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oltipraz | | 1,2-dithiole;
pyrazines | angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| atracurium | | diester;
quaternary ammonium ion | muscle relaxant;
nicotinic antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atracurium besylate | | organosulfonate salt;
quaternary ammonium salt | muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| butoconazole nitrate | | aryl sulfide;
conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
organic nitrate salt | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| moxalactam | | cephalosporin;
oxacephem | antibacterial drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| nicorandil | | nitrate ester;
pyridinecarboxamide | potassium channel opener;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| endralazine | | benzamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pergolide | | diamine;
methyl sulfide;
organic heterotetracyclic compound | antiparkinson drug;
dopamine agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pergolide mesylate | | methanesulfonate salt | antiparkinson drug;
dopamine agonist;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefadroxil anhydrous | | cephalosporin | antibacterial drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| encainide | | benzamides;
piperidines | anti-arrhythmia drug;
sodium channel blocker | 2008 | 2010 | 14.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| talniflumate | | benzofurans | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenoldopam mesylate | | benzazepine | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| fiacitabine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fialuridine | | | | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cefaclor anhydrous | | cephalosporin | antibacterial drug;
drug allergen | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pefloxacin | | fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone | antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| mitoxantrone hydrochloride | | hydrochloride | antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| alfentanil | | monocarboxylic acid amide;
piperidines | central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| miglustat | | piperidines;
tertiary amino compound | anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| haloperidol decanoate | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefotetan | | | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| recainam | | | | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 3 | 0 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| flupirtine | | aminopyridine | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| tolrestat | | naphthalenes | EC 1.1.1.21 (aldehyde reductase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| enoximone | | aromatic ketone | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| stepronin | | N-acyl-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piritrexim | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| idazoxan | | benzodioxine;
imidazolines | alpha-adrenergic antagonist | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| remoxipride | | dimethoxybenzene | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| balsalazide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| cabergoline | | N-acylurea | antineoplastic agent;
antiparkinson drug;
dopamine agonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bambuterol | | carbamate ester;
phenylethanolamines | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent | 2008 | 2010 | 14.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| atomoxetine hydrochloride | | hydrochloride | adrenergic uptake inhibitor;
antidepressant | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atomoxetine | | aromatic ether;
secondary amino compound;
toluenes | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic | 2008 | 2022 | 11.9 | medium | 0 | 0 | 0 | 5 | 1 | 1 |
| quinapril | | dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| alpidem | | imidazoles | | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| gepirone | | N-arylpiperazine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mifepristone | | 3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound | abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| amifloxacin | | quinolines | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| trospectomycin | | dioxanes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fosphenytoin | | imidazolidine-2,4-dione | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| salmeterol xinafoate | | naphthoic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ranolazine | | aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| brequinar | | biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| finasteride | | 3-oxo steroid;
aza-steroid;
delta-lactam | androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| imiquimod | | imidazoquinoline | antineoplastic agent;
interferon inducer | 2013 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| sematilide | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| esmolol | | aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| temafloxacin | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| clinafloxacin | | quinolines | | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| sertindole | | heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole | alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adapalene | | adamantanes;
monocarboxylic acid;
naphthoic acid | dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adefovir | | 6-aminopurines;
ether;
phosphonic acids | antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| loxiglumide | | organic molecular entity | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| aromasil | | 17-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sparfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| zileuton | | 1-benzothiophenes;
ureas | anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| clopidogrel | | methyl ester;
monochlorobenzenes;
thienopyridine | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cidofovir anhydrous | | phosphonic acids;
pyrimidone | anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| tiagabine | | beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes | anticonvulsant;
GABA reuptake inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| mibefradil | | tetralins | T-type calcium channel blocker | 2008 | 2010 | 14.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| topotecan | | pyranoindolizinoquinoline | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| bromfenac | | aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| celgosivir | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gemcitabine hydrochloride | | hydrochloride;
organofluorine compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 2008 | 2023 | 10.0 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| ibutilide | | benzenes;
organic amino compound | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| remifentanil | | alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester | intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| atorvastatin calcium anhydrous | | organic calcium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lamivudine | | monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol | allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| duloxetine hydrochloride | | duloxetine hydrochloride | antidepressant | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| duloxetine | | duloxetine | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| valsartan | | biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| ibandronic acid | | | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ziprasidone | | 1,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines | antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| zanamivir | | guanidines | antiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor | 2008 | 2023 | 11.5 | low | 0 | 0 | 0 | 3 | 0 | 1 |
| zolmitriptan | | oxazolidinone;
tryptamines | anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2008 | 2022 | 11.0 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| adefovir dipivoxil | | 6-aminopurines;
carbonate ester;
ether;
organic phosphonate | antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug | 2010 | 2023 | 8.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| emtricitabine | | monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2013 | 2023 | 6.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| tasosartan | | biphenyls | | 2010 | 2016 | 12.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| saquinavir monomethanesulfonate | | organic molecular entity | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| tiludronic acid | | organochlorine compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tirofiban | | L-tyrosine derivative;
piperidines;
sulfonamide | anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| adenosine | | adenosines;
purines D-ribonucleoside | analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| octyl gallate | | gallate ester | food antioxidant;
hypoglycemic agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| allyl formate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| paroxetine hydrochloride | | hydrochloride | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desferrioxamine b mesylate | | methanesulfonate salt | antidote;
ferroptosis inhibitor;
iron chelator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bupropion hydrochloride | | aromatic ketone | | 2010 | 2013 | 13.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| cisatracurium | | diester;
quaternary ammonium ion | muscle relaxant;
nicotinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| halofuginone | | quinazolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diltiazem hydrochloride | | hydrochloride | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trazodone hydrochloride | | hydrochloride | adrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| fosinoprilat | | L-proline derivative;
phosphinic acids | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ortho-cept | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trovafloxacin | | | | 2008 | 2022 | 11.9 | low | 0 | 0 | 0 | 5 | 1 | 1 |
| verapamil hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| cefprozil | | cephalosporin;
semisynthetic derivative | antibacterial drug | 2008 | 2016 | 12.7 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| doxazosin mesylate | | methanesulfonate salt | geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ciprofloxacin hydrochloride anhydrous | | hydrochloride | antibacterial drug;
antiinfective agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| efavirenz | | acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2010 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 2010 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| amantadine hydrochloride | | hydrochloride | antiviral agent;
dopamine agonist;
NMDA receptor antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| doxapram hydrochloride | | hydrochloride | central nervous system stimulant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| mevastatin | | 2-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bupivacaine hydrochloride | | hydrochloride;
racemate | adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenofibric acid | | aromatic ketone;
chlorobenzophenone;
monocarboxylic acid | drug metabolite;
marine xenobiotic metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 1,5-anhydroglucitol | | anhydro sugar | human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betulinic acid | | hydroxy monocarboxylic acid;
pentacyclic triterpenoid | anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| arctigenin | | lignan | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| baicalin | | dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative | antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| plerixafor | | azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound | anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant | 2013 | 2023 | 6.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| amprenavir | | carbamate ester;
sulfonamide;
tetrahydrofuryl ester | antiviral drug;
HIV protease inhibitor | 2010 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| oseltamivir | | acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound | antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| epigallocatechin gallate | | flavans;
gallate ester;
polyphenol | antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | | gallate ester;
galloyl beta-D-glucose | anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cephalotaxine | | benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
cyclic acetal;
enol ether;
organic heteropentacyclic compound;
secondary alcohol;
tertiary amino compound | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| dobutamine hydrochloride | | hydrochloride | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| desipramine hydrochloride | | hydrochloride | drug allergen | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mefloquine hydrochloride | | hydrochloride | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ticlopidine hydrochloride | | hydrochloride | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epirubicin hydrochloride | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| glutathione disulfide | | glutathione derivative;
organic disulfide | Escherichia coli metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iopamidol | | benzenedicarboxamide;
organoiodine compound;
pentol | environmental contaminant;
radioopaque medium;
xenobiotic | 2008 | 2010 | 14.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| sulconazole, mononitrate, (+-)-isomer | | conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| histamine phosphate | | phosphate salt | histamine agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipramine n-oxide | | dibenzooxazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tilbroquinol | | organohalogen compound;
quinolines | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bendamustine | | benzimidazoles | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| erdosteine | | N-acyl-amino acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aloxistatin | | epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide | anticoronaviral agent;
cathepsin B inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| droxicam | | organic heterotricyclic compound;
pyridines | cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| propazole | | benzimidazoles | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ebrotidine | | sulfonamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mizolastine | | benzimidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexloxiglumide | | glutamic acid derivative | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| prulifloxacin | | fluoroquinolone antibiotic;
quinolone antibiotic | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| intoplicine | | pyridoindole | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| pazufloxacin | | quinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| repaglinide | | piperidines | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2023 | 11.2 | low | 0 | 0 | 0 | 6 | 4 | 2 |
| inogatran | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bergenin | | trihydroxybenzoic acid | metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dexfenfluramine | | fenfluramine | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 2-methoxyestradiol | | 17beta-hydroxy steroid;
3-hydroxy steroid | angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethinyl estradiol-17-sulfate | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| trimethobenzamide monohydrochloride | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| amiloride hydrochloride | | hydrate | diuretic;
sodium channel blocker | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| miconazole nitrate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethinylestradiol-3-sulfate | | 17beta-hydroxy steroid;
steroid sulfate | antineoplastic agent;
estrogen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| econazole nitrate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| medetomidine | | imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sertraline | | dichlorobenzene;
secondary amino compound;
tetralins | antidepressant;
serotonin uptake inhibitor | 2010 | 2016 | 12.6 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| lomefloxacin hydrochloride | | hydrochloride | antimicrobial agent;
antitubercular agent;
photosensitizing agent | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| picosulfate sodium | | aryl sulfate;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefcanel | | | | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| zoledronic acid | | 1,1-bis(phosphonic acid);
imidazoles | bone density conservation agent | 2008 | 2023 | 10.2 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| epristeride | | steroid acid | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| talinolol | | ureas | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| artemisinin | | organic peroxide;
sesquiterpene lactone | antimalarial;
plant metabolite | 2013 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| brinzolamide | | sulfonamide;
thienothiazine | antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2013 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| dienogest | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone | progesterone receptor agonist;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flunoxaprofen | | 1,3-benzoxazoles;
monocarboxylic acid;
organofluorine compound | antirheumatic drug;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
protein kinase C agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tianeptine | | dibenzothiazepine;
monocarboxylic acid;
organochlorine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| drospirenone | | 3-oxo-Delta(4) steroid;
steroid lactone | aldosterone antagonist;
contraceptive drug;
progestin | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| artemether | | artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid | antimalarial | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| morphazinamide | | morpholines;
pyrazines;
secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipropylacetamide | | fatty amide | geroprotector;
metabolite;
teratogenic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| denaverine | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acamprosate | | acetamides;
organosulfonic acid | environmental contaminant;
neurotransmitter agent;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isaxonine | | aminopyrimidine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxprenolol hydrochloride | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| diprafenone | | aromatic compound | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nebivolol | | chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound | | 2008 | 2016 | 12.0 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| uk 68798 | | aromatic ether;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
potassium channel blocker | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| ljc 10627 | | carbapenems;
organic sulfide;
pyrazolotriazole | antibacterial drug | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| hp 873 | | 1,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dexrazoxane | | razoxane | antineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| loxapine succinate | | succinate salt | geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| loperamide hydrochloride | | hydrochloride | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| fenoxypropazine | | aromatic ether | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| opipramol hydrochloride | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| betamipron | | organonitrogen compound;
organooxygen compound | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| moroxydine | | biguanides | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bufuralol | | benzofurans | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| uroxatral | | hydrochloride | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aceclofenac | | amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nitrefazole | | imidazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| panipenem | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perindoprilat | | dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclobutyrol | | hydroxy monocarboxylic acid | bile therapy drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| thiocolchicoside | | glycoside | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terlipressin | | polypeptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thioxolone | | benzoxathiole | antiseborrheic | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 7-hydroxystaurosporine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methotrimeprazine | | phenothiazines;
tertiary amine | anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| honokiol | | biphenyls | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| isoflavone | | isoflavones | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| clevudine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nobiletin | | methoxyflavone | antineoplastic agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lycorine | | indolizidine alkaloid | anticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 9-aminocamptothecin | | pyranoindolizinoquinoline | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| leupeptin | | aldehyde;
tripeptide | bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sch 34343 | | | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| grepafloxacin | | fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| squalamine | | bile acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrandrine | | bisbenzylisoquinoline alkaloid;
isoquinolines | | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| doripenem | | carbapenems | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| calpeptin | | amino acid amide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fangchinoline | | aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle | anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| maslinic acid | | dihydroxy monocarboxylic acid;
pentacyclic triterpenoid | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 2-naphthylisothiocyanate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| atovaquone | | hydroxy-1,2-naphthoquinone | | 2005 | 2023 | 12.2 | low | 0 | 0 | 0 | 4 | 1 | 1 |
| rivastigmine | | carbamate ester;
tertiary amino compound | cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| frovatriptan | | carbazoles | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| eletriptan | | indoles;
N-alkylpyrrolidine;
sulfone | non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rosiglitazone | | aminopyridine;
thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| tamiflu | | phosphate salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bexarotene | | benzoic acids;
naphthalenes;
retinoid | antineoplastic agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| s20098 | | acetamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flunisolide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone | anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chloroquine diphosphate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| orphenadrine citrate | | citrate salt | H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| ketorolac tromethamine | | organoammonium salt | analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor | 2010 | 2013 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| clarithromycin | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| loganin | | beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol | anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| n-(3,5-dichlorophenyl)succinimide | | pyrrolidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| moexipril | | peptide | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| phentolamine mesylate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| aucubin | | organic molecular entity | metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| oxybutynin hydrochloride | | hydrochloride | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| catalpol | | organic molecular entity | metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 1-cyano-2-hydroxy-3-butene | | secondary alcohol | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gliquidone | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cordium | | hydrate;
hydrochloride | | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| lekoptin | | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mci 9038 | | peptide | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lopinavir | | amphetamines;
dicarboxylic acid diamide | anticoronaviral agent;
antiviral drug;
HIV protease inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| moxifloxacin hydrochloride | | hydrochloride | antibacterial drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-methyladenosine | | methyladenosine | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mizoribine | | imidazoles | anticoronaviral agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipenem, anhydrous | | beta-lactam antibiotic allergen;
carbapenems;
zwitterion | antibacterial drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sn 38 | | delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol | antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 2010 | 2013 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| bosentan anhydrous | | primary alcohol;
pyrimidines;
sulfonamide | antihypertensive agent;
endothelin receptor antagonist | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| selenomethionine | | amino acid zwitterion;
selenomethionine | plant metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sivelestat | | N-acylglycine;
pivalate ester | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| racecadotril | | N-acyl-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyronaridine | | aminoquinoline | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| geniposide | | terpene glycoside | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| asulacrine | | acridines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroxycotinine | | N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fingolimod | | aminodiol;
primary amino compound | antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| daidzin | | 7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative | plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| quinaprilat | | dicarboxylic acid;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| 2-hydroxyimipramine | | dibenzoazepine | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ecteinascidin 743 | | acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound | alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tadalafil | | benzodioxoles;
pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| norbuprenorphine | | phenanthrenes | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paliperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sophocarpine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nitisinone | | (trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione | EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| plavix | | azaheterocycle sulfate salt;
organoammonium sulfate salt | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| marimastat | | hydroxamic acid;
secondary carboxamide | antineoplastic agent;
matrix metalloproteinase inhibitor | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| clofarabine | | adenosines;
organofluorine compound | antimetabolite;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| elacridar | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pramipexole | | benzothiazoles;
diamine | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| valdecoxib | | isoxazoles;
sulfonamide | antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mitiglinide | | benzenes;
monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ezogabine | | carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline | anticonvulsant;
potassium channel modulator | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| celastrol | | monocarboxylic acid;
pentacyclic triterpenoid | anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| imatinib mesylate | | methanesulfonate salt | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| almotriptan | | indoles;
sulfonamide;
tertiary amine | non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mk 0663 | | bipyridines;
organochlorine compound;
sulfone | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2008 | 2016 | 11.8 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine | | leucine derivative | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | | adenosines;
monocarboxylic acid amide;
organoiodine compound | adenosine A3 receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vadimezan | | monocarboxylic acid;
xanthones | antineoplastic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| e 64 | | dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion | antimalarial;
antiparasitic agent;
protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| desloratadine | | benzocycloheptapyridine | anti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| desvenlafaxine | | cyclohexanols;
phenols;
tertiary amino compound | antidepressant;
drug metabolite;
marine xenobiotic metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| tamsulosin | | 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide | alpha-adrenergic antagonist;
antineoplastic agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| rufinamide | | aromatic amide;
heteroarene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| antiprimod | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulbactam | | penicillanic acids | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| olmesartan medoxomil | | biphenyls | | 2010 | 2021 | 9.0 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| dexpanthenol | | amino alcohol;
monocarboxylic acid amide | cholinergic drug;
provitamin | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| umifenovir | | indolyl carboxylic acid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fosamprenavir | | sulfonamide | prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| safinamide | | amino acid amide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ilomastat | | hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| abiraterone | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines | antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dilevalol | | 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide | | 2008 | 2010 | 15.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| 2-(4-(dimethylamino)benzylidene)malononitrile | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| escitalopram | | 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile | antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lexapro | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 10-propargyl-10-deazaaminopterin | | N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| docetaxel | | hydrate;
secondary alpha-hydroxy ketone | antineoplastic agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| docetaxel anhydrous | | secondary alpha-hydroxy ketone;
tetracyclic diterpenoid | antimalarial;
antineoplastic agent;
photosensitizing agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| irofulven | | cyclohexenones | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atazanavir | | carbohydrazide | antiviral drug;
HIV protease inhibitor | 2010 | 2023 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| ym 872 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nsc-141549 | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| levofloxacin | | 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| ezetimibe | | azetidines;
beta-lactam;
organofluorine compound | anticholesteremic drug;
antilipemic drug;
antimetabolite | 2005 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ertapenem | | carbapenemcarboxylic acid;
pyrrolidinecarboxamide | antibacterial drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dx 8951 | | pyranoindolizinoquinoline | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cox 189 | | amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cilomilast | | methoxybenzenes | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| conivaptan | | benzazepine | aquaretic;
vasopressin receptor antagonist | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cariporide | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tezosentan | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sabarubicin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| vx 497 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pralnacasan | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clevidipine | | dihydropyridine | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| jtt 501 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| solifenacin | | isoquinolines | | 2008 | 2016 | 13.2 | high | 0 | 0 | 0 | 3 | 2 | 0 |
| dexmethylphenidate | | methyl phenyl(piperidin-2-yl)acetate | adrenergic agent | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bcx 1812 | | 3-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines | antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bazedoxifene | | phenylindole | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xamoterol | | morpholines | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| naproxen | | methoxynaphthalene;
monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2005 | 2023 | 11.6 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| cinacalcet | | (trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound | calcimimetic;
P450 inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lubiprostone | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| olmesartan | | biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| telbivudine | | pyrimidine 2'-deoxyribonucleoside | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2013 | 2023 | 6.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| celastrol methyl ester | | carboxylic ester | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| resiquimod | | imidazoquinoline | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cyc 202 | | 2,6-diaminopurines | antiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| abanoquil | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tanshinone ii a | | abietane diterpenoid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| paromomycin | | amino cyclitol glycoside;
aminoglycoside antibiotic | anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| anidulafungin | | antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| avasimibe | | monoterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anacardic acid | | hydroxy monocarboxylic acid;
hydroxybenzoic acid | anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 17 alpha-hydroxyprogesterone caproate | | corticosteroid hormone | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| varenicline | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| biotin | | biotins;
vitamin B7 | coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| fiduxosin | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atropine | | | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| ropivacaine | | piperidinecarboxamide;
ropivacaine | local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| migalastat | | piperidines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| limonin | | epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound | inhibitor;
metabolite;
volatile oil component | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| melagatran | | azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| scutellarin | | glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone | antineoplastic agent;
proteasome inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| aflatoxin b1 | | aflatoxin;
aromatic ether;
aromatic ketone | carcinogenic agent;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| etravirine | | aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound | antiviral agent;
HIV-1 reverse transcriptase inhibitor | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| chelidonine | | alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| troleandomycin | | acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative | EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| 4-n-butylresorcinol | | resorcinols | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dronedarone | | 1-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
environmental contaminant;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tesaglitazar | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| ramelteon | | indanes | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| darunavir | | carbamate ester;
furofuran;
sulfonamide | antiviral drug;
HIV protease inhibitor | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| dapivirine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| deferasirox | | benzoic acids;
monocarboxylic acid;
phenols;
triazoles | iron chelator | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| bms204352 | | | | 2005 | 2013 | 15.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| fosfluconazole | | conazole antifungal drug;
triazole antifungal drug;
triazoles | prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tbc-11251 | | benzodioxoles | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| tolvaptan | | benzazepine;
benzenedicarboxamide | aquaretic;
vasopressin receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lenalidomide | | aromatic amine;
dicarboximide;
isoindoles;
piperidones | angiogenesis inhibitor;
antineoplastic agent;
immunomodulator | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| regadenoson | | purine nucleoside | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lacosamide | | N-acyl-amino acid | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cp 101,606 | | | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sitosterol, (3beta)-isomer | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol | anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fludrocortisone acetate | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
fluorinated steroid;
mineralocorticoid;
tertiary alpha-hydroxy ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| vincaleukoblastine | | acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 5 alpha-androstane-3 beta,17 beta-diol | | 17beta-hydroxy steroid;
3beta-hydroxy steroid;
androstane-3,17-diol | Daphnia magna metabolite;
human metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vincristine sulfate | | organic sulfate salt | antineoplastic agent;
geroprotector | 2010 | 2013 | 13.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| nsc 74859 | | amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester | STAT3 inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| benzarone | | 1-benzofurans | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nsc-89199 | | carbamate ester;
organochlorine compound;
steroid phosphate | | 2008 | 2010 | 15.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| estramustine | | 17beta-hydroxy steroid;
carbamate ester;
organochlorine compound | alkylating agent;
antineoplastic agent;
radiation protective agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenethicillin | | penicillin allergen;
penicillin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| berbamine | | bisbenzylisoquinoline alkaloid;
isoquinolines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| homoharringtonine | | alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acivicin | | isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite | 2008 | 2010 | 14.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| u-104 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| wortmannin | | acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound | anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one | | glycoside | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| o-(chloroacetylcarbamoyl)fumagillol | | carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide | angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bortezomib | | amino acid amide;
L-phenylalanine derivative;
pyrazines | antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor | 2008 | 2023 | 10.0 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 2010 | 2023 | 11.1 | low | 0 | 0 | 0 | 4 | 3 | 1 |
| tizoxanide | | salicylamides | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nexavar | | organosulfonate salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glucosamine | | D-glucosamine | Escherichia coli metabolite;
geroprotector;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| oxytocin | | heterodetic cyclic peptide;
peptide hormone | oxytocic;
vasodilator agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| puromycin | | puromycins | antiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| pentostatin | | coformycins | antimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| taurolithocholic acid | | bile acid taurine conjugate;
monocarboxylic acid amide | human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| (+)-limonene | | limonene | plant metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| arbutin | | beta-D-glucoside;
monosaccharide derivative | Escherichia coli metabolite;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| quinidine | | cinchona alkaloid | alpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| conessine | | steroid alkaloid;
tertiary amino compound | antibacterial agent;
antimalarial;
H3-receptor antagonist;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| meropenem | | alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide | antibacterial agent;
antibacterial drug;
drug allergen | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| griseofulvin | | 1-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound | antibacterial agent;
Penicillium metabolite | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| cefoxitin | | beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative | antibacterial drug | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| digitoxin | | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| moxalactam disodium | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| saquinavir | | L-asparagine derivative;
quinolines | antiviral drug;
HIV protease inhibitor | 2008 | 2023 | 10.7 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| pancuronium | | acetate ester;
steroid ester | cholinergic antagonist;
muscle relaxant;
nicotinic antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rocuronium | | 3alpha-hydroxy steroid;
acetate ester;
androstane;
morpholines;
quaternary ammonium ion;
tertiary amino compound | drug allergen;
muscle relaxant;
neuromuscular agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| abacavir | | 2,6-diaminopurines | antiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 1 | 1 |
| netilmicin | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| trimethaphan camsylate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perindopril erbumine | | addition compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| miglitol | | piperidines | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| mometasone furoate | | 11beta-hydroxy steroid;
2-furoate ester;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
organochlorine compound;
steroid ester | anti-allergic agent;
anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| metyrosine | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rocuronium bromide | | organic bromide salt;
quaternary ammonium salt | muscle relaxant;
neuromuscular agent | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| nortriptyline hydrochloride | | organic tricyclic compound | geroprotector | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| erythromycin estolate | | aminoglycoside sulfate salt;
erythromycin derivative | enzyme inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| kanamycin sulfate | | aminoglycoside sulfate salt | antibacterial drug;
geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| paromomycin sulfate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| linezolid | | acetamides;
morpholines;
organofluorine compound;
oxazolidinone | antibacterial drug;
protein synthesis inhibitor | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| cephaelin | | pyridoisoquinoline | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| (-)-usnic acid | | usnic acid | EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| cyclopamine | | piperidines | glioma-associated oncogene inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetylleucyl-leucyl-norleucinal | | aldehyde;
tripeptide | cysteine protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| devazepide | | 1,4-benzodiazepinone;
indolecarboxamide | antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloramphenicol palmitate | | hexadecanoate ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| clindamycin phosphate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| calcium pantothenate | | polymer | | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| pemirolast potassium salt | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| eplerenone | | 3-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester | aldosterone antagonist;
antihypertensive agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tolterodine | | tertiary amine | antispasmodic drug;
muscarinic antagonist;
muscle relaxant | 2008 | 2022 | 11.5 | medium | 0 | 0 | 0 | 4 | 1 | 1 |
| doxorubicin hydrochloride | | anthracycline | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| erythromycin ethylsuccinate | | cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ao 128 | | organic molecular entity | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| loteprednol etabonate | | 11beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester | anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| darifenacin | | 1-benzofurans;
monocarboxylic acid amide;
pyrrolidines | antispasmodic drug;
muscarinic antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fluticasone propionate | | 11beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester | adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| acarbose | | amino cyclitol;
glycoside | | 2008 | 2010 | 14.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| maleic acid | | butenedioic acid | algal metabolite;
mouse metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| resveratrol | | resveratrol | antioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| retinol | | retinol;
vitamin A | human metabolite;
mouse metabolite;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cyanoginosin lr | | microcystin | bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| alpha-D-fructofuranose 1,6-bisphosphate | | D-fructofuranose 1,6-bisphosphate | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| docosahexaenoate | | docosahexaenoic acid;
omega-3 fatty acid | algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oleic acid | | octadec-9-enoic acid | antioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2005 | 2023 | 12.2 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| cerivastatin | | dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic) | | 2008 | 2010 | 14.5 | low | 0 | 0 | 0 | 6 | 0 | 0 |
| rosuvastatin | | dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide | anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2016 | 13.4 | medium | 0 | 0 | 0 | 4 | 1 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2005 | 2016 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mupirocin | | alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol | antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clindamycin | | | | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| lycopene | | acyclic carotene | antioxidant;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fosfomycin | | epoxide;
phosphonic acids | antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| zithromax | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
xenobiotic | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| drf 2725 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| diethylstilbestrol | | olefinic compound;
polyphenol | antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bms 214662 | | benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| octreotide | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| eptifibatide | | homodetic cyclic peptide;
macrocycle;
organic disulfide | anticoagulant;
platelet aggregation inhibitor | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alitretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| roflumilast | | aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound | anti-asthmatic drug;
phosphodiesterase IV inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| L-cycloserine | | 4-amino-1,2-oxazolidin-3-one | anti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| h 89 | | N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gs 4071 | | acetate ester;
amino acid;
cyclohexenecarboxylic acid;
primary amino compound | antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
marine xenobiotic metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| decitabine | | 2'-deoxyribonucleoside | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| sm 8668 | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| teniposide | | aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2016 | 12.8 | medium | 0 | 0 | 0 | 3 | 2 | 0 |
| troxacitabine | | carbohydrate derivative;
nucleobase-containing molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valrubicin | | anthracycline;
trifluoroacetamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefamandole | | cephalosporin;
semisynthetic derivative | antibacterial drug | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dactinomycin | | actinomycin | mutagen | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| bevirimat | | dicarboxylic acid monoester;
monocarboxylic acid;
pentacyclic triterpenoid | HIV-1 maturation inhibitor;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| azaserine | | carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid | antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| melphalan | | L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| sitafloxacin | | fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic | | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 3 | 0 | 0 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | | amino aldehyde;
carbamate ester;
tripeptide | proteasome inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tenofovir | | nucleoside analogue;
phosphonic acids | antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 2013 | 2023 | 6.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| dibekacin | | kanamycins | antibacterial agent;
protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gw 257406x | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rubitecan | | C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| micafungin | | antibiotic antifungal drug;
echinocandin | antiinfective agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| shikonin | | hydroxy-1,4-naphthoquinone | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide | | tropane alkaloid | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| cmx 001 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amd 8664 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| bay 41-4109 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bay 57-1293 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| riboflavin | | flavin;
vitamin B2 | anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2'-c-methylcytidine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| isoxanthohumol | | flavanones | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sodium bicarbonate | | one-carbon compound;
organic sodium salt | antacid;
food anticaking agent | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sodium acetate, anhydrous | | organic sodium salt | NMR chemical shift reference compound | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium benzoate | | organic sodium salt | algal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arsenic trioxide | | arsenic oxide | antineoplastic agent;
insecticide | 2010 | 2016 | 12.0 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| dipyrone | | organic sodium salt | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ditiocarb sodium | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide | | aromatic ether | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tolfenamic acid | | aminobenzoic acid;
organochlorine compound;
secondary amino compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mecarbinate | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| idarubicin hydrochloride | | anthracycline | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| sr 90107 | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbenoxolone sodium | | triterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| carbenoxolone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meglumine iodipamide | | organoammonium salt | radioopaque medium | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trans-4-coumaric acid | | 4-coumaric acid | food component;
mouse metabolite;
plant metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thyrotropin-releasing hormone | | peptide hormone;
tripeptide | human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| discodermolide | | diterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cannabidiol | | olefinic compound;
phytocannabinoid;
resorcinols | antimicrobial agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine vasopressin | | vasopressin | cardiovascular drug;
hematologic agent;
mitogen | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| s 1033 | | (trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetyl-aspartyl-glutamyl-valyl-aspartal | | tetrapeptide | protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mezlocillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| trilostane | | 17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile | abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tropisetron | | indolyl carboxylic acid | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| leuprolide acetate | | acetate salt | antineoplastic agent;
gonadotropin releasing hormone agonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| leuprolide | | oligopeptide | anti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| octotropine methylbromide | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fludarabine | | purine nucleoside | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propylthiouracil | | pyrimidinethione | antidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| prothionamide | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etomidate | | ethyl ester;
imidazoles | intravenous anaesthetic;
sedative | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mercaptopurine | | aryl thiol;
purines;
thiocarbonyl compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| jrf 12 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ethyl coumarate | | cinnamate ester | | 2019 | 2019 | 5.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| levosulpiride | | sulpiride | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3,4'-dihydroxyflavone | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| caffeic acid | | caffeic acid | geroprotector;
mouse metabolite | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pyrantel | | 1,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes | antinematodal drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-(3,4-dimethoxyphenyl)propenoic acid | | methoxycinnamic acid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| isoferulic acid | | ferulic acids | antioxidant;
biomarker;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cyclouridine | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| cotinine | | N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid | antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| thiothixene | | N-methylpiperazine | anticoronaviral agent | 2010 | 2016 | 12.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| eszopiclone | | zopiclone | central nervous system depressant;
sedative | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 2020 | 2023 | 2.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| benztropine | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methimazole | | 1,3-dihydroimidazole-2-thiones | antithyroid drug | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| cinnarizine | | diarylmethane;
N-alkylpiperazine;
olefinic compound | anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| zucapsaicin | | methoxybenzenes;
phenols | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| terbinafine | | acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| epalrestat | | monocarboxylic acid;
thiazolidines | EC 1.1.1.21 (aldehyde reductase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nbd 556 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| drotaverin | | isoquinolines | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| thioguanine anhydrous | | 2-aminopurines | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2010 | 2023 | 10.2 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| (1R,2S)-tranylcypromine hydrochloride | | hydrochloride | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tacrine hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium propionate | | organic sodium salt | antifungal drug;
food preservative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thioacetamide | | thiocarboxamide | hepatotoxic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| succimer | | dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid | chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 2008 | 2016 | 13.6 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| 4,5,6,7-tetrachloroindan-1,3-dione | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| streptozocin | | | | 2010 | 2016 | 12.5 | medium | 0 | 0 | 0 | 3 | 1 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2005 | 2016 | 13.3 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| ethionamide | | pyridines;
thiocarboxamide | antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| srpin340 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pr-619 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| p5091 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cancidas | | | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fusidic acid | | 11alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester | EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lincomycin | | carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound | antimicrobial agent;
bacterial metabolite | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| valinomycin | | cyclodepsipeptide;
macrocycle | antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiopental | | barbiturates | anticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| trovirdine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| estrone sulfate | | 17-oxo steroid;
steroid sulfate | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ranitidine | | C-nitro compound;
furans;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aplaviroc | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hmr 3647 | | | | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| latoconazole | | conazole antifungal drug;
imidazole antifungal drug | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| maraviroc | | tropane alkaloid | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fti 277 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| toremifene citrate | | stilbenoid | anticoronaviral agent | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| u 0126 | | aryl sulfide;
dinitrile;
enamine;
substituted aniline | antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| vicriviroc | | (trifluoromethyl)benzenes | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| telaprevir | | cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines | antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| nelarabine | | beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside | antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine | | aromatic ether | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 3 | 1 | 0 |
| dermatan sulfate | | amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| droloxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dolasetron | | indolyl carboxylic acid | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| or 1259 | | hydrazone;
nitrile;
pyridazinone | anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| almokalant | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gestodene | | steroid | estrogen | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| orlistat | | beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative | anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor | 2010 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| idoxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinine | | cinchona alkaloid | antimalarial;
muscle relaxant;
non-narcotic analgesic | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| alpha-hydroxytamoxifen | | stilbenoid | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isepamicin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ifetroban | | benzenes;
monocarboxylic acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lamifiban | | N-acylglycine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fospropofol | | alkylbenzene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azilect | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rasagiline | | indanes;
secondary amine;
terminal acetylenic compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2023 | 6.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| zd 6474 | | aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine | antineoplastic agent;
tyrosine kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| telavancin | | glycopeptide | antibacterial drug;
antimicrobial agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| silybin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| yya-021 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| chloramine-t | | organic sodium salt | allergen;
antifouling biocide;
disinfectant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 415286 | | C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline | antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sitagliptin | | triazolopyrazine;
trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| flosequinan | | quinolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tolcapone | | 2-nitrophenols;
benzophenones;
catechols | antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2002 | 2019 | 13.6 | low | 0 | 0 | 0 | 10 | 7 | 0 |
| tak-220 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| jtk-303 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | HIV-1 integrase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nbd 557 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 2008 | 2013 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dinoprostone | | prostaglandins E | human metabolite;
mouse metabolite;
oxytocic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dinoprost | | monocarboxylic acid;
prostaglandins Falpha | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| beta carotene | | carotenoid beta-end derivative;
cyclic carotene | antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| retinol palmitate | | all-trans-retinyl ester;
retinyl palmitate | antioxidant;
Escherichia coli metabolite;
human xenobiotic metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 5'-o-caffeoylquinic acid | | cinnamate ester;
cyclitol carboxylic acid | plant metabolite | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| luteolin-7-glucoside | | beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone | antioxidant;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| alprostadil | | prostaglandins E | anticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cyclosporine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| vitamin d 2 | | hydroxy seco-steroid;
seco-ergostane;
vitamin D | bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cholecalciferol | | D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone | geroprotector;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| harmine | | harmala alkaloid | anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amphotericin b | | antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic | antiamoebic agent;
antiprotozoal drug;
bacterial metabolite | 2010 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| clavulanic acid | | oxapenam | antibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2008 | 2010 | 14.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| pulmicort | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone | anti-inflammatory drug;
bronchodilator agent;
drug allergen | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| oxymetholone | | | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| eprosartan | | dicarboxylic acid;
imidazoles;
thiophenes | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| montelukast | | aliphatic sulfide;
monocarboxylic acid;
quinolines | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist | 2008 | 2016 | 13.6 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| mivacurium | | isoquinolines | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| timolol maleate | | maleate salt | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| brompheniramine maleate | | maleate salt | anti-allergic agent | 2010 | 2013 | 13.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| chlorpheniramine maleate | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| clemastine fumarate | | fumarate salt | anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| dexchlorpheniramine maleate | | organic molecular entity | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| methylergonovine maleate | | ergoline alkaloid | geroprotector | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| hemabate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mycophenolate mofetil | | carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound | anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug | 2010 | 2023 | 8.5 | medium | 0 | 0 | 0 | 1 | 2 | 1 |
| paricalcitol | | hydroxy seco-steroid;
seco-cholestane | antiparathyroid drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| astaxanthine | | carotenol;
carotenone | animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amentoflavone | | biflavonoid;
hydroxyflavone;
ring assembly | angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| baicalein | | trihydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| diosmin | | dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside | anti-inflammatory agent;
antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| genkwanin | | dihydroxyflavone;
monomethoxyflavone | metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hyperoside | | beta-D-galactoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone | hepatoprotective agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mangostin | | aromatic ether;
phenols;
xanthones | antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3-methylquercetin | | 7-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone | anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| kaempferide | | 7-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone | antihypertensive agent;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| orientin | | 3'-hydroxyflavonoid;
C-glycosyl compound;
tetrahydroxyflavone | antioxidant;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| quercetagetin | | flavonols;
hexahydroxyflavone | antioxidant;
antiviral agent;
plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| scutellarein | | tetrahydroxyflavone | metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| trans-2,3',4,5'-tetrahydroxystilbene | | stilbenoid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| polydatin | | beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid | anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| chicoric acid | | organooxygen compound | geroprotector;
HIV-1 integrase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cynarine | | alkyl caffeate ester;
quinic acid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| caffeic acid phenethyl ester | | alkyl caffeate ester | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| acteoside | | catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol | anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| flupenthixol | | flupenthixol | dopaminergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sdz psc 833 | | homodetic cyclic peptide | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| estradiol-17 beta-glucuronide | | 3-hydroxy steroid;
steroid glucosiduronic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| l 660,711 | | quinolines | | 2013 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| travoprost | | (trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha | antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tranilast | | amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide | anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 7432 s | | cephalosporin;
dicarboxylic acid | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipenem | | carbapenems | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| etretinate | | enoate ester;
ethyl ester;
retinoid | keratolytic drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isotretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
teratogenic agent | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| misoprostol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ketotifen fumarate | | organoammonium salt | anti-asthmatic drug;
H1-receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epoprostenol | | prostaglandins I | mouse metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indocyanine green | | 1,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye | | 2008 | 2016 | 12.0 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| dinoprost tromethamine | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ozagrel | | cinnamic acids | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triprolidine | | N-alkylpyrrolidine;
olefinic compound;
pyridines | H1-receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pitavastatin | | cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic) | antioxidant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rosuvastatin calcium | | N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt | anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| terbinafine hydrochloride | | allylamine antifungal drug;
hydrochloride | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cis-flupenthixol dihydrochloride | | hydrochloride | geroprotector | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| ethamolin | | long-chain fatty acid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alatrofloxacin mesylate | | | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| codeine | | morphinane alkaloid;
organic heteropentacyclic compound | antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic | 2005 | 2016 | 14.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| cyclosporine | | homodetic cyclic peptide | anti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite | 2005 | 2016 | 13.9 | low | 0 | 0 | 0 | 7 | 2 | 0 |
| phenoxybenzamine hydrochloride | | organic molecular entity | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| natamycin | | antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic | antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| acitretin | | acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid | keratolytic drug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| dorzolamide | | sulfonamide;
thiophenes | antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dothiepin | | dothiepin | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| estropipate | | piperazinium salt;
steroid sulfate | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydromorphone | | morphinane alkaloid;
organic heteropentacyclic compound | mu-opioid receptor agonist;
opioid analgesic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| levetiracetam | | pyrrolidin-2-ones | anticonvulsant;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ly 163892 | | carbacephem;
zwitterion | antibacterial drug;
antimicrobial agent | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| nabilone | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nalmefene | | morphinane alkaloid | | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| nalorphine | | morphinane alkaloid | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 2005 | 2016 | 13.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| oxycodone | | organic heteropentacyclic compound;
semisynthetic derivative | antitussive;
mu-opioid receptor agonist;
opioid analgesic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| oxymorphone | | morphinane alkaloid | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vitamin k 1 | | phylloquinones;
vitamin K | cofactor;
human metabolite;
plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| topiramate | | cyclic ketal;
ketohexose derivative;
sulfamate ester | anticonvulsant;
sodium channel blocker | 2010 | 2023 | 9.6 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| trospium chloride | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alvocidib | | dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound | antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2005 | 2010 | 16.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| seocalcitol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenretinide | | monocarboxylic acid amide;
retinoid | antineoplastic agent;
antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| geldanamycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound | antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 2005 | 2016 | 14.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| demycarosylturimycin h | | | | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| acipimox | | pyrazinecarboxylic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atosiban | | oligopeptide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzphetamine | | amphetamines;
tertiary amine | adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bimatoprost | | monocarboxylic acid amide | antiglaucoma drug;
antihypertensive agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cicaprost | | monoterpenoid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deamino arginine vasopressin | | heterodetic cyclic peptide | diagnostic agent;
renal agent;
vasopressin receptor agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexmedetomidine | | medetomidine | alpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| goserelin | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzyloxycarbonyl-phe-ala-fluormethylketone | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| iloprost | | carbobicyclic compound;
monocarboxylic acid;
secondary alcohol | platelet aggregation inhibitor;
vasodilator agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| latanoprost | | isopropyl ester;
prostaglandins Falpha;
triol | antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | | carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester | EC 3.4.23.46 (memapsin 2) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nalbuphine | | organic heteropentacyclic compound | mu-opioid receptor antagonist;
opioid analgesic | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| nateglinide | | phenylalanine derivative | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| vinorelbine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid | antineoplastic agent;
photosensitizing agent | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| silodosin | | indolecarboxamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| casticin | | dihydroxyflavone;
tetramethoxyflavone | apoptosis inducer;
plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ethyl caffeate | | alkyl caffeate ester;
ethyl ester;
hydroxycinnamic acid | anti-inflammatory agent;
antineoplastic agent;
metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | | dihydroxyflavone;
monomethoxyflavone | antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside | | beta-D-glucoside;
resorcinols;
stilbenoid | anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| furazolidone | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 3 | 0 | 0 |
| fluvoxamine | | (trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime | antidepressant;
anxiolytic drug;
serotonin uptake inhibitor | 2010 | 2016 | 12.6 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| ag 99 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tyrphostin ag 555 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| semaxinib | | olefinic compound;
oxindoles;
pyrroles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orantinib | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| romidepsin | | cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | dihydroxy monocarboxylic acid;
indoles;
organofluorine compound | | 2008 | 2016 | 12.8 | medium | 0 | 0 | 0 | 4 | 2 | 0 |
| molsidomine | | ethyl ester;
morpholines;
oxadiazole;
zwitterion | antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pd 151746 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| octylmethoxycinnamate | | cinnamate ester | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| levorphanol | | morphinane alkaloid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naltrexone | | cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound | antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic | 2005 | 2016 | 14.2 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| morphine-6-glucuronide | | morphinane alkaloid | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dextromethorphan | | 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene | antitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| butorphanol | | morphinane alkaloid | antitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cefodizime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylnaltrexone | | phenanthrenes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefixime | | cephalosporin | antibacterial drug;
drug allergen | 2008 | 2016 | 13.0 | medium | 0 | 0 | 0 | 4 | 2 | 0 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| benazepril | | benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ramipril | | azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester | bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| verteporfin | | | | 2016 | 2023 | 4.5 | medium | 0 | 0 | 0 | 0 | 1 | 1 |
| batimastat | | hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide | angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| indinavir sulfate | | dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide | HIV protease inhibitor | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| zimeldine | | styrenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enalapril maleate | | maleate salt | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enalapril | | dicarboxylic acid monoester;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vinblastine sulfate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nitrofurazone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trientine hydrochloride | | | | 2010 | 2016 | 12.0 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| n-methylscopolamine bromide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bleomycin | | bleomycin | antineoplastic agent;
metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dextromethorphan hydrobromide | | hydrate;
hydrobromide | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| indinavir sulfate | | azaheterocycle sulfate salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enalaprilat anhydrous | | dicarboxylic acid;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| imidapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulindac sulfone | | monocarboxylic acid;
organofluorine compound;
sulfone | apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| solanesol | | nonaprenol;
primary alcohol | plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pepstatin | | pentapeptide;
secondary carboxamide | bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ximelagatran | | amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cefuroxime | | 3-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether | drug allergen | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ceftriaxone | | 1,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| cefepime | | cephalosporin;
oxime O-ether | antibacterial drug | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| hr 810 | | cephalosporin;
cyclopentapyridine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 685458 | | carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pafuramidine | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ceftazidime | | cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| trandolapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| morphine-3-glucuronide | | morphinane alkaloid | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pregabalin | | gamma-amino acid | anticonvulsant;
calcium channel blocker | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cefetamet | | cephalosporin | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| alvimopan anhydrous | | peptide | | 2013 | 2022 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| aliskiren | | monocarboxylic acid amide;
monomethoxybenzene | antihypertensive agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bms 806 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| guanabenz acetate | | dichlorobenzene | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| famotidine | | 1,3-thiazoles;
guanidines;
sulfonamide | anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2008 | 2016 | 13.1 | medium | 0 | 0 | 0 | 5 | 2 | 0 |
| fenoterol | | hydrobromide | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tulobuterol hydrochloride | | organic molecular entity | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| salubrinal | | aminal;
organochlorine compound;
quinolines;
secondary carboxamide;
thioureas | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cefotaxime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| aztreonam | | beta-lactam antibiotic allergen;
monobactam | antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2008 | 2016 | 13.6 | low | 0 | 0 | 0 | 6 | 1 | 0 |
| benzyl caffeate | | | | 2016 | 2019 | 6.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| proguanil | | biguanides;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cci 15641 | | cephalosporin | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rifamycin sv | | acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins | antimicrobial agent;
antitubercular agent;
bacterial metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ginkgolide b | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| cefpodoxime | | carboxylic acid;
cephalosporin | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| palonosetron | | azabicycloalkane;
delta-lactam;
organic heterotricyclic compound | antiemetic;
serotonergic antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| epoprostenol sodium | | prostanoid | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tenofovir disoproxil fumarate | | fumarate salt | antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefatrizine | | amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles | antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| enclomiphene citrate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| diphenoxylate hydrochloride | | hydrochloride | antidiarrhoeal drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| eniporide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexbrompheniramine maleate | | brompheniramine maleate | anti-allergic agent;
H1-receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cilastatin | | carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide | EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| rifaximin | | acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative | antimicrobial agent;
gastrointestinal drug;
orphan drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| germacrone | | germacrane sesquiterpenoid;
olefinic compound | androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ergonovine maleate | | maleate salt | diagnostic agent;
oxytocic | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| (2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lithospermic acid | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| laq824 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ixabepilone | | 1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle | antineoplastic agent;
microtubule-destabilising agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ekb 569 | | aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile | protein kinase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rilpivirine | | aminopyrimidine;
nitrile | EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| (1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one | | germacranolide | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| 4,5-di-O-caffeoylquinic acid | | quinic acid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| indigo carmine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| azlocillin | | penicillin allergen;
penicillin;
semisynthetic derivative | antibacterial drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| verlukast | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefpodoxime proxetil | | carboxylic acid;
carboxylic ester;
cephalosporin | antibacterial drug;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ceftizoxime | | cephalosporin | antibacterial drug | 2008 | 2016 | 13.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| 1-methyl-d-lysergic acid butanolamide | | ergot alkaloid;
monocarboxylic acid amide | serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carumonam | | monobactam | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluphenazine | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dantrolene sodium | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 3 | 0 | 0 |
| nitrofurantoin | | imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2008 | 2016 | 13.1 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| nifurtimox | | nitrofuran antibiotic | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| eritoran | | lipid As | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dantrolene | | | | 2008 | 2022 | 8.7 | medium | 0 | 0 | 0 | 1 | 1 | 1 |
| roxithromycin | | roxithromycin | environmental contaminant;
xenobiotic | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cefdinir | | cephalosporin;
ketoxime | antibacterial drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| etonogestrel | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound | contraceptive drug;
female contraceptive drug;
progestin | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bisoprolol, fumarate (1:1) salt | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| artesunate | | artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid | antimalarial;
antineoplastic agent;
ferroptosis inducer | 2008 | 2023 | 9.3 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| beraprost | | enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol | anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lanreotide | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| etoposide phosphate | | furonaphthodioxole | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexniguldipine | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ciclesonide | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| napsagatran | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| temsirolimus | | macrolide lactam | | 2008 | 2016 | 11.7 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| dutasteride | | (trifluoromethyl)benzenes;
aza-steroid;
delta-lactam | antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone | | oligopeptide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tekturna | | fumarate salt | antihypertensive agent | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| lu 208075 | | diarylmethane | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bms188797 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| bibx 1382bs | | substituted aniline | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vildagliptin | | amino acid amide | | 2013 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| fesoterodine | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| belinostat | | hydroxamic acid;
olefinic compound;
sulfonamide | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hdac-42 | | amidobenzoic acid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| acetylcarnitine | | O-acetylcarnitine;
saturated fatty acyl-L-carnitine | human metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorhexidine | | biguanides;
monochlorobenzenes | antibacterial agent;
antiinfective agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sgd 301-76 | | conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt | antiinfective agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluvoxamine maleate | | (trifluoromethyl)benzenes | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thioacetazone | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azimilide | | imidazolidine-2,4-dione | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nifurtoinol | | hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| gemifloxacin | | 1,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gs-7340 | | 6-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester | antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 5-hydroxydantrolene | | imidazolidine-2,4-dione | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| dexlansoprazole | | benzimidazoles;
sulfoxide | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| gemifloxacin mesylate | | methanesulfonate salt | antimicrobial agent;
topoisomerase IV inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosinopril | | | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| armodafinil | | 2-[(diphenylmethyl)sulfinyl]acetamide | central nervous system stimulant;
eugeroic | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| iniparib | | carbonyl compound;
organohalogen compound | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pri-2205 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mk 0752 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| eflucimibe | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| givinostat | | carbamate ester | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tomopenem | | | | 2008 | 2009 | 15.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| pd 144418 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| bicyclol | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| midostaurin | | benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound | antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sincalide | | oligopeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tapentadol | | alkylbenzene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nebicapone | | | | 2002 | 2010 | 18.3 | medium | 0 | 0 | 0 | 3 | 0 | 0 |
| etomoxir | | aromatic ether | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ly 450139 | | peptide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ursodoxicoltaurine | | bile acid taurine conjugate | anti-inflammatory agent;
apoptosis inhibitor;
bone density conservation agent;
cardioprotective agent;
human metabolite;
neuroprotective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bb-83698 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| pentagastrin | | organic molecular entity | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fimasartan | | biphenyls | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cefditoren | | carboxylic acid;
cephalosporin | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rivaroxaban | | aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor | 2013 | 2023 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| zotarolimus | | lactam;
macrolide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 3ct compound | | aromatic ether | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| molindone hydrochloride | | indoles | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| ginsenoside rb1 | | ginsenoside;
glycoside;
tetracyclic triterpenoid | anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gentamicin sulfate | | | | 2008 | 2010 | 14.6 | low | 0 | 0 | 0 | 5 | 0 | 0 |
| bn 52020 | | | | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tofacitinib | | N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound | antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rucaparib | | azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- | | organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cetilistat | | benzoxazine | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ym 201636 | | aromatic amide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 5-hydroxyrofecoxib | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| linagliptin | | aminopiperidine;
quinazolines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pazopanib | | aminopyrimidine;
indazoles;
sulfonamide | angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 2013 | 2016 | 9.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| odanacatib | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| prasugrel hydrochloride | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apilimod | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| apixaban | | aromatic ether;
lactam;
piperidones;
pyrazolopyridine | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| betrixaban | | benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| edoxaban | | chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| saracatinib | | aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | | tripeptide;
ureas | antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ly 411575 | | dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| galidesivir | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| PB28 | | aromatic ether;
piperazines;
tetralins | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amg 009 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vinflunine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid | antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefotaxime sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| baci-im | | homodetic cyclic peptide;
polypeptide;
zwitterion | antibacterial agent;
antimicrobial agent | 2010 | 2016 | 12.5 | medium | 0 | 0 | 0 | 3 | 1 | 0 |
| degrasyn | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| epoxomicin | | morpholines;
tripeptide | proteasome inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bms 477118 | | adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| pha 680632 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tmc 353121 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| amd 070 | | aminoquinoline | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| danoprevir | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nystatin a1 | | nystatins | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bms-626529 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bms-663068 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ks370g | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amenamevir | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| vx 765 | | dipeptide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Dihydrotanshinone I | | abietane diterpenoid | anticoronaviral agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| alogliptin | | nitrile;
piperidines;
primary amino compound;
pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fr 180204 | | pyrazoles;
ring assembly | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| quisinostat | | indoles | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| carfilzomib | | epoxide;
morpholines;
tetrapeptide | antineoplastic agent;
proteasome inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hcv 796 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cytidine diphosphate choline | | nucleotide-(amino alcohol)s;
phosphocholines | human metabolite;
mouse metabolite;
neuroprotective agent;
psychotropic drug;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| resminostat | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| milnacipran | | acetamides | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vindesine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zk 756326 | | aromatic ether | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| balapiravir | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| trametinib | | acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| deoxyarbutin | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| abexinostat | | benzofurans | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| losartan potassium | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| silvestrol | | dioxanes;
ether;
methyl ester;
organic heterotricyclic compound | antineoplastic agent;
metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| narlaprevir | | azabicyclohexane;
cyclopropanes;
pyrrolidinecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide;
ureas | anticoronaviral agent;
antiviral drug;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
hepatitis C protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| teneligliptin | | amino acid amide | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| dextrothyroxine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| veliparib | | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| scopolamine hydrobromide | | | | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf 03491390 | | | | 2010 | 2023 | 7.5 | medium | 0 | 0 | 0 | 1 | 0 | 1 |
| alloin | | anthracenes;
C-glycosyl compound;
cyclic ketone;
phenols | laxative;
metabolite | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| rabeprazole sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mdv 3100 | | (trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound | androgen antagonist;
antineoplastic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| amodiaquine hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clindamycin hydrochloride | | S-glycosyl compound | | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| bms-650032 | | oligopeptide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bisaramil | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rg 7128 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bivalirudin | | polypeptide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| somatostatin | | heterodetic cyclic peptide;
peptide hormone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| teicoplanin | | | | 2008 | 2009 | 15.5 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| tannins | | tannin | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enfuvirtide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ganirelix | | polypeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| teriparatide | | polypeptide | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| salmon calcitonin | | heterodetic cyclic peptide;
peptide hormone;
polypeptide | bone density conservation agent;
metabolite | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ly-146032 | | heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide | antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| dalbavancin | | carbohydrate acid derivative;
glycopeptide;
monosaccharide derivative;
semisynthetic derivative | antibacterial drug;
antimicrobial agent | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide | | polypeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oritavancin | | disaccharide derivative;
glycopeptide;
semisynthetic derivative | antibacterial drug;
antimicrobial agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| exenatide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin sodium | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| quinine sulfate | | hydrate | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| pevonedistat | | cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate | antineoplastic agent;
apoptosis inducer | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| uk 453,061 | | aromatic ether | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pravastatin sodium | | organic sodium salt;
statin (semi-synthetic) | anticholesteremic drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alendronate sodium | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| N-(2-aminophenyl)-2-pyrazinecarboxamide | | aromatic amide | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| sl 80.0750 | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cefotiam hydrochloride | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| tegobuvir | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pf-429242 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mesna | | organosulfonic acid | | 2010 | 2021 | 9.0 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| potassium aminobenzoate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| ampicillin sodium | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cerivastatin sodium | | organic sodium salt;
statin (synthetic) | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clavulanate potassium | | potassium salt | antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2013 | 2021 | 7.0 | high | 0 | 0 | 0 | 0 | 1 | 1 |
| sodium lactate | | lactate salt;
organic sodium salt | food acidity regulator;
food preservative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piperacillin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| monensin | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium iothalamate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methicillin sodium | | organic sodium salt | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| nafcillin sodium | | organic sodium salt | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| oxacillin sodium | | organic sodium salt | | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| penicillin g sodium | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| cefamandole nafate | | organic sodium salt | antibacterial drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| sodium diatrizoate | | organic sodium salt;
organoiodine compound | radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephapirin sodium | | cephalosporin;
organic sodium salt | antibacterial drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| sodium cephalothin | | organic sodium salt | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| cefazolin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dicloxacillin sodium | | hydrate | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| azlocillin sodium | | organic sodium salt | | 2010 | 2013 | 13.0 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| olaparib | | cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines | antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cx 4945 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pci 34051 | | indolecarboxamide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lomibuvir | | thiophenecarboxylic acid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| delanzomib | | C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative | antineoplastic agent;
apoptosis inducer;
proteasome inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pitavastatin(1-) | | hydroxy monocarboxylic acid anion | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| GRL-0617 | | benzamides;
naphthalenes;
secondary carboxamide;
substituted aniline | anticoronaviral agent;
protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester | | carbamate ester | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| niraparib | | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| jzl 184 | | benzodioxoles | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gsk 650394 | | phenylpyridine | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| oprozomib | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cetrorelix | | oligopeptide | antineoplastic agent;
GnRH antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| az 960 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| golgicide a | | diastereoisomeric mixture | cis-Golgi ArfGEF GBF inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bms-790052 | | biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative | antiviral drug;
nonstructural protein 5A inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ixazomib | | benzamides;
boronic acids;
dichlorobenzene;
glycine derivative | antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ucph 101 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine | | aryl sulfide;
thienopyrimidine | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| baricitinib | | azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide | anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| KOM70144 | | acetamides;
benzamides;
naphthalenes;
secondary carboxamide | anticoronaviral agent;
protease inhibitor | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| e-52862 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ly2811376 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| anagliptin | | amino acid amide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gardiquimod | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| grazoprevir | | aromatic ether;
azamacrocycle;
carbamate ester;
cyclopropanes;
lactam;
N-sulfonylcarboxamide;
quinoxaline derivative | antiviral drug;
hepatitis C protease inhibitor;
hepatoprotective agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| abt-450 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| letermovir | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sofosbuvir | | isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester | antiviral drug;
hepatitis C protease inhibitor;
prodrug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine | | benzoxazole | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| blz 945 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| azd3839 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| pf 3084014 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| unc 0638 | | quinazolines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gs-9620 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bms 708163 | | oxadiazole;
ring assembly | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| jq1 compound | | carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gsk525762a | | benzodiazepine | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ML240 | | aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound | antineoplastic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| birinapant | | dipeptide | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ly2886721 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| nms-p118 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| tubastatin a | | hydroxamic acid;
pyridoindole;
tertiary amino compound | EC 3.5.1.98 (histone deacetylase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pracinostat | | benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound | antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| spautin-1 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ldn 57444 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gsk1210151a | | imidazoquinoline | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| i-bet726 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| acy-1215 | | pyrimidinecarboxylic acid | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lesinurad | | aryl sulfide;
cyclopropanes;
monocarboxylic acid;
naphthalenes;
organobromine compound;
triazoles | uricosuric drug | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cudc-907 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| raltegravir | | 1,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide | antiviral drug;
HIV-1 integrase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| novobiocin | | carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols | antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| tetracycline | | | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| chlortetracycline | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxytetracycline, anhydrous | | | | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| minocycline | | | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| dicumarol | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piroxicam | | benzothiazine;
monocarboxylic acid amide;
pyridines | analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 12.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| roquinimex | | aromatic amide | | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| acenocoumarol | | C-nitro compound;
hydroxycoumarin;
methyl ketone | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| mobic | | 1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide | analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2008 | 2023 | 11.6 | low | 0 | 0 | 0 | 5 | 2 | 1 |
| mobiflex | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| isoxicam | | benzothiazine;
isoxazoles;
monocarboxylic acid amide | antirheumatic drug;
non-steroidal anti-inflammatory drug | 2008 | 2013 | 14.0 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 2008 | 2016 | 13.5 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| demeclocycline | | | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenprocoumon | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tipranavir | | sulfonamide | antiviral drug;
HIV protease inhibitor | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| chlortetracycline hydrochloride | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| tasquinimod | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rolitetracycline | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sudoxicam | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methacycline monohydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| minocycline hydrochloride | | | | 2010 | 2013 | 13.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| demeclocycline hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tigecycline | | | | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| lornoxicam | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gsk1265744 | | difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide | HIV-1 integrase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| abt-267 | | aromatic amide;
carbamate ester;
dipeptide;
pyrrolidines | antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| abt-333 | | aromatic ether;
naphthalenes;
pyrimidone;
sulfonamide | antiviral drug;
nonnucleoside hepatitis C virus polymerase inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rgfp966 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rg2833 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| pi-1840 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| acy-738 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| pelabresib | | monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide | antineoplastic agent;
bromodomain-containing protein 4 inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gs-5806 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| doravirine | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gn6958 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| vx-787 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ledipasvir | | azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound | antiviral drug;
hepatitis C protease inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| gs-5816 | | carbamate ester;
ether;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heteropentacyclic compound;
ring assembly | antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| g007-lk | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ajmaline | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| selinexor | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| verdinexor | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cb-839 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mk-8742 | | carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly | antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| atglistatin | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| xen445 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| santacruzamate a | | organonitrogen compound;
organooxygen compound | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| fertinex | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ldc4297 | | aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound | antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| enasidenib | | 1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| s 8932 | | aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine | anticoronaviral agent;
antiviral drug;
prodrug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| entecavir | | 2-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2010 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| acyclovir | | 2-aminopurines;
oxopurine | antimetabolite;
antiviral drug | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| nu 1025 | | phenols;
quinazolines | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| inosine | | inosines;
purines D-ribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2010 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 3 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| dacarbazine | | dacarbazine | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| didanosine | | purine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor | 2008 | 2023 | 11.9 | low | 0 | 0 | 0 | 6 | 2 | 1 |
| ganciclovir | | 2-aminopurines;
oxopurine | antiinfective agent;
antiviral drug | 2008 | 2023 | 11.3 | low | 0 | 0 | 0 | 4 | 2 | 1 |
| valtrex | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valacyclovir | | L-valyl ester | antiviral drug | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| sildenafil | | piperazines;
pyrazolopyrimidine;
sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| olanzapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor | 2005 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| penciclovir | | 2-aminopurines;
propane-1,3-diols | antiviral drug | 2008 | 2023 | 12.0 | low | 0 | 0 | 0 | 4 | 0 | 1 |
| oxypurinol | | pyrazolopyrimidine | drug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| raltitrexed | | N-acyl-amino acid | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vardenafil | | imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 2008 | 2016 | 13.2 | medium | 0 | 0 | 0 | 3 | 1 | 0 |
| allopurinol | | nucleobase analogue;
organic heterobicyclic compound | antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger | 2008 | 2016 | 13.2 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| citrovorum factor | | tetrahydrofolic acid | | 2010 | 2016 | 11.8 | high | 0 | 0 | 0 | 2 | 2 | 0 |
| leucovorin | | formyltetrahydrofolic acid | Escherichia coli metabolite;
mouse metabolite | 2008 | 2016 | 13.4 | high | 0 | 0 | 0 | 4 | 1 | 0 |
| rifapentine | | N-alkylpiperazine;
N-iminopiperazine;
rifamycins | antitubercular agent;
leprostatic drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 4-hydroxyquinazoline | | quinazolines | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| alanosine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bl 4162a | | imidazoquinazoline | anticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tegaserod | | carboxamidine;
guanidines;
hydrazines;
indoles | gastrointestinal drug;
serotonergic agonist | 2008 | 2023 | 10.8 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| norclozapine | | dibenzodiazepine;
organochlorine compound;
piperazines | delta-opioid receptor agonist;
metabolite;
serotonergic antagonist | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pemetrexed | | N-acyl-L-glutamic acid;
pyrrolopyrimidine | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor | 2016 | 2023 | 3.7 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| tirapazamine | | aromatic amine;
benzotriazines;
N-oxide | antibacterial agent;
antineoplastic agent;
apoptosis inducer | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sildenafil citrate | | citrate salt | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valganciclovir | | L-valyl ester;
purines | antiviral drug;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles | antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist | 2008 | 2023 | 9.8 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| fosaprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles | antiemetic;
neurokinin-1 receptor antagonist;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tegaserod maleate | | maleate salt | serotonergic agonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ceftobiprole | | cephalosporin;
thiadiazoles | antimicrobial agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rifabutin | | | | 2008 | 2016 | 13.2 | high | 0 | 0 | 0 | 6 | 2 | 0 |
| azilsartan | | 1,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hesperadin | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 6-bromoindirubin-3'-acetoxime | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide | | catechols;
hydrazide;
hydrazone;
naphthols | EC 3.6.5.5 (dynamin GTPase) inhibitor | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| levomefolate calcium | | organic calcium salt | antidepressant | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| XL413 | | benzofuropyrimidine;
organochlorine compound;
pyrrolidines | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| opicapone | | oxadiazole;
ring assembly | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| me0328 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| nvp-tnks656 | | | | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.Journal of medicinal chemistry, , 05-12, Volume: 59, Issue:9, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.Journal of medicinal chemistry, , 05-12, Volume: 59, Issue:9, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.Journal of medicinal chemistry, , 05-12, Volume: 59, Issue:9, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.Journal of medicinal chemistry, , 05-12, Volume: 59, Issue:9, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.Bioorganic & medicinal chemistry letters, , 06-15, Volume: 30, Issue:12, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.Journal of medicinal chemistry, , 08-25, Volume: 59, Issue:16, 2016
Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry.Journal of medicinal chemistry, , 05-26, Volume: 59, Issue:10, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.Journal of medicinal chemistry, , Apr-22, Volume: 53, Issue:8, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase.Journal of medicinal chemistry, , Dec-15, Volume: 48, Issue:25, 2005
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase.Journal of medicinal chemistry, , Dec-02, Volume: 47, Issue:25, 2004
Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.Journal of medicinal chemistry, , Jan-31, Volume: 45, Issue:3, 2002
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:9, 2012
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.Journal of medicinal chemistry, , Apr-22, Volume: 53, Issue:8, 2010
Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase.Journal of medicinal chemistry, , Dec-15, Volume: 48, Issue:25, 2005
Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase.Journal of medicinal chemistry, , Jan-31, Volume: 45, Issue:3, 2002
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.Journal of medicinal chemistry, , 05-12, Volume: 59, Issue:9, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.Journal of medicinal chemistry, , 12-09, Volume: 64, Issue:23, 2021
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.Journal of medicinal chemistry, , 11-10, Volume: 65, Issue:21, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Species independence in brain tissue binding using brain homogenates.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physicochemical determinants of human renal clearance.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| arsenic acid | | arsenic oxoacid | Escherichia coli metabolite | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbamates | | amino-acid anion | | 2000 | 2002 | 22.7 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| catechol | | catechols | allelochemical;
genotoxin;
plant metabolite | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| methane | | alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound | bacterial metabolite;
fossil fuel;
greenhouse gas | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| choline | | cholines | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| chlorine | | halide anion;
monoatomic chlorine | cofactor;
Escherichia coli metabolite;
human metabolite | 2011 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hydrochloric acid | | chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride | mouse metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| octanoic acid | | medium-chain fatty acid;
straight-chain saturated fatty acid | antibacterial agent;
Escherichia coli metabolite;
human metabolite | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| 3,4-dihydroxyphenylacetic acid | | catechols;
dihydroxyphenylacetic acid | human metabolite | 1992 | 2015 | 26.4 | low | 0 | 0 | 8 | 2 | 1 | 0 |
| dihydroxyphenylalanine | | hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative | human metabolite | 1992 | 2016 | 25.3 | low | 2 | 0 | 10 | 2 | 2 | 0 |
| nitrous oxide | | gas molecular entity;
nitrogen oxide | analgesic;
bacterial metabolite;
food packaging gas;
food propellant;
general anaesthetic;
greenhouse gas;
inhalation anaesthetic;
NMDA receptor antagonist;
raising agent;
refrigerant;
vasodilator agent | 2001 | 2007 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 4-nitrophenol | | 4-nitrophenols | human xenobiotic metabolite;
mouse metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| normetanephrine | | catecholamine | | 2004 | 2019 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | | methylpyridines;
phenylpyridine;
tetrahydropyridine | neurotoxin | 1997 | 2007 | 20.8 | low | 0 | 0 | 1 | 4 | 0 | 0 |
| 2,4-dinitrophenol | | dinitrophenol | allergen;
antiseptic drug;
bacterial xenobiotic metabolite;
geroprotector;
oxidative phosphorylation inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-methyl-3,4-methylenedioxyamphetamine | | amphetamines;
benzodioxoles | neurotoxin | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 3-hydroxybenzylhydrazine | | phenols | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-methoxytyramine | | monomethoxybenzene;
phenols;
phenylethylamine;
primary amino compound | biomarker;
human blood serum metabolite;
human urinary metabolite | 1993 | 2016 | 21.7 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| 3-methoxytyrosine | | tyrosine derivative | | 1991 | 2016 | 21.6 | low | 6 | 0 | 8 | 4 | 5 | 0 |
| homovanillic acid | | guaiacols;
monocarboxylic acid | human metabolite;
mouse metabolite | 1992 | 2005 | 29.3 | low | 2 | 0 | 9 | 1 | 0 | 0 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroxyindoleacetic acid | | indole-3-acetic acids | drug metabolite;
human metabolite;
mouse metabolite | 1992 | 2008 | 23.5 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| amantadine | | adamantanes;
primary aliphatic amine | analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic | 1999 | 2020 | 16.8 | low | 2 | 0 | 1 | 8 | 3 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benserazide | | carbohydrazide;
catechols;
primary alcohol;
primary amino compound | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 1997 | 2017 | 13.5 | low | 6 | 0 | 1 | 6 | 6 | 0 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloral hydrate | | aldehyde hydrate;
ethanediol;
organochlorine compound | general anaesthetic;
mouse metabolite;
sedative;
xenobiotic | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| clonazepam | | 1,4-benzodiazepinone;
monochlorobenzenes | anticonvulsant;
anxiolytic drug;
GABA modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| debrisoquin | | carboxamidine;
isoquinolines | adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 1991 | 1995 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| amphetamine | | primary amine | | 1991 | 1993 | 31.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| fluphenazine | | N-alkylpiperazine;
organofluorine compound;
phenothiazines | anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| foscarnet | | carboxylic acid;
one-carbon compound;
phosphonic acids | antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydralazine | | azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines | antihypertensive agent;
vasodilator agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 1996 | 1996 | 28.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 1995 | 1995 | 29.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| mazindol | | organic molecular entity | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mebendazole | | aromatic ketone;
benzimidazoles;
carbamate ester | antinematodal drug;
microtubule-destabilising agent;
tubulin modulator | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mepivacaine | | piperidinecarboxamide | drug allergen;
local anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 1996 | 1998 | 27.0 | low | 1 | 0 | 2 | 0 | 0 | 0 |
| clorgyline | | aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound | antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 1991 | 1993 | 32.0 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| nomifensine | | isoquinolines | dopamine uptake inhibitor | 1991 | 1992 | 32.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| oxidopamine | | benzenetriol;
catecholamine;
primary amino compound | drug metabolite;
human metabolite;
neurotoxin | 2004 | 2016 | 14.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| pargyline | | aromatic amine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piribedil | | N-arylpiperazine | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| propofol | | phenols | anticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ropinirole | | indolones;
tertiary amine | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist | 1997 | 2013 | 19.8 | low | 1 | 0 | 4 | 7 | 2 | 0 |
| talipexole | | azepine | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tolbutamide | | N-sulfonylurea | human metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trihexyphenidyl | | amine | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zonisamide | | 1,2-benzoxazoles;
sulfonamide | anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apomorphine | | aporphine alkaloid | alpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug | 2000 | 2012 | 19.6 | low | 1 | 0 | 1 | 7 | 1 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 1991 | 2023 | 16.4 | low | 82 | 0 | 46 | 122 | 69 | 16 |
| tyrosine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 1991 | 2016 | 21.0 | low | 6 | 0 | 8 | 6 | 5 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan | antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| trifluoroacetic acid | | fluoroalkanoic acid | human xenobiotic metabolite;
NMR chemical shift reference compound;
reagent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-naphthol | | naphthol | genotoxin;
human xenobiotic metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-naphthol | | naphthol | antinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 1991 | 2002 | 27.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| catechin | | catechin | antioxidant;
plant metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isoxazoles | | isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 1997 | 2018 | 21.0 | low | 2 | 0 | 4 | 6 | 1 | 0 |
| ephedrine | | phenethylamine alkaloid;
phenylethanolamines | bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hydrazine | | azane;
hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| caprolactone | | epsilon-lactone | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methoxyhydroxyphenylglycol | | methoxybenzenes;
phenols | | 1994 | 2004 | 24.0 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| 3-hydroxyflavone | | flavonols;
monohydroxyflavone | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apocodeine | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| uridine diphosphate glucuronic acid | | UDP-D-glucuronic acid | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-hydroxypyrene | | pyrenes | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimethaphan | | sulfonium compound | anaesthesia adjuvant;
antihypertensive agent;
nicotinic antagonist;
vasodilator agent | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| silver | | copper group element atom;
elemental silver | Escherichia coli metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hypochlorous acid | | chlorine oxoacid;
reactive oxygen species | EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| selegiline | | selegiline;
terminal acetylenic compound | geroprotector | 1991 | 2019 | 20.7 | low | 2 | 0 | 7 | 4 | 4 | 0 |
| lisuride | | monocarboxylic acid amide | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| stannic oxide | | tin oxide | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| norapomorphine | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 2000 | 2013 | 17.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| zidovudine | | azide;
pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dobutamine | | catecholamine;
secondary amine | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyldopa | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent | 1992 | 2014 | 18.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ethylcholine aziridinium | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| pergolide | | diamine;
methyl sulfide;
organic heterotetracyclic compound | antiparkinson drug;
dopamine agonist | 2000 | 2018 | 16.7 | low | 1 | 0 | 1 | 4 | 2 | 0 |
| cabergoline | | N-acylurea | antineoplastic agent;
antiparkinson drug;
dopamine agonist | 1997 | 2013 | 18.2 | low | 2 | 0 | 2 | 4 | 2 | 0 |
| fosphenytoin | | imidazolidine-2,4-dione | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluorodopa f 18 | | (18)F radiopharmaceutical;
6-fluoro-L-dopa | | 1993 | 2001 | 28.8 | low | 2 | 0 | 7 | 1 | 0 | 0 |
| finasteride | | 3-oxo steroid;
aza-steroid;
delta-lactam | androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glucose, (beta-d)-isomer | | D-glucopyranose | epitope;
mouse metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiazolyl blue | | organic bromide salt | colorimetric reagent;
dye | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epigallocatechin gallate | | flavans;
gallate ester;
polyphenol | antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-methoxyestradiol | | 17beta-hydroxy steroid;
3-hydroxy steroid | angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| fluorodeoxyglucose f18 | | 2-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| budipine | | diarylmethane | | 2003 | 2006 | 19.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| atovaquone | | hydroxy-1,2-naphthoquinone | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3,4-dihydroxyphenylglycol | | catechols;
tetrol | metabolite;
mouse metabolite | 1994 | 2004 | 25.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| homocysteine | | amino acid zwitterion;
homocysteine;
serine family amino acid | fundamental metabolite;
mouse metabolite | 2005 | 2022 | 13.2 | low | 7 | 0 | 0 | 10 | 5 | 2 |
| droxidopa | | catechols;
L-tyrosine derivative | antihypertensive agent;
prodrug;
vasoconstrictor agent | 2011 | 2013 | 12.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| carbidopa, levodopa drug combination | | | | 1995 | 2021 | 13.0 | low | 11 | 0 | 3 | 4 | 12 | 1 |
| vitamin b 6 | | | | 2007 | 2008 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| caprylates | | fatty acid anion 8:0;
straight-chain saturated fatty acid anion | human metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| pramipexole | | benzothiazoles;
diamine | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger | 1997 | 2015 | 18.1 | low | 3 | 0 | 4 | 9 | 5 | 0 |
| peroxynitrous acid | | nitrogen oxoacid | | 2016 | 2021 | 5.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| ro 8-0576 | | | | 2014 | 2015 | 9.3 | low | 2 | 0 | 0 | 0 | 3 | 0 |
| skf 82957 | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| docetaxel anhydrous | | secondary alpha-hydroxy ketone;
tetracyclic diterpenoid | antimalarial;
antineoplastic agent;
photosensitizing agent | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydroxyl radical | | oxygen hydride;
oxygen radical;
reactive oxygen species | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| angiotensin ii | | amino acid zwitterion;
angiotensin II | human metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lignin | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(3-pyridylmethyl)adriamycin | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| dronedarone | | 1-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
environmental contaminant;
xenobiotic | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| acivicin | | isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cysteinylglycine | | dipeptide zwitterion;
dipeptide | Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| linezolid | | acetamides;
morpholines;
organofluorine compound;
oxazolidinone | antibacterial drug;
protein synthesis inhibitor | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosfomycin | | epoxide;
phosphonic acids | antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enkephalin, leucine | | pentapeptide;
peptide zwitterion | analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| stilbenes | | stilbene | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| arginine vasopressin | | vasopressin | cardiovascular drug;
hematologic agent;
mitogen | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| 3,3',4,5'-tetrahydroxystilbene | | catechols;
polyphenol;
resorcinols;
stilbenol | antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benztropine | | diarylmethane | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tat 59 | | aryl phosphate | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rasagiline | | indanes;
secondary amine;
terminal acetylenic compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent | 2005 | 2019 | 13.0 | low | 2 | 0 | 0 | 5 | 5 | 0 |
| sodium dodecyl sulfate | | organic sodium salt | detergent;
protein denaturant | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ro 41-0960 | | | | 1991 | 1996 | 30.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| or486 | | | | 1996 | 2014 | 19.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| tolcapone | | 2-nitrophenols;
benzophenones;
catechols | antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 1992 | 2021 | 19.8 | high | 3 | 0 | 33 | 33 | 18 | 1 |
| nitrocatechol | | | | 2013 | 2014 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bilirubin | | biladienes;
dicarboxylic acid | antioxidant;
human metabolite;
mouse metabolite | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dinoprost | | monocarboxylic acid;
prostaglandins Falpha | human metabolite;
mouse metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| luteolin | | 3'-hydroxyflavonoid;
tetrahydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| scopoletin | | hydroxycoumarin | plant growth regulator;
plant metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| hymecromone | | hydroxycoumarin | antineoplastic agent;
hyaluronic acid synthesis inhibitor | 2005 | 2016 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| esculetin | | hydroxycoumarin | antioxidant;
plant metabolite;
ultraviolet filter | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fisetin | | 3'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone | anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 8-epi-prostaglandin f2alpha | | F2-isoprostane | biomarker;
bronchoconstrictor agent;
vasoconstrictor agent | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| istradefylline | | oxopurine | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isorhapontigenin | | stilbenoid | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rhapontigenin | | stilbenoid | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfur | | chalcogen;
nonmetal atom | macronutrient | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cysteine | | cysteinium | fundamental metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nitecapone | | hydroxycinnamic acid | | 1991 | 2001 | 28.2 | medium | 0 | 0 | 8 | 1 | 0 | 0 |
| ergoline | | diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound | | 1997 | 2013 | 18.2 | low | 2 | 0 | 2 | 4 | 2 | 0 |
| isoborneol | | borneol | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-(2-pyridone-6-yl)-n',n'-di-n-propylformamidine | | pyridone | | 1992 | 1998 | 29.3 | high | 0 | 0 | 7 | 0 | 0 | 0 |
| stalevo | | | | 2004 | 2011 | 18.3 | high | 3 | 0 | 0 | 5 | 1 | 0 |
| nebicapone | | | | 2010 | 2014 | 12.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-synuclein | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxadiazoles | | | | 2014 | 2023 | 5.5 | low | 2 | 0 | 0 | 0 | 7 | 4 |
| scopolamine hydrobromide | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cyanidin-3-o-beta-glucopyranoside | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dynorphins | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| s-adenosylmethionine | | organic cation;
sulfonium compound | coenzyme;
cofactor;
human metabolite;
micronutrient;
Mycoplasma genitalium metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2007 | 2019 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| piperidines | | | | 2003 | 2006 | 19.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| nitrophenols | | | | 1992 | 2017 | 20.9 | low | 3 | 0 | 34 | 33 | 13 | 0 |
| vitamin b 12 | | | | 2005 | 2021 | 15.6 | low | 4 | 0 | 0 | 6 | 0 | 1 |
| myelin oligodendrocyte glycoprotein (35-55) | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| orabase | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| muramidase | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2005 | 2021 | 15.6 | low | 4 | 0 | 0 | 6 | 0 | 1 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanylyl imidodiphosphate | | nucleoside triphosphate analogue | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| opicapone | | oxadiazole;
ring assembly | | 2014 | 2023 | 5.2 | medium | 2 | 0 | 0 | 0 | 7 | 5 |
| carbidopa | | | | 1991 | 2023 | 15.0 | low | 38 | 0 | 16 | 40 | 39 | 8 |
| preproenkephalin | | | | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 2019 Novel Coronavirus Disease | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Abnormal Movements | 0 | | 2001 | 2017 | 14.6 | low | 3 | 0 | 0 | 4 | 3 | 0 |
| Acathisia, Drug-Induced | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Action Tremor | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Acute Brain Injuries | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Kidney Failure | 0 | | 2021 | 2022 | 2.5 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Acute Kidney Injury | 0 | | 2021 | 2022 | 2.5 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Acute Liver Injury, Drug-Induced | 0 | | 2002 | 2018 | 14.4 | low | 0 | 0 | 0 | 9 | 6 | 0 |
| Adult-Onset Dystonias | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Advanced Sleep Phase Syndrome | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Adverse Drug Event | 0 | | 2010 | 2022 | 10.0 | low | 1 | 0 | 0 | 1 | 2 | 1 |
| Affective Psychosis, Bipolar | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Age-Related Macular Degeneration | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Age-Related Memory Disorders | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allergic Encephalomyelitis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allergy, Drug | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Ambulation Disorders, Neurologic | 0 | | 2009 | 2012 | 13.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Amentia | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Amyotonia Congenita | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anasarca | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anoxemia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Antidiuretic Hormone, Inappropriate Secretion | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Apical Ballooning Syndrome | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ataxia of Gait | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Atherosclerotic Parkinsonism | 0 | | 1999 | 2004 | 22.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Aura | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Autonomic Failure, Progressive | 0 | | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Autonomic Failure, Pure | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Autosomal Dominant Juvenile Parkinson Disease | 0 | | 2000 | 2015 | 18.6 | low | 1 | 0 | 1 | 10 | 1 | 0 |
| Behavior Disorders | 0 | | 2001 | 2005 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Bilateral Headache | 0 | | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Bipolar Disorder | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bleb | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Pressure, High | 0 | | 2000 | 2003 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Body Weight | 0 | | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Bradykinesia | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Brain Inflammation | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Injuries | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Break-Bone Fever | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Breast Cancer | 0 | | 2018 | 2019 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Breast Neoplasms | 0 | | 2018 | 2019 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Breathlessness | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Colon | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Esophagus | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cancer of Liver | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Lung | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Prostate | 0 | | 2010 | 2019 | 9.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Cardiac Hypertrophy | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiomegaly | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiovascular Diseases | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Catatonia | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Catatonic Rigidity | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2002 | 2018 | 14.4 | low | 0 | 0 | 0 | 9 | 6 | 0 |
| Chemical and Drug Induced Liver Injury, Chronic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cholera Infantum | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cocaine Abuse | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cocaine-Related Disorders | 1 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cognition Disorders | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colitis, Lymphocytic | 0 | | 2021 | 2023 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 3 |
| Colonic Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Complications, Pregnancy | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cortical Lewy Body Disease | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Daytime Sleepiness | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Delayed Effects, Prenatal Exposure | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Delusional Disorder | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dementia | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Dementia Praecox | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Dengue | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Depression | 0 | | 1995 | 2001 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Depression, Endogenous | 0 | | 1996 | 2001 | 25.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Depressive Disorder | 0 | | 1996 | 2001 | 25.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Dermatitis Medicamentosa | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Developmental Psychomotor Disorders | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Diarrhea | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Exacerbation | 0 | | 1999 | 2014 | 15.0 | low | 1 | 0 | 1 | 3 | 3 | 0 |
| Disease Models, Animal | 0 | | 1995 | 2020 | 15.2 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| Disorders of Excessive Somnolence | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Disruptive, Impulse Control, and Conduct Disorders | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug Hypersensitivity | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Drug Withdrawal Symptoms | 0 | | 1997 | 2001 | 25.0 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Drug-Related Side Effects and Adverse Reactions | 0 | | 2010 | 2022 | 10.0 | low | 1 | 0 | 0 | 1 | 2 | 1 |
| Dysarthosis | 0 | | 2007 | 2011 | 15.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Dyskinesia Syndromes | 0 | | 1997 | 2008 | 21.2 | low | 1 | 0 | 2 | 4 | 0 | 0 |
| Dyskinesia, Drug-Induced | 0 | | 1997 | 2019 | 17.3 | low | 6 | 0 | 4 | 20 | 7 | 0 |
| Dyskinesia, Medication-Induced | 0 | | 1997 | 2019 | 17.3 | low | 6 | 0 | 4 | 20 | 7 | 0 |
| Dyspnea | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dystonia | 0 | | 2006 | 2013 | 14.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Dystonic Disorders | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Edema | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalitis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalitis Lethargica Type Parkinsonism | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalitis, Japanese | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalitis, Japanese B | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalitis, West Nile Fever | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Encephalopathy, Toxic | 0 | | 2005 | 2008 | 17.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Epilepsy | 1 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Esophageal Neoplasms | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Extensively Drug-Resistant Tuberculosis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fever | 0 | | 2008 | 2019 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Foot Diseases | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Frigidity | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Gambling | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Gambling, Pathologic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Gestational Hypertension | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hallucination of Body Sensation | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hallucinations | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Headache | 0 | | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Heart Disease, Ischemic | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hospital-Acquired Condition | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperactivity, Motor | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperhomocysteinemia | 0 | | 2005 | 2021 | 15.0 | low | 4 | 0 | 0 | 8 | 2 | 1 |
| Hypertension | 0 | | 2000 | 2003 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Hypertension, Pregnancy-Induced | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypertension, Pulmonary | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperventilation | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypotension, Orthostatic | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypotension, Postural | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypoxia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Idiopathic Parkinson Disease | 0 | | 1991 | 2023 | 16.7 | high | 80 | 0 | 49 | 123 | 62 | 15 |
| Inappropriate ADH Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Inflammation | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Injury, Ischemia-Reperfusion | 0 | | 2021 | 2022 | 2.3 | low | 0 | 0 | 0 | 0 | 0 | 3 |
| Innate Inflammatory Response | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Kidney Diseases | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukemia L 1210 | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Lewy Body Disease | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Diseases | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Dysfunction | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Neoplasms | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lung Neoplasms | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphocytic Colitis | 0 | | 2021 | 2023 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 3 |
| Macular Degeneration | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Memory Disorders | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Mental Disorders | 0 | | 2001 | 2005 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Movement Disorders | 0 | | 1997 | 2008 | 21.2 | low | 1 | 0 | 2 | 4 | 0 | 0 |
| MPTP Neurotoxicity Syndrome | 0 | | 2005 | 2013 | 16.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| MS (Multiple Sclerosis) | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Sclerosis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple System Atrophy | 0 | | 2005 | 2011 | 16.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Multiple System Atrophy Syndrome | 0 | | 2005 | 2011 | 16.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Muscle Rigidity | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Myocardial Ischemia | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Nausea | 0 | | 2004 | 2014 | 17.5 | low | 1 | 0 | 0 | 3 | 1 | 0 |
| Neuroblastoma | 0 | | 2004 | 2019 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Neuromuscular Diseases | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Parkinson Disease | 1 | | 1991 | 2023 | 16.7 | high | 80 | 0 | 49 | 123 | 62 | 15 |
| Parkinson Disease, Postencephalitic | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Parkinson Disease, Secondary | 0 | | 1999 | 2004 | 22.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Parkinsonian Disorders | 0 | | 2000 | 2015 | 18.6 | low | 1 | 0 | 1 | 10 | 1 | 0 |
| Peripheral Nerve Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Peripheral Nervous System Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Polyneuropathies | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Polyneuropathy, Acquired | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pregnancy | 0 | | 1998 | 2017 | 15.2 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| Prostatic Neoplasms | 0 | | 2010 | 2019 | 9.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Protein Aggregation, Pathological | 0 | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Psychoses | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Psychotic Disorders | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pulmonary Hypertension | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pyrexia | 0 | | 2008 | 2019 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Reperfusion Injury | 0 | | 2021 | 2022 | 2.3 | low | 0 | 0 | 0 | 0 | 0 | 3 |
| Respiratory Tract Diseases | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Restless Leg Syndrome | 0 | | 2002 | 2008 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Restless Legs Syndrome | 0 | | 2002 | 2008 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Schizophrenia | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Sensitivity and Specificity | 0 | | 1996 | 2017 | 19.4 | low | 1 | 0 | 3 | 2 | 2 | 0 |
| Sexual Dysfunctions, Psychological | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sleep Disorders, Circadian Rhythm | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Substance Withdrawal Syndrome | 0 | | 1997 | 2001 | 25.0 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Symptom Cluster | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Syndrome | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Takotsubo Cardiomyopathy | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tauopathies | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tremor | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Tuberculosis, Drug-Resistant | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tuberculosis, Multidrug-Resistant | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Weight Gain | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| West Nile Fever | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
[Parkinson's disease].Presse medicale (Paris, France : 1983), , Mar-03, Volume: 30, Issue:8, 2001
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.Clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 1996
Opicapone for the treatment of Parkinson's disease: an update.Expert opinion on pharmacotherapy, , Volume: 20, Issue:18, 2019
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.The Lancet. Neurology, , Volume: 15, Issue:2, 2016
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.The European journal of neuroscience, , Volume: 37, Issue:5, 2013
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.Clinical neurology and neurosurgery, , Volume: 115, Issue:2, 2013
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.JAMA, , Jun-06, Volume: 307, Issue:21, 2012
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.Annals of neurology, , Volume: 69, Issue:2, 2011
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.European journal of neurology, , Volume: 18 Suppl 1, 2011
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.Annals of neurology, , Volume: 68, Issue:1, 2010
Entacapone.Expert opinion on drug metabolism & toxicology, , Volume: 6, Issue:8, 2010
Continuous dopaminergic therapy in Parkinson disease: time to stride back?Annals of neurology, , Volume: 68, Issue:1, 2010
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.Movement disorders : official journal of the Movement Disorder Society, , Jan-15, Volume: 24, Issue:1, 2009
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.European journal of neurology, , Volume: 15, Issue:7, 2008
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.European journal of neurology, , Volume: 14, Issue:3, 2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.The Annals of pharmacotherapy, , Volume: 41, Issue:11, 2007
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.Experimental neurology, , Volume: 208, Issue:2, 2007
Efficacy and safety of high-dose cabergoline in Parkinson's disease.Acta neurologica Scandinavica, , Volume: 113, Issue:1, 2006
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Expert opinion on pharmacotherapy, , Volume: 7, Issue:10, 2006
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.Geriatrics, , Volume: 61, Issue:9, 2006
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20, Issue:3, 2005
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.Experimental neurology, , Volume: 192, Issue:1, 2005
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.Neurology, , Mar-08, Volume: 64, Issue:5, 2005
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Safety and tolerability of COMT inhibitors.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.Movement disorders : official journal of the Movement Disorder Society, , Volume: 18, Issue:5, 2003
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.European journal of neurology, , Volume: 10, Issue:2, 2003
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.European neurology, , Volume: 46, Issue:1, 2001
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.The European journal of neuroscience, , Volume: 12, Issue:3, 2000
Medical treatment of later-stage motor problems of Parkinson disease.Mayo Clinic proceedings, , Volume: 74, Issue:12, 1999
COMT inhibition in the treatment of Parkinson's disease.Journal of neurology, , Volume: 245, Issue:11 Suppl 3, 1998
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.Annals of neurology, , Volume: 42, Issue:5, 1997
Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.Clinical neuropharmacology, , Volume: 36, Issue:3
Rasagiline for motor complications in Parkinson's disease.Lancet (London, England), , Volume: 365, Issue:9463
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.Lancet (London, England), , Volume: 365, Issue:9463
Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.Clinical neuropharmacology, , Volume: 35, Issue:1
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.European journal of neurology, , Volume: 15, Issue:3, 2008
Novel pharmacological strategies for motor complications in Parkinson's disease.Expert opinion on investigational drugs, , Volume: 14, Issue:4, 2005
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20 Suppl 11, 2005
Entacapone/levodopa/carbidopa combination tablet: Stalevo.Drugs in R&D, , Volume: 4, Issue:5, 2003
What is new in movement disorders?Wiener klinische Wochenschrift, , Sep-17, Volume: 111, Issue:17, 1999
Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.Movement disorders : official journal of the Movement Disorder Society, , Volume: 12, Issue:6, 1997
[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].Neurologia (Barcelona, Spain), , Volume: 14, Issue:7
Pooled analysis of phase III with entacapone in Parkinson's disease.Acta neurologica Scandinavica, , Volume: 130, Issue:4, 2014
Stalevo for Parkinson's disease.The Medical letter on drugs and therapeutics, , May-10, Volume: 46, Issue:1182, 2004
Safety and tolerability of COMT inhibitors.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Levodopa/carbidopa/entacapone (Stalevo).Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Current and novel infusion therapies for patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 130, Issue:11, 2023
Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.European journal of neurology, , Volume: 30, Issue:10, 2023
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 130, Issue:7, 2023
A novel treatment option for intrajejunal levodopa administration.Expert review of neurotherapeutics, , Volume: 23, Issue:1, 2023
Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.European journal of drug metabolism and pharmacokinetics, , Volume: 48, Issue:1, 2023
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease].Ideggyogyaszati szemle, , Nov-30, Volume: 75, Issue:11-12, 2022
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.Cells, , 04-30, Volume: 11, Issue:9, 2022
A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.The international journal of neuropsychopharmacology, , 08-04, Volume: 25, Issue:7, 2022
[78-year-old patient with urine discoloration].Deutsche medizinische Wochenschrift (1946), , Volume: 147, Issue:1-02, 2022
Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 42, Issue:11, 2021
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 88, 2021
Opicapone: A Review in Parkinson's Disease.CNS drugs, , Volume: 35, Issue:1, 2021
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.Parkinsonism & related disorders, , Volume: 91, 2021
Entacapone - Another Parkinson's medication associated with lymphocytic colitis.Parkinsonism & related disorders, , Volume: 91, 2021
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.Scientific reports, , 10-22, Volume: 10, Issue:1, 2020
Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime.Expert opinion on pharmacotherapy, , Volume: 21, Issue:18, 2020
Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.Revista de neurologia, , Jun-12, Volume: 70, Issue:s01, 2020
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 41, Issue:8, 2020
A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.Journal of Parkinson's disease, , Volume: 10, Issue:1, 2020
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.Neuromolecular medicine, , Volume: 21, Issue:3, 2019
Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.Parkinsonism & related disorders, , Volume: 64, 2019
Managing treatment fluctuations in Parkinson disease: "On" again-, "off" again.Neurology, , 03-26, Volume: 92, Issue:13, 2019
Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.European journal of pharmacology, , Mar-15, Volume: 847, 2019
Opicapone for the treatment of Parkinson's disease: an update.Expert opinion on pharmacotherapy, , Volume: 20, Issue:18, 2019
The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.Journal of the neurological sciences, , 09-15, Volume: 392, 2018
Entacapone and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study.Parkinsonism & related disorders, , Volume: 53, 2018
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.Neuromolecular medicine, , Volume: 20, Issue:2, 2018
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.Neurology, , 05-22, Volume: 90, Issue:21, 2018
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.Journal of Parkinson's disease, , Volume: 8, Issue:2, 2018
The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study.Brain and behavior, , Volume: 8, Issue:8, 2018
Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, , Volume: 37, Issue:3, 2017
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.Movement disorders : official journal of the Movement Disorder Society, , Volume: 32, Issue:2, 2017
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.European neurology, , Volume: 78, Issue:3-4, 2017
Novel Levodopa Formulations for Parkinson's Disease.CNS drugs, , Volume: 30, Issue:11, 2016
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?BioMed research international, , Volume: 2016, 2016
Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.Small (Weinheim an der Bergstrasse, Germany), , Volume: 12, Issue:27, 2016
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.The Lancet. Neurology, , Volume: 15, Issue:2, 2016
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.Journal of Parkinson's disease, , Volume: 5, Issue:4, 2015
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 122, Issue:12, 2015
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.European review for medical and pharmacological sciences, , Volume: 19, Issue:11, 2015
Entacapone and prostate cancer risk in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Apr-15, Volume: 30, Issue:5, 2015
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.Parkinsonism & related disorders, , Volume: 20, Issue:12, 2014
Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on.Parkinsonism & related disorders, , Volume: 20, Issue:11, 2014
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:10, 2014
Pooled analysis of phase III with entacapone in Parkinson's disease.Acta neurologica Scandinavica, , Volume: 130, Issue:4, 2014
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.Movement disorders : official journal of the Movement Disorder Society, , Volume: 29, Issue:12, 2014
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.Journal of medicinal chemistry, , Nov-13, Volume: 57, Issue:21, 2014
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.Mayo Clinic proceedings, , Volume: 89, Issue:7, 2014
Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study.PloS one, , Volume: 9, Issue:5, 2014
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, , Mar-10, Volume: 103, Issue:3, 2014
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 121, Issue:11, 2014
Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 121, Issue:6, 2014
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 121, Issue:4, 2014
Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.Neurologia (Barcelona, Spain), , Volume: 29, Issue:3, 2014
Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:1, 2014
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].Zhonghua yi xue za zhi, , Feb-19, Volume: 93, Issue:7, 2013
Anti-Parkinson's disease drugs and pharmacogenetic considerations.Expert opinion on drug metabolism & toxicology, , Volume: 9, Issue:7, 2013
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.Movement disorders : official journal of the Movement Disorder Society, , Volume: 28, Issue:4, 2013
L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.Medical hypotheses, , Volume: 80, Issue:2, 2013
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.Clinical neurology and neurosurgery, , Volume: 115, Issue:2, 2013
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.Neuro endocrinology letters, , Volume: 33, Issue:7, 2012
Drugs for treating Parkinson disease.Nursing, , Volume: 42, Issue:7, 2012
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.JAMA, , Jun-06, Volume: 307, Issue:21, 2012
Finasteride attenuates pathological gambling in patients with Parkinson disease.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Expert review of neurotherapeutics, , Volume: 12, Issue:2, 2012
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.European journal of neurology, , Volume: 19, Issue:6, 2012
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.Hiroshima journal of medical sciences, , Volume: 60, Issue:3, 2011
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.European journal of neurology, , Volume: 18, Issue:12, 2011
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.The International journal of neuroscience, , Volume: 121, Issue:11, 2011
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.Parkinsonism & related disorders, , Volume: 17, Issue:7, 2011
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 383, Issue:6, 2011
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.Annals of neurology, , Volume: 69, Issue:2, 2011
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.Annals of neurology, , Volume: 69, Issue:1, 2011
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.European journal of neurology, , Volume: 18 Suppl 1, 2011
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.CNS drugs, , Volume: 25, Issue:1, 2011
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.Journal of clinical pharmacology, , Volume: 51, Issue:1, 2011
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.International review of neurobiology, , Volume: 95, 2010
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.Nature reviews. Neurology, , Volume: 6, Issue:11, 2010
Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.Parkinsonism & related disorders, , Volume: 16, Issue:10, 2010
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.Clinical drug investigation, , Volume: 30, Issue:11, 2010
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.CNS neuroscience & therapeutics, , Volume: 16, Issue:6, 2010
Isolated delusional syndrome in Parkinson's Disease.Parkinsonism & related disorders, , Volume: 16, Issue:8, 2010
Continuous dopaminergic therapy in Parkinson disease: time to stride back?Annals of neurology, , Volume: 68, Issue:1, 2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.Annals of neurology, , Volume: 68, Issue:1, 2010
Entacapone.Expert opinion on drug metabolism & toxicology, , Volume: 6, Issue:8, 2010
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 31, Issue:5, 2010
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.Current medical research and opinion, , Volume: 26, Issue:7, 2010
The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.Movement disorders : official journal of the Movement Disorder Society, , Feb-15, Volume: 25, Issue:3, 2010
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 117, Issue:3, 2010
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.European journal of neurology, , Volume: 16, Issue:12, 2009
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.Movement disorders : official journal of the Movement Disorder Society, , Jul-15, Volume: 24, Issue:9, 2009
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.European journal of neurology, , Volume: 16, Issue:2, 2009
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Apr-15, Volume: 24, Issue:5, 2009
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Mar-15, Volume: 24, Issue:4, 2009
Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The HoneymoonEuropean neurology, , Volume: 61, Issue:2, 2009
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.Parkinsonism & related disorders, , Volume: 15, Issue:6, 2009
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.Movement disorders : official journal of the Movement Disorder Society, , Jan-15, Volume: 24, Issue:1, 2009
Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.Neurological research, , Volume: 31, Issue:1, 2009
Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.Movement disorders : official journal of the Movement Disorder Society, , Nov-15, Volume: 24, Issue:15, 2009
Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.Clinical drug investigation, , Volume: 29, Issue:10, 2009
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 116, Issue:10, 2009
Levodopa/carbidopa/entacapone in Parkinson's disease.Expert review of neurotherapeutics, , Volume: 9, Issue:7, 2009
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.European journal of neurology, , Volume: 15, Issue:3, 2008
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 115, Issue:6, 2008
[Treatment of Parkinson's disease at present and in the future].Rinsho shinkeigaku = Clinical neurology, , Volume: 48, Issue:11, 2008
Homocysteine in restless legs syndrome.Sleep medicine, , Volume: 9, Issue:4, 2008
Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .Current medical research and opinion, , Volume: 24, Issue:11, 2008
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.Journal of the neurological sciences, , Dec-15, Volume: 275, Issue:1-2, 2008
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.European journal of neurology, , Volume: 15, Issue:7, 2008
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Jul-30, Volume: 23, Issue:10, 2008
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.CNS neuroscience & therapeutics, ,Spring, Volume: 14, Issue:1, 2008
Parkinson disease: an incremental challenge.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 60, Issue:12, 2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.The Annals of pharmacotherapy, , Volume: 41, Issue:11, 2007
Current pharmacotherapeutic treatment options in Parkinson's disease.Disease-a-month : DM, , Volume: 53, Issue:4, 2007
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.European neurology, , Volume: 58, Issue:2, 2007
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:11, 2007
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.Movement disorders : official journal of the Movement Disorder Society, , Aug-15, Volume: 22, Issue:11, 2007
Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.Movement disorders : official journal of the Movement Disorder Society, , Jul-30, Volume: 22, Issue:10, 2007
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.Neurology, , Apr-24, Volume: 68, Issue:17, 2007
Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?Neurology, , Apr-24, Volume: 68, Issue:17, 2007
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.European journal of neurology, , Volume: 14, Issue:3, 2007
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.Movement disorders : official journal of the Movement Disorder Society, , Volume: 22, Issue:1, 2007
Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 22, Issue:1, 2007
Entacapone improves complex movement performance in patients with Parkinson's disease.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 14, Issue:5, 2007
Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.Journal of the American Medical Directors Association, , Volume: 7, Issue:7 Suppl 2, 2006
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:12, 2006
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.Geriatrics, , Volume: 61, Issue:9, 2006
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).Acta neurologica Scandinavica, , Volume: 114, Issue:3, 2006
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Expert opinion on pharmacotherapy, , Volume: 7, Issue:10, 2006
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.Neurology, , Jun-27, Volume: 66, Issue:12, 2006
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 113, Issue:10, 2006
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.Journal of motor behavior, , Volume: 38, Issue:1, 2006
Efficacy and safety of high-dose cabergoline in Parkinson's disease.Acta neurologica Scandinavica, , Volume: 113, Issue:1, 2006
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:3, 2006
Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.Neurology, , Dec-13, Volume: 65, Issue:11, 2005
Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.Journal of mass spectrometry : JMS, , Volume: 40, Issue:12, 2005
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.Parkinsonism & related disorders, , Volume: 11, Issue:6, 2005
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditionalEuropean neurology, , Volume: 53, Issue:4, 2005
Entacapone in the treatment of Parkinson's disease.The Lancet. Neurology, , Volume: 4, Issue:6, 2005
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].Neurologia (Barcelona, Spain), , Volume: 20, Issue:4, 2005
Novel pharmacological strategies for motor complications in Parkinson's disease.Expert opinion on investigational drugs, , Volume: 14, Issue:4, 2005
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.Parkinsonism & related disorders, , Volume: 11, Issue:4, 2005
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20 Suppl 11, 2005
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.Neurology, , Mar-08, Volume: 64, Issue:5, 2005
Improving quality of life in early Parkinson's.Health news (Waltham, Mass.), , Volume: 11, Issue:2, 2005
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.Acta neurologica Scandinavica, , Volume: 111, Issue:1, 2005
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20, Issue:1, 2005
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).Expert review of neurotherapeutics, , Volume: 4, Issue:4, 2004
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.The Cochrane database of systematic reviews, , Oct-18, Issue:4, 2004
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.Archives of neurology, , Volume: 61, Issue:10, 2004
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.European journal of neurology, , Volume: 11, Issue:9, 2004
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.Movement disorders : official journal of the Movement Disorder Society, , Volume: 19, Issue:9, 2004
Clinical advantages of COMT inhibition with entacapone - a review.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:10-11, 2004
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:8, 2004
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 25, Issue:2, 2004
Role of entacapone in later Parkinson's disease not yet established.Journal of neurology, neurosurgery, and psychiatry, , Volume: 75, Issue:7, 2004
[Treatment in Parkinson disease].Orvosi hetilap, , Apr-11, Volume: 145, Issue:15, 2004
Bullous skin eruption associated with entacapone.International journal of dermatology, , Volume: 43, Issue:6, 2004
Stalevo for Parkinson's disease.The Medical letter on drugs and therapeutics, , May-10, Volume: 46, Issue:1182, 2004
[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 104, Issue:1, 2004
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:2, 2004
Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.Current medical research and opinion, , Volume: 20, Issue:1, 2004
The value of post-marketing medication surveys in Parkinson's disease.Current medical research and opinion, , Volume: 20, Issue:1, 2004
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Safety and tolerability of COMT inhibitors.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
The role of COMT inhibition in the treatment of Parkinson's disease.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 24, Issue:3, 2003
The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 24, Issue:3, 2003
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:6, 2003
Entacapone/levodopa/carbidopa combination tablet: Stalevo.Drugs in R&D, , Volume: 4, Issue:5, 2003
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.Expert opinion on drug safety, , Volume: 2, Issue:3, 2003
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:8, 2003
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.Journal of neurology, neurosurgery, and psychiatry, , Volume: 74, Issue:8, 2003
The economic evaluation of pharmacotherapies for Parkinson's disease.Parkinsonism & related disorders, , Volume: 9, Issue:5, 2003
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:3, 2003
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.European journal of neurology, , Volume: 10, Issue:2, 2003
Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.Fundamental & clinical pharmacology, , Volume: 17, Issue:1, 2003
Excessive daytime sleepiness and 'sleep attacks' induced by entacapone.Fundamental & clinical pharmacology, , Volume: 17, Issue:1, 2003
Position of COMT inhibition in the treatment of Parkinson's disease.Advances in neurology, , Volume: 91, 2003
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.Parkinsonism & related disorders, , Volume: 8, Issue:5, 2002
Entacapone-induced hepatotoxicity and hepatic dysfunction.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:6, 2002
[Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome].Der Nervenarzt, , Volume: 73, Issue:8, 2002
COMT inhibitors: management of Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17 Suppl 4, 2002
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.PharmacoEconomics, , Volume: 20, Issue:9, 2002
Entacapone in the management of Parkinson's disease.Expert opinion on pharmacotherapy, , Volume: 3, Issue:7, 2002
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).Acta neurologica Scandinavica, , Volume: 105, Issue:4, 2002
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.Neurology, , Feb-26, Volume: 58, Issue:4, 2002
Twelve-month safety of entacapone in patients with Parkinson's disease.European journal of neurology, , Volume: 8, Issue:1, 2001
Current advances in Parkinson's disease.Trends in neurosciences, , Volume: 24, Issue:7, 2001
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.European neurology, , Volume: 46, Issue:1, 2001
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.Clinical therapeutics, , Volume: 23, Issue:6, 2001
[Parkinson disease. Value of COMT inhibitors is verified].MMW Fortschritte der Medizin, , May-03, Volume: 143, Issue:18, 2001
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.Seminars in neurology, , Volume: 21, Issue:1, 2001
[Parkinson's disease].Presse medicale (Paris, France : 1983), , Mar-03, Volume: 30, Issue:8, 2001
Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 108, Issue:1, 2001
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].Neurologia (Barcelona, Spain), , Volume: 16, Issue:2, 2001
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.European neurology, , Volume: 45, Issue:2, 2001
Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.Synapse (New York, N.Y.), , Volume: 40, Issue:1, 2001
[Dopaminergic agonists in the treatment of Parkinson's disease].Revue medicale de Bruxelles, , Volume: 21, Issue:6, 2000
The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
Practical issues with COMT inhibitors in Parkinson's disease.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
COMT inhibitors and liver toxicity.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
Issues important for rational COMT inhibition.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
Entacapone.The Annals of pharmacotherapy, , Volume: 34, Issue:9, 2000
The role of entacapone in the management of Parkinson's disease.Hospital medicine (London, England : 1998), , Volume: 61, Issue:4, 2000
Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.Journal of the American Geriatrics Society, , Volume: 48, Issue:6, 2000
COMT inhibition in Parkinson's disease: rationale and clinical relevance.Acta neurologica Belgica, , Volume: 100, Issue:1, 2000
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry, , Volume: 68, Issue:5, 2000
[Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].Der Nervenarzt, , Volume: 71, Issue:2, 2000
Entacapone for Parkinson's disease.The Medical letter on drugs and therapeutics, , Jan-24, Volume: 42, Issue:1070, 2000
[Entacapone in the therapy of Parkinson disease].Duodecim; laaketieteellinen aikakauskirja, , Volume: 115, Issue:24, 1999
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.Pharmacotherapy, , Volume: 19, Issue:11 Pt 2, 1999
What is new in movement disorders?Wiener klinische Wochenschrift, , Sep-17, Volume: 111, Issue:17, 1999
Several classes of new drugs emerging for Parkinson disease.JAMA, , Sep-08, Volume: 282, Issue:10, 1999
Entacapone. A review of its use in Parkinson's disease.Drugs, , Volume: 58, Issue:1, 1999
COMT inhibition with entacapone in the treatment of Parkinson's disease.Advances in neurology, , Volume: 80, 1999
[Peripheral COMT-inhibition with Entacapon. Optimal therapy of Parkinson disease].Der Nervenarzt, , Volume: 70, Issue:6 Suppl, 1999
[COMT inhibitors].Medizinische Monatsschrift fur Pharmazeuten, , Volume: 22, Issue:5, 1999
Monoamine oxidase and catechol-O-methyltransferase inhibitors.The Medical clinics of North America, , Volume: 83, Issue:2, 1999
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.Neurology, , Volume: 51, Issue:5, 1998
COMT inhibition in the treatment of Parkinson's disease.Journal of neurology, , Volume: 245, Issue:11 Suppl 3, 1998
Entacapone and motor fluctuations in Parkinson's disease.Annals of neurology, , Volume: 44, Issue:2, 1998
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.Clinical pharmacology and therapeutics, , Volume: 64, Issue:1, 1998
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.Lancet (London, England), , Apr-25, Volume: 351, Issue:9111, 1998
Extending levodopa action: COMT inhibition.Neurology, , Volume: 50, Issue:6 Suppl 6, 1998
COMT inhibition: a new treatment strategy for Parkinson's disease.Neurology, , Volume: 50, Issue:5 Suppl 5, 1998
Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.Advances in pharmacology (San Diego, Calif.), , Volume: 42, 1998
X-ray crystallography of catechol O-methyltransferase: perspectives for target-based drug development.Advances in pharmacology (San Diego, Calif.), , Volume: 42, 1998
Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.Advances in pharmacology (San Diego, Calif.), , Volume: 42, 1998
New options for treatment of Parkinson's disease.Bailliere's clinical neurology, , Volume: 6, Issue:1, 1997
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.Annals of neurology, , Volume: 42, Issue:5, 1997
New pharmacotherapy for Parkinson's disease.The Annals of pharmacotherapy, , Volume: 31, Issue:10, 1997
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 12, Issue:4, 1997
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.Clinical neuropharmacology, , Volume: 19, Issue:4, 1996
Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, , Volume: 16, Issue:5, 1996
Validation of assay of catechol-O-methyltransferase activity in human erythrocytes.Journal of pharmaceutical and biomedical analysis, , Volume: 14, Issue:5, 1996
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.Clinical neuropharmacology, , Volume: 19, Issue:3, 1996
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.Clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 1996
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.Journal of neurology, neurosurgery, and psychiatry, , Volume: 60, Issue:1, 1996
Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.Journal of neural transmission. Parkinson's disease and dementia section, , Volume: 10, Issue:2-3, 1995
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.Neurology, , Volume: 44, Issue:1, 1994
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.Neurology, , Volume: 44, Issue:5, 1994
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry, , Volume: 57, Issue:2, 1994
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.Neurology, , Volume: 44, Issue:7, 1994
Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.Movement disorders : official journal of the Movement Disorder Society, , Volume: 8, Issue:3, 1993
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.European journal of clinical pharmacology, , Volume: 45, Issue:5, 1993
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.Clinical neuropharmacology, , Volume: 14, Issue:4, 1991
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.Clinical neuropharmacology, , Volume: 31, Issue:1
The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.Clinical neuropharmacology, , Volume: 31, Issue:5
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.Clinical neuropharmacology, , Volume: 29, Issue:3
Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.Clinical neuropharmacology, , Volume: 29, Issue:2
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.Clinical neuropharmacology, , Volume: 29, Issue:2
Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.Clinical neuropharmacology, , Volume: 31, Issue:3
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.Clinical neuropharmacology, , Volume: 28, Issue:3
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.Lancet (London, England), , Volume: 365, Issue:9463
Rasagiline for motor complications in Parkinson's disease.Lancet (London, England), , Volume: 365, Issue:9463
Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease.Clinical neuropharmacology, , Volume: 27, Issue:3
Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.Clinical neuropharmacology, , Volume: 36, Issue:3
A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.Clinical neuropharmacology, , Volume: 35, Issue:4
Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.Clinical neuropharmacology, , Volume: 35, Issue:1
Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 4, Issue:4
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.Clinical neuropharmacology, , Volume: 24, Issue:5
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.Clinical neuropharmacology, , Volume: 24, Issue:3
The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.Clinical neuropharmacology, , Volume: 24, Issue:1
Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone.Neurology India, , Volume: 65, Issue:4
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.Journal of medical economics, , Volume: 24, Issue:1
Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.Clinical neuropharmacology, , Volume: 34, Issue:1
[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].Neurologia (Barcelona, Spain), , Volume: 14, Issue:7
[Recent advances in Parkinson disease].Revista de neurologia, , Volume: 29, Issue:2
[Entacapone: is it useful as complimentary treatment with levodopa?].Revista de neurologia, , Volume: 28, Issue:8
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Medical treatment of later-stage motor problems of Parkinson disease.Mayo Clinic proceedings, , Volume: 74, Issue:12, 1999
Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, , Volume: 37, Issue:3, 2017
Endothelial dysfunction in gestational hypertension induced by catechol-O-methyltransferase inhibition.Experimental physiology, , Volume: 98, Issue:3, 2013
Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.Movement disorders : official journal of the Movement Disorder Society, , Jul-30, Volume: 22, Issue:10, 2007
Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.Advances in pharmacology (San Diego, Calif.), , Volume: 42, 1998
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.Molecular and cellular endocrinology, , 05-15, Volume: 488, 2019
Entacapone and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study.Parkinsonism & related disorders, , Volume: 53, 2018
Entacapone and prostate cancer risk in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Apr-15, Volume: 30, Issue:5, 2015
Entacapone: prostate cancer?Prescrire international, , Volume: 19, Issue:109, 2010
Continuous dopaminergic therapy in Parkinson disease: time to stride back?Annals of neurology, , Volume: 68, Issue:1, 2010
Homocysteine in restless legs syndrome.Sleep medicine, , Volume: 9, Issue:4, 2008
Entacapone in restless legs syndrome.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:2, 2002
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.Clinical neuropharmacology, , Volume: 30, Issue:6
Micelle-enhanced spectrofluorimetric method for quantification of entacapone in tablets and human plasma.Luminescence : the journal of biological and chemical luminescence, , Volume: 32, Issue:5, 2017
Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.Journal of pharmaceutical and biomedical analysis, , Apr-15, Volume: 77, 2013
LC determination of entacapone in tablets: in vitro dissolution studies.Journal of chromatographic science, , Volume: 48, Issue:9, 2010
Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry.Journal of chromatography. B, Biomedical sciences and applications, , Aug-15, Volume: 759, Issue:2, 2001
Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine.Journal of chromatography. A, , Mar-19, Volume: 836, Issue:1, 1999
Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, , Volume: 16, Issue:5, 1996
Validation of assay of catechol-O-methyltransferase activity in human erythrocytes.Journal of pharmaceutical and biomedical analysis, , Volume: 14, Issue:5, 1996
Entacapone alleviates acute kidney injury by inhibiting ferroptosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 36, Issue:7, 2022
The potential protective effects of estradiol and 2-methoxyestradiol in ischemia reperfusion-induced kidney injury in ovariectomized female rats.Life sciences, , May-01, Volume: 296, 2022
Entacapone scavenges peroxynitrite and protects against kidney and liver injuries induced by renal ischemia/reperfusion in rats.International urology and nephrology, , Volume: 53, Issue:8, 2021
Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.World journal of gastroenterology, , Mar-28, Volume: 21, Issue:12, 2015
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.Brain research, , Jan-14, Volume: 1309, 2010
Long-term retention rate of entacapone in the treatment of Parkinson's disease.European journal of neurology, , Volume: 15, Issue:4, 2008
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.Neurobiology of disease, , Volume: 32, Issue:3, 2008
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:5, 2006
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.Experimental neurology, , Volume: 192, Issue:1, 2005
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].Neurologia (Barcelona, Spain), , Volume: 20, Issue:4, 2005
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.Movement disorders : official journal of the Movement Disorder Society, , Volume: 18, Issue:5, 2003
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
[Parkinson's disease].Presse medicale (Paris, France : 1983), , Mar-03, Volume: 30, Issue:8, 2001
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 108, Issue:2, 2001
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
[no title available]CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , 01-23, Volume: 195, Issue:3, 2023
Lymphocytic colitis associated with entacapone.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , 10-17, Volume: 194, Issue:40, 2022
Entacapone - Another Parkinson's medication associated with lymphocytic colitis.Parkinsonism & related disorders, , Volume: 91, 2021
[Entocapone-related lymphocytic colitis].Gastroenterologie clinique et biologique, , Volume: 32, Issue:8-9
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.Toxicological sciences : an official journal of the Society of Toxicology, , 02-01, Volume: 161, Issue:2, 2018
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.Toxicologic pathology, , Volume: 40, Issue:6, 2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Identification and categorization of liver toxicity markers induced by a related pair of drugs.International journal of molecular sciences, , Volume: 12, Issue:7, 2011
Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 113, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
The liver toxicity biomarker study: phase I design and preliminary results.Toxicologic pathology, , Volume: 37, Issue:1, 2009
Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.Neurology, , Dec-13, Volume: 65, Issue:11, 2005
Assessment of catechol induction and glucuronidation in rat liver microsomes.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 32, Issue:12, 2004
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.Expert opinion on drug safety, , Volume: 2, Issue:3, 2003
Entacapone-induced hepatotoxicity and hepatic dysfunction.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:6, 2002
A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.Clinical neuropharmacology, , Volume: 35, Issue:4
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
[78-year-old patient with urine discoloration].Deutsche medizinische Wochenschrift (1946), , Volume: 147, Issue:1-02, 2022
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 117, Issue:3, 2010
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:10, 2014
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.JAMA, , Jun-06, Volume: 307, Issue:21, 2012
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.Hiroshima journal of medical sciences, , Volume: 60, Issue:3, 2011
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.Clinical drug investigation, , Volume: 30, Issue:11, 2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.Annals of neurology, , Volume: 68, Issue:1, 2010
Parkinson disease: an incremental challenge.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 60, Issue:12, 2007
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.Pharmacotherapy, , Volume: 19, Issue:11 Pt 2, 1999
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 88, 2021
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?BioMed research international, , Volume: 2016, 2016
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.Movement disorders : official journal of the Movement Disorder Society, , Volume: 29, Issue:12, 2014
Homocysteine in restless legs syndrome.Sleep medicine, , Volume: 9, Issue:4, 2008
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.Neurology, , Apr-24, Volume: 68, Issue:17, 2007
Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.Parkinsonism & related disorders, , Volume: 13, Issue:8, 2007
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.Neurology, , Jun-27, Volume: 66, Issue:12, 2006
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].Neurologia (Barcelona, Spain), , Volume: 20, Issue:4, 2005
The effect of entacapone on homocysteine levels in Parkinson disease.Neurology, , Apr-26, Volume: 64, Issue:8, 2005
The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 112, Issue:9, 2005
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.Parkinsonism & related disorders, , Volume: 11, Issue:4, 2005
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.JAMA, , Jun-06, Volume: 307, Issue:21, 2012
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Apr-15, Volume: 24, Issue:5, 2009
The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.Psychopharmacology, , Volume: 197, Issue:2, 2008
On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.Neuropharmacology, , Volume: 54, Issue:5, 2008
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.Neurology, , Mar-08, Volume: 64, Issue:5, 2005
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.The European journal of neuroscience, , Volume: 37, Issue:5, 2013
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].Neurologia (Barcelona, Spain), , Volume: 20, Issue:4, 2005
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20, Issue:3, 2005
Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.World journal of gastroenterology, , Mar-28, Volume: 21, Issue:12, 2015
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.Brain research, , Jan-14, Volume: 1309, 2010
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.Neurobiology of disease, , Volume: 32, Issue:3, 2008
Long-term retention rate of entacapone in the treatment of Parkinson's disease.European journal of neurology, , Volume: 15, Issue:4, 2008
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:5, 2006
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].Neurologia (Barcelona, Spain), , Volume: 20, Issue:4, 2005
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.Experimental neurology, , Volume: 192, Issue:1, 2005
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.Movement disorders : official journal of the Movement Disorder Society, , Volume: 18, Issue:5, 2003
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
[Parkinson's disease].Presse medicale (Paris, France : 1983), , Mar-03, Volume: 30, Issue:8, 2001
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 108, Issue:2, 2001
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.European neurology, , Volume: 78, Issue:3-4, 2017
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, , Mar-10, Volume: 103, Issue:3, 2014
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.Parkinsonism & related disorders, , Volume: 17, Issue:7, 2011
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 117, Issue:3, 2010
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.Movement disorders : official journal of the Movement Disorder Society, , Aug-15, Volume: 22, Issue:11, 2007
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:5, 2006
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].Neurologia (Barcelona, Spain), , Volume: 16, Issue:2, 2001
[no title available]CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , 01-23, Volume: 195, Issue:3, 2023
Lymphocytic colitis associated with entacapone.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , 10-17, Volume: 194, Issue:40, 2022
Entacapone - Another Parkinson's medication associated with lymphocytic colitis.Parkinsonism & related disorders, , Volume: 91, 2021
[Entocapone-related lymphocytic colitis].Gastroenterologie clinique et biologique, , Volume: 32, Issue:8-9
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.Toxicological sciences : an official journal of the Society of Toxicology, , 02-01, Volume: 161, Issue:2, 2018
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.Toxicologic pathology, , Volume: 40, Issue:6, 2012
Identification and categorization of liver toxicity markers induced by a related pair of drugs.International journal of molecular sciences, , Volume: 12, Issue:7, 2011
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 113, Issue:1, 2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010
Developing structure-activity relationships for the prediction of hepatotoxicity.Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
The liver toxicity biomarker study: phase I design and preliminary results.Toxicologic pathology, , Volume: 37, Issue:1, 2009
Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.Neurology, , Dec-13, Volume: 65, Issue:11, 2005
Assessment of catechol induction and glucuronidation in rat liver microsomes.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 32, Issue:12, 2004
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.Expert opinion on drug safety, , Volume: 2, Issue:3, 2003
Entacapone-induced hepatotoxicity and hepatic dysfunction.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:6, 2002
A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.Clinical neuropharmacology, , Volume: 35, Issue:4
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
[78-year-old patient with urine discoloration].Deutsche medizinische Wochenschrift (1946), , Volume: 147, Issue:1-02, 2022
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 117, Issue:3, 2010
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
[Parkinson's disease].Presse medicale (Paris, France : 1983), , Mar-03, Volume: 30, Issue:8, 2001
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.Clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 1996
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.Toxicological sciences : an official journal of the Society of Toxicology, , 02-01, Volume: 161, Issue:2, 2018
Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.World journal of gastroenterology, , Mar-28, Volume: 21, Issue:12, 2015
The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis.Journal of neuroimmunology, , Nov-15, Volume: 276, Issue:1-2, 2014
On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.Neuropharmacology, , Volume: 54, Issue:5, 2008
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:5, 2006
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.Experimental neurology, , Volume: 192, Issue:1, 2005
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Entacapone protects from angiotensin II-induced inflammation and renal injury.Journal of hypertension, , Volume: 21, Issue:12, 2003
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.European journal of pharmacology, , Feb-14, Volume: 274, Issue:1-3, 1995
Establishing the probable mechanism of L-DOPA in Alzheimer's disease management.Acta poloniae pharmaceutica, , Volume: 66, Issue:5
Opicapone for the treatment of Parkinson's disease: an update.Expert opinion on pharmacotherapy, , Volume: 20, Issue:18, 2019
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.The Lancet. Neurology, , Volume: 15, Issue:2, 2016
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.Clinical neurology and neurosurgery, , Volume: 115, Issue:2, 2013
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.The European journal of neuroscience, , Volume: 37, Issue:5, 2013
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.JAMA, , Jun-06, Volume: 307, Issue:21, 2012
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.Annals of neurology, , Volume: 69, Issue:2, 2011
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.European journal of neurology, , Volume: 18 Suppl 1, 2011
Continuous dopaminergic therapy in Parkinson disease: time to stride back?Annals of neurology, , Volume: 68, Issue:1, 2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.Annals of neurology, , Volume: 68, Issue:1, 2010
Entacapone.Expert opinion on drug metabolism & toxicology, , Volume: 6, Issue:8, 2010
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.Movement disorders : official journal of the Movement Disorder Society, , Jan-15, Volume: 24, Issue:1, 2009
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.European journal of neurology, , Volume: 15, Issue:7, 2008
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.Experimental neurology, , Volume: 208, Issue:2, 2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.The Annals of pharmacotherapy, , Volume: 41, Issue:11, 2007
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.European journal of neurology, , Volume: 14, Issue:3, 2007
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.Geriatrics, , Volume: 61, Issue:9, 2006
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Expert opinion on pharmacotherapy, , Volume: 7, Issue:10, 2006
Efficacy and safety of high-dose cabergoline in Parkinson's disease.Acta neurologica Scandinavica, , Volume: 113, Issue:1, 2006
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.Neurology, , Mar-08, Volume: 64, Issue:5, 2005
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.Experimental neurology, , Volume: 192, Issue:1, 2005
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20, Issue:3, 2005
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Safety and tolerability of COMT inhibitors.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.Movement disorders : official journal of the Movement Disorder Society, , Volume: 18, Issue:5, 2003
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.European journal of neurology, , Volume: 10, Issue:2, 2003
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.European neurology, , Volume: 46, Issue:1, 2001
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.The European journal of neuroscience, , Volume: 12, Issue:3, 2000
Medical treatment of later-stage motor problems of Parkinson disease.Mayo Clinic proceedings, , Volume: 74, Issue:12, 1999
COMT inhibition in the treatment of Parkinson's disease.Journal of neurology, , Volume: 245, Issue:11 Suppl 3, 1998
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.Annals of neurology, , Volume: 42, Issue:5, 1997
Rasagiline for motor complications in Parkinson's disease.Lancet (London, England), , Volume: 365, Issue:9463
Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.Clinical neuropharmacology, , Volume: 36, Issue:3
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.Lancet (London, England), , Volume: 365, Issue:9463
Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.Clinical neuropharmacology, , Volume: 35, Issue:1
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.European journal of neurology, , Volume: 15, Issue:3, 2008
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20 Suppl 11, 2005
Novel pharmacological strategies for motor complications in Parkinson's disease.Expert opinion on investigational drugs, , Volume: 14, Issue:4, 2005
Entacapone/levodopa/carbidopa combination tablet: Stalevo.Drugs in R&D, , Volume: 4, Issue:5, 2003
What is new in movement disorders?Wiener klinische Wochenschrift, , Sep-17, Volume: 111, Issue:17, 1999
Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.Movement disorders : official journal of the Movement Disorder Society, , Volume: 12, Issue:6, 1997
[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].Neurologia (Barcelona, Spain), , Volume: 14, Issue:7
Current and novel infusion therapies for patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 130, Issue:11, 2023
Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.European journal of neurology, , Volume: 30, Issue:10, 2023
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 130, Issue:7, 2023
A novel treatment option for intrajejunal levodopa administration.Expert review of neurotherapeutics, , Volume: 23, Issue:1, 2023
Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.European journal of drug metabolism and pharmacokinetics, , Volume: 48, Issue:1, 2023
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease].Ideggyogyaszati szemle, , Nov-30, Volume: 75, Issue:11-12, 2022
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.Cells, , 04-30, Volume: 11, Issue:9, 2022
A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease.Frontiers in cellular and infection microbiology, , Volume: 12, 2022
Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.The international journal of neuropsychopharmacology, , 08-04, Volume: 25, Issue:7, 2022
[78-year-old patient with urine discoloration].Deutsche medizinische Wochenschrift (1946), , Volume: 147, Issue:1-02, 2022
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.Parkinsonism & related disorders, , Volume: 91, 2021
Entacapone - Another Parkinson's medication associated with lymphocytic colitis.Parkinsonism & related disorders, , Volume: 91, 2021
Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 42, Issue:11, 2021
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 88, 2021
Opicapone: A Review in Parkinson's Disease.CNS drugs, , Volume: 35, Issue:1, 2021
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.Scientific reports, , 10-22, Volume: 10, Issue:1, 2020
Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime.Expert opinion on pharmacotherapy, , Volume: 21, Issue:18, 2020
Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.Revista de neurologia, , Jun-12, Volume: 70, Issue:s01, 2020
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 41, Issue:8, 2020
A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.Journal of Parkinson's disease, , Volume: 10, Issue:1, 2020
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.Neuromolecular medicine, , Volume: 21, Issue:3, 2019
Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.Parkinsonism & related disorders, , Volume: 64, 2019
Managing treatment fluctuations in Parkinson disease: "On" again-, "off" again.Neurology, , 03-26, Volume: 92, Issue:13, 2019
Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.European journal of pharmacology, , Mar-15, Volume: 847, 2019
Opicapone for the treatment of Parkinson's disease: an update.Expert opinion on pharmacotherapy, , Volume: 20, Issue:18, 2019
The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.Journal of the neurological sciences, , 09-15, Volume: 392, 2018
The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study.Brain and behavior, , Volume: 8, Issue:8, 2018
Entacapone and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study.Parkinsonism & related disorders, , Volume: 53, 2018
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.Neuromolecular medicine, , Volume: 20, Issue:2, 2018
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.Neurology, , 05-22, Volume: 90, Issue:21, 2018
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.Journal of Parkinson's disease, , Volume: 8, Issue:2, 2018
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.European neurology, , Volume: 78, Issue:3-4, 2017
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.Movement disorders : official journal of the Movement Disorder Society, , Volume: 32, Issue:2, 2017
Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, , Volume: 37, Issue:3, 2017
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.The Lancet. Neurology, , Volume: 15, Issue:2, 2016
Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.Small (Weinheim an der Bergstrasse, Germany), , Volume: 12, Issue:27, 2016
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?BioMed research international, , Volume: 2016, 2016
Novel Levodopa Formulations for Parkinson's Disease.CNS drugs, , Volume: 30, Issue:11, 2016
Entacapone and prostate cancer risk in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Apr-15, Volume: 30, Issue:5, 2015
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.European review for medical and pharmacological sciences, , Volume: 19, Issue:11, 2015
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 122, Issue:12, 2015
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.Journal of Parkinson's disease, , Volume: 5, Issue:4, 2015
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.Parkinsonism & related disorders, , Volume: 20, Issue:12, 2014
Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on.Parkinsonism & related disorders, , Volume: 20, Issue:11, 2014
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:10, 2014
Pooled analysis of phase III with entacapone in Parkinson's disease.Acta neurologica Scandinavica, , Volume: 130, Issue:4, 2014
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.Movement disorders : official journal of the Movement Disorder Society, , Volume: 29, Issue:12, 2014
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.Journal of medicinal chemistry, , Nov-13, Volume: 57, Issue:21, 2014
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.Mayo Clinic proceedings, , Volume: 89, Issue:7, 2014
Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study.PloS one, , Volume: 9, Issue:5, 2014
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, , Mar-10, Volume: 103, Issue:3, 2014
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 121, Issue:11, 2014
Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 121, Issue:6, 2014
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 121, Issue:4, 2014
Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.Neurologia (Barcelona, Spain), , Volume: 29, Issue:3, 2014
Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:1, 2014
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.Clinical neurology and neurosurgery, , Volume: 115, Issue:2, 2013
L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.Medical hypotheses, , Volume: 80, Issue:2, 2013
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].Zhonghua yi xue za zhi, , Feb-19, Volume: 93, Issue:7, 2013
Anti-Parkinson's disease drugs and pharmacogenetic considerations.Expert opinion on drug metabolism & toxicology, , Volume: 9, Issue:7, 2013
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.Movement disorders : official journal of the Movement Disorder Society, , Volume: 28, Issue:4, 2013
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.European journal of neurology, , Volume: 19, Issue:6, 2012
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Expert review of neurotherapeutics, , Volume: 12, Issue:2, 2012
Finasteride attenuates pathological gambling in patients with Parkinson disease.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.Neuro endocrinology letters, , Volume: 33, Issue:7, 2012
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.JAMA, , Jun-06, Volume: 307, Issue:21, 2012
Drugs for treating Parkinson disease.Nursing, , Volume: 42, Issue:7, 2012
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.Journal of clinical pharmacology, , Volume: 51, Issue:1, 2011
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.CNS drugs, , Volume: 25, Issue:1, 2011
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.European journal of neurology, , Volume: 18 Suppl 1, 2011
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.Annals of neurology, , Volume: 69, Issue:1, 2011
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.Annals of neurology, , Volume: 69, Issue:2, 2011
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 383, Issue:6, 2011
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.Parkinsonism & related disorders, , Volume: 17, Issue:7, 2011
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.The International journal of neuroscience, , Volume: 121, Issue:11, 2011
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.European journal of neurology, , Volume: 18, Issue:12, 2011
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.Hiroshima journal of medical sciences, , Volume: 60, Issue:3, 2011
Continuous dopaminergic therapy in Parkinson disease: time to stride back?Annals of neurology, , Volume: 68, Issue:1, 2010
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 117, Issue:3, 2010
The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.Movement disorders : official journal of the Movement Disorder Society, , Feb-15, Volume: 25, Issue:3, 2010
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.Current medical research and opinion, , Volume: 26, Issue:7, 2010
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 31, Issue:5, 2010
Entacapone.Expert opinion on drug metabolism & toxicology, , Volume: 6, Issue:8, 2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.Annals of neurology, , Volume: 68, Issue:1, 2010
Isolated delusional syndrome in Parkinson's Disease.Parkinsonism & related disorders, , Volume: 16, Issue:8, 2010
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.CNS neuroscience & therapeutics, , Volume: 16, Issue:6, 2010
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.Clinical drug investigation, , Volume: 30, Issue:11, 2010
Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.Parkinsonism & related disorders, , Volume: 16, Issue:10, 2010
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.Nature reviews. Neurology, , Volume: 6, Issue:11, 2010
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.International review of neurobiology, , Volume: 95, 2010
Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.Neurological research, , Volume: 31, Issue:1, 2009
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.Movement disorders : official journal of the Movement Disorder Society, , Jan-15, Volume: 24, Issue:1, 2009
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.Parkinsonism & related disorders, , Volume: 15, Issue:6, 2009
Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The HoneymoonEuropean neurology, , Volume: 61, Issue:2, 2009
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Mar-15, Volume: 24, Issue:4, 2009
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Apr-15, Volume: 24, Issue:5, 2009
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.European journal of neurology, , Volume: 16, Issue:2, 2009
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.Movement disorders : official journal of the Movement Disorder Society, , Jul-15, Volume: 24, Issue:9, 2009
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.European journal of neurology, , Volume: 16, Issue:12, 2009
Levodopa/carbidopa/entacapone in Parkinson's disease.Expert review of neurotherapeutics, , Volume: 9, Issue:7, 2009
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 116, Issue:10, 2009
Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.Clinical drug investigation, , Volume: 29, Issue:10, 2009
Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.Movement disorders : official journal of the Movement Disorder Society, , Nov-15, Volume: 24, Issue:15, 2009
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Jul-30, Volume: 23, Issue:10, 2008
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.European journal of neurology, , Volume: 15, Issue:7, 2008
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.Journal of the neurological sciences, , Dec-15, Volume: 275, Issue:1-2, 2008
Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .Current medical research and opinion, , Volume: 24, Issue:11, 2008
[Treatment of Parkinson's disease at present and in the future].Rinsho shinkeigaku = Clinical neurology, , Volume: 48, Issue:11, 2008
Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.CNS neuroscience & therapeutics, ,Spring, Volume: 14, Issue:1, 2008
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.European journal of neurology, , Volume: 15, Issue:3, 2008
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 115, Issue:6, 2008
Homocysteine in restless legs syndrome.Sleep medicine, , Volume: 9, Issue:4, 2008
Entacapone improves complex movement performance in patients with Parkinson's disease.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 14, Issue:5, 2007
Parkinson disease: an incremental challenge.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 60, Issue:12, 2007
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.The Annals of pharmacotherapy, , Volume: 41, Issue:11, 2007
Current pharmacotherapeutic treatment options in Parkinson's disease.Disease-a-month : DM, , Volume: 53, Issue:4, 2007
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.European neurology, , Volume: 58, Issue:2, 2007
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:11, 2007
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.Movement disorders : official journal of the Movement Disorder Society, , Aug-15, Volume: 22, Issue:11, 2007
Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.Movement disorders : official journal of the Movement Disorder Society, , Jul-30, Volume: 22, Issue:10, 2007
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.Neurology, , Apr-24, Volume: 68, Issue:17, 2007
Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?Neurology, , Apr-24, Volume: 68, Issue:17, 2007
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.European journal of neurology, , Volume: 14, Issue:3, 2007
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.Movement disorders : official journal of the Movement Disorder Society, , Volume: 22, Issue:1, 2007
Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 22, Issue:1, 2007
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.Geriatrics, , Volume: 61, Issue:9, 2006
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).Acta neurologica Scandinavica, , Volume: 114, Issue:3, 2006
Efficacy and safety of high-dose cabergoline in Parkinson's disease.Acta neurologica Scandinavica, , Volume: 113, Issue:1, 2006
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Expert opinion on pharmacotherapy, , Volume: 7, Issue:10, 2006
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.Neurology, , Jun-27, Volume: 66, Issue:12, 2006
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 113, Issue:10, 2006
Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.Journal of the American Medical Directors Association, , Volume: 7, Issue:7 Suppl 2, 2006
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.Journal of motor behavior, , Volume: 38, Issue:1, 2006
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:3, 2006
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:12, 2006
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].Neurologia (Barcelona, Spain), , Volume: 20, Issue:4, 2005
Novel pharmacological strategies for motor complications in Parkinson's disease.Expert opinion on investigational drugs, , Volume: 14, Issue:4, 2005
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.Parkinsonism & related disorders, , Volume: 11, Issue:4, 2005
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20 Suppl 11, 2005
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.Neurology, , Mar-08, Volume: 64, Issue:5, 2005
Improving quality of life in early Parkinson's.Health news (Waltham, Mass.), , Volume: 11, Issue:2, 2005
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.Acta neurologica Scandinavica, , Volume: 111, Issue:1, 2005
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.Movement disorders : official journal of the Movement Disorder Society, , Volume: 20, Issue:1, 2005
Entacapone in the treatment of Parkinson's disease.The Lancet. Neurology, , Volume: 4, Issue:6, 2005
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditionalEuropean neurology, , Volume: 53, Issue:4, 2005
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.Parkinsonism & related disorders, , Volume: 11, Issue:6, 2005
Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.Journal of mass spectrometry : JMS, , Volume: 40, Issue:12, 2005
Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.Neurology, , Dec-13, Volume: 65, Issue:11, 2005
The role of COMT inhibition in the treatment of Parkinson's disease.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).Expert review of neurotherapeutics, , Volume: 4, Issue:4, 2004
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
The value of post-marketing medication surveys in Parkinson's disease.Current medical research and opinion, , Volume: 20, Issue:1, 2004
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.The Cochrane database of systematic reviews, , Oct-18, Issue:4, 2004
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.Archives of neurology, , Volume: 61, Issue:10, 2004
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.European journal of neurology, , Volume: 11, Issue:9, 2004
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.Movement disorders : official journal of the Movement Disorder Society, , Volume: 19, Issue:9, 2004
Clinical advantages of COMT inhibition with entacapone - a review.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:10-11, 2004
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:8, 2004
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 25, Issue:2, 2004
Role of entacapone in later Parkinson's disease not yet established.Journal of neurology, neurosurgery, and psychiatry, , Volume: 75, Issue:7, 2004
[Treatment in Parkinson disease].Orvosi hetilap, , Apr-11, Volume: 145, Issue:15, 2004
Bullous skin eruption associated with entacapone.International journal of dermatology, , Volume: 43, Issue:6, 2004
Safety and tolerability of COMT inhibitors.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
Stalevo for Parkinson's disease.The Medical letter on drugs and therapeutics, , May-10, Volume: 46, Issue:1182, 2004
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:2, 2004
Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.Current medical research and opinion, , Volume: 20, Issue:1, 2004
[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 104, Issue:1, 2004
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.Expert opinion on drug safety, , Volume: 2, Issue:3, 2003
Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.Fundamental & clinical pharmacology, , Volume: 17, Issue:1, 2003
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.European journal of neurology, , Volume: 10, Issue:2, 2003
Position of COMT inhibition in the treatment of Parkinson's disease.Advances in neurology, , Volume: 91, 2003
Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 24, Issue:3, 2003
The economic evaluation of pharmacotherapies for Parkinson's disease.Parkinsonism & related disorders, , Volume: 9, Issue:5, 2003
The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 24, Issue:3, 2003
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:8, 2003
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:6, 2003
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.Journal of neurology, neurosurgery, and psychiatry, , Volume: 74, Issue:8, 2003
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:3, 2003
Excessive daytime sleepiness and 'sleep attacks' induced by entacapone.Fundamental & clinical pharmacology, , Volume: 17, Issue:1, 2003
Entacapone/levodopa/carbidopa combination tablet: Stalevo.Drugs in R&D, , Volume: 4, Issue:5, 2003
Entacapone in the management of Parkinson's disease.Expert opinion on pharmacotherapy, , Volume: 3, Issue:7, 2002
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).Acta neurologica Scandinavica, , Volume: 105, Issue:4, 2002
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.Neurology, , Feb-26, Volume: 58, Issue:4, 2002
COMT inhibitors: management of Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17 Suppl 4, 2002
[Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome].Der Nervenarzt, , Volume: 73, Issue:8, 2002
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.Parkinsonism & related disorders, , Volume: 8, Issue:5, 2002
Entacapone-induced hepatotoxicity and hepatic dysfunction.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:6, 2002
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.PharmacoEconomics, , Volume: 20, Issue:9, 2002
Twelve-month safety of entacapone in patients with Parkinson's disease.European journal of neurology, , Volume: 8, Issue:1, 2001
Current advances in Parkinson's disease.Trends in neurosciences, , Volume: 24, Issue:7, 2001
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.European neurology, , Volume: 46, Issue:1, 2001
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.Clinical therapeutics, , Volume: 23, Issue:6, 2001
[Parkinson disease. Value of COMT inhibitors is verified].MMW Fortschritte der Medizin, , May-03, Volume: 143, Issue:18, 2001
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.Seminars in neurology, , Volume: 21, Issue:1, 2001
[Parkinson's disease].Presse medicale (Paris, France : 1983), , Mar-03, Volume: 30, Issue:8, 2001
Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 108, Issue:1, 2001
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].Neurologia (Barcelona, Spain), , Volume: 16, Issue:2, 2001
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.European neurology, , Volume: 45, Issue:2, 2001
Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.Synapse (New York, N.Y.), , Volume: 40, Issue:1, 2001
[Dopaminergic agonists in the treatment of Parkinson's disease].Revue medicale de Bruxelles, , Volume: 21, Issue:6, 2000
The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
Practical issues with COMT inhibitors in Parkinson's disease.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
COMT inhibitors and liver toxicity.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
Issues important for rational COMT inhibition.Neurology, , Volume: 55, Issue:11 Suppl 4, 2000
Entacapone.The Annals of pharmacotherapy, , Volume: 34, Issue:9, 2000
The role of entacapone in the management of Parkinson's disease.Hospital medicine (London, England : 1998), , Volume: 61, Issue:4, 2000
Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.Journal of the American Geriatrics Society, , Volume: 48, Issue:6, 2000
COMT inhibition in Parkinson's disease: rationale and clinical relevance.Acta neurologica Belgica, , Volume: 100, Issue:1, 2000
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry, , Volume: 68, Issue:5, 2000
[Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].Der Nervenarzt, , Volume: 71, Issue:2, 2000
Entacapone for Parkinson's disease.The Medical letter on drugs and therapeutics, , Jan-24, Volume: 42, Issue:1070, 2000
[Peripheral COMT-inhibition with Entacapon. Optimal therapy of Parkinson disease].Der Nervenarzt, , Volume: 70, Issue:6 Suppl, 1999
[Entacapone in the therapy of Parkinson disease].Duodecim; laaketieteellinen aikakauskirja, , Volume: 115, Issue:24, 1999
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.Pharmacotherapy, , Volume: 19, Issue:11 Pt 2, 1999
What is new in movement disorders?Wiener klinische Wochenschrift, , Sep-17, Volume: 111, Issue:17, 1999
Several classes of new drugs emerging for Parkinson disease.JAMA, , Sep-08, Volume: 282, Issue:10, 1999
Entacapone. A review of its use in Parkinson's disease.Drugs, , Volume: 58, Issue:1, 1999
COMT inhibition with entacapone in the treatment of Parkinson's disease.Advances in neurology, , Volume: 80, 1999
[COMT inhibitors].Medizinische Monatsschrift fur Pharmazeuten, , Volume: 22, Issue:5, 1999
Monoamine oxidase and catechol-O-methyltransferase inhibitors.The Medical clinics of North America, , Volume: 83, Issue:2, 1999
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.Neurology, , Volume: 51, Issue:5, 1998
COMT inhibition in the treatment of Parkinson's disease.Journal of neurology, , Volume: 245, Issue:11 Suppl 3, 1998
Entacapone and motor fluctuations in Parkinson's disease.Annals of neurology, , Volume: 44, Issue:2, 1998
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.Clinical pharmacology and therapeutics, , Volume: 64, Issue:1, 1998
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.Lancet (London, England), , Apr-25, Volume: 351, Issue:9111, 1998
Extending levodopa action: COMT inhibition.Neurology, , Volume: 50, Issue:6 Suppl 6, 1998
COMT inhibition: a new treatment strategy for Parkinson's disease.Neurology, , Volume: 50, Issue:5 Suppl 5, 1998
Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.Advances in pharmacology (San Diego, Calif.), , Volume: 42, 1998
X-ray crystallography of catechol O-methyltransferase: perspectives for target-based drug development.Advances in pharmacology (San Diego, Calif.), , Volume: 42, 1998
Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.Advances in pharmacology (San Diego, Calif.), , Volume: 42, 1998
New options for treatment of Parkinson's disease.Bailliere's clinical neurology, , Volume: 6, Issue:1, 1997
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.Annals of neurology, , Volume: 42, Issue:5, 1997
New pharmacotherapy for Parkinson's disease.The Annals of pharmacotherapy, , Volume: 31, Issue:10, 1997
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Volume: 12, Issue:4, 1997
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.Clinical neuropharmacology, , Volume: 19, Issue:4, 1996
Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, , Volume: 16, Issue:5, 1996
Validation of assay of catechol-O-methyltransferase activity in human erythrocytes.Journal of pharmaceutical and biomedical analysis, , Volume: 14, Issue:5, 1996
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.Clinical neuropharmacology, , Volume: 19, Issue:3, 1996
Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.Clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 1996
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.Journal of neurology, neurosurgery, and psychiatry, , Volume: 60, Issue:1, 1996
Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.Journal of neural transmission. Parkinson's disease and dementia section, , Volume: 10, Issue:2-3, 1995
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.Neurology, , Volume: 44, Issue:1, 1994
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.Neurology, , Volume: 44, Issue:5, 1994
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry, , Volume: 57, Issue:2, 1994
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.Neurology, , Volume: 44, Issue:7, 1994
Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.Movement disorders : official journal of the Movement Disorder Society, , Volume: 8, Issue:3, 1993
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.European journal of clinical pharmacology, , Volume: 45, Issue:5, 1993
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.Clinical neuropharmacology, , Volume: 14, Issue:4, 1991
Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 4, Issue:4
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.Clinical neuropharmacology, , Volume: 24, Issue:5
Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.Clinical neuropharmacology, , Volume: 35, Issue:1
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.Clinical neuropharmacology, , Volume: 24, Issue:3
The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.Clinical neuropharmacology, , Volume: 24, Issue:1
Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.Clinical neuropharmacology, , Volume: 31, Issue:3
The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.Clinical neuropharmacology, , Volume: 31, Issue:5
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.Lancet (London, England), , Volume: 365, Issue:9463
Rasagiline for motor complications in Parkinson's disease.Lancet (London, England), , Volume: 365, Issue:9463
[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].Neurologia (Barcelona, Spain), , Volume: 14, Issue:7
[Recent advances in Parkinson disease].Revista de neurologia, , Volume: 29, Issue:2
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.Clinical neuropharmacology, , Volume: 29, Issue:2
[Entacapone: is it useful as complimentary treatment with levodopa?].Revista de neurologia, , Volume: 28, Issue:8
Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease.Clinical neuropharmacology, , Volume: 27, Issue:3
A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.Clinical neuropharmacology, , Volume: 35, Issue:4
Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.Clinical neuropharmacology, , Volume: 34, Issue:1
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.Clinical neuropharmacology, , Volume: 31, Issue:1
The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.Clinical neuropharmacology, , Volume: 29, Issue:3
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.Clinical neuropharmacology, , Volume: 28, Issue:3
Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.Clinical neuropharmacology, , Volume: 29, Issue:2
Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.Clinical neuropharmacology, , Volume: 36, Issue:3
Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone.Neurology India, , Volume: 65, Issue:4
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.Journal of medical economics, , Volume: 24, Issue:1
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1, 2004
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Medical treatment of later-stage motor problems of Parkinson disease.Mayo Clinic proceedings, , Volume: 74, Issue:12, 1999
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.Molecular and cellular endocrinology, , 05-15, Volume: 488, 2019
Entacapone and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study.Parkinsonism & related disorders, , Volume: 53, 2018
Entacapone and prostate cancer risk in patients with Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society, , Apr-15, Volume: 30, Issue:5, 2015
Continuous dopaminergic therapy in Parkinson disease: time to stride back?Annals of neurology, , Volume: 68, Issue:1, 2010
Entacapone: prostate cancer?Prescrire international, , Volume: 19, Issue:109, 2010
Homocysteine in restless legs syndrome.Sleep medicine, , Volume: 9, Issue:4, 2008
Entacapone in restless legs syndrome.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:2, 2002
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.Clinical neuropharmacology, , Volume: 30, Issue:6
Entacapone alleviates acute kidney injury by inhibiting ferroptosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 36, Issue:7, 2022
The potential protective effects of estradiol and 2-methoxyestradiol in ischemia reperfusion-induced kidney injury in ovariectomized female rats.Life sciences, , May-01, Volume: 296, 2022
Entacapone scavenges peroxynitrite and protects against kidney and liver injuries induced by renal ischemia/reperfusion in rats.International urology and nephrology, , Volume: 53, Issue:8, 2021
Safety/Toxicity (29)
| Article | Year |
|---|
A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease.
Frontiers in cellular and infection microbiology, , Volume: 12 | 2022 |
Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19.
BMC pharmacology & toxicology, , 10-21, Volume: 22, Issue:1 | 2021 |
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
European neurology, , Volume: 78, Issue:3-4 | 2017 |
Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.
Journal of medicinal chemistry, , 08-25, Volume: 59, Issue:16 | 2016 |
Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry.
Journal of medicinal chemistry, , 05-26, Volume: 59, Issue:10 | 2016 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 122, Issue:12 | 2015 |
A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
Clinical neuropharmacology, , Volume: 35, Issue:4 | |
The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.
Toxicologic pathology, , Volume: 40, Issue:6 | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, , Volume: 7, Issue:12 | 2011 |
Identification and categorization of liver toxicity markers induced by a related pair of drugs.
International journal of molecular sciences, , Volume: 12, Issue:7 | 2011 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7 | 2010 |
Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.
The Journal of biological chemistry, , May-14, Volume: 285, Issue:20 | 2010 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 117, Issue:3 | 2010 |
Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 113, Issue:1 | 2010 |
Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis.
PLoS computational biology, , Volume: 5, Issue:7 | 2009 |
The liver toxicity biomarker study: phase I design and preliminary results.
Toxicologic pathology, , Volume: 37, Issue:1 | 2009 |
On the role of tyrosine and peripheral metabolism in 3,4-methylenedioxymethamphetamine-induced serotonin neurotoxicity in rats.
Neuropharmacology, , Volume: 54, Issue:5 | 2008 |
The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity.
Psychopharmacology, , Volume: 197, Issue:2 | 2008 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Acta neurologica Scandinavica, , Volume: 113, Issue:1 | 2006 |
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Movement disorders : official journal of the Movement Disorder Society, , Volume: 19, Issue:9 | 2004 |
Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Neuropharmacology, , Volume: 46, Issue:4 | 2004 |
Safety and tolerability of COMT inhibitors.
Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1 | 2004 |
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:6 | 2003 |
Entacapone-induced hepatotoxicity and hepatic dysfunction.
Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:6 | 2002 |
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Acta neurologica Scandinavica, , Volume: 105, Issue:4 | 2002 |
Twelve-month safety of entacapone in patients with Parkinson's disease.
European journal of neurology, , Volume: 8, Issue:1 | 2001 |
Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 108, Issue:1 | 2001 |
COMT inhibitors and liver toxicity.
Neurology, , Volume: 55, Issue:11 Suppl 4 | 2000 |
Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Pharmacology & toxicology, , Volume: 69, Issue:1 | 1991 |
Long-term Use (10)
| Article | Year |
|---|
[no title available]
Drug delivery, , Volume: 29, Issue:1 | 2022 |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
Neuromolecular medicine, , Volume: 21, Issue:3 | 2019 |
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Neuromolecular medicine, , Volume: 20, Issue:2 | 2018 |
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
Neurology, , 05-22, Volume: 90, Issue:21 | 2018 |
Levodopa/carbidopa/entacapone in Parkinson's disease.
Expert review of neurotherapeutics, , Volume: 9, Issue:7 | 2009 |
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Expert opinion on pharmacotherapy, , Volume: 7, Issue:10 | 2006 |
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Expert review of neurotherapeutics, , Volume: 4, Issue:4 | 2004 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society, , Volume: 20 Suppl 11 | 2005 |
Clinical advantages of COMT inhibition with entacapone - a review.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:10-11 | 2004 |
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
Parkinsonism & related disorders, , Volume: 8, Issue:5 | 2002 |
Pharmacokinetics (32)
| Article | Year |
|---|
Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.
European journal of drug metabolism and pharmacokinetics, , Volume: 48, Issue:1 | 2023 |
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Scientific reports, , 10-22, Volume: 10, Issue:1 | 2020 |
Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.
European journal of pharmacology, , Mar-15, Volume: 847 | 2019 |
Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
Biopharmaceutics & drug disposition, , Volume: 36, Issue:9 | 2015 |
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:10 | 2014 |
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
European journal of clinical pharmacology, , Volume: 70, Issue:9 | 2014 |
Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Clinical neuropharmacology, , Volume: 36, Issue:3 | |
Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15 | 2009 |
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Movement disorders : official journal of the Movement Disorder Society, , Jul-15, Volume: 24, Issue:9 | 2009 |
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
European journal of clinical pharmacology, , Volume: 65, Issue:5 | 2009 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7 | 2008 |
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Clinical neuropharmacology, , Volume: 31, Issue:1 | |
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Expert opinion on pharmacotherapy, , Volume: 7, Issue:10 | 2006 |
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.
Clinical neuropharmacology, , Volume: 29, Issue:2 | |
Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases.
Analytical biochemistry, , Jun-01, Volume: 341, Issue:1 | 2005 |
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Movement disorders : official journal of the Movement Disorder Society, , Volume: 19, Issue:9 | 2004 |
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 25, Issue:2 | 2004 |
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:2 | 2004 |
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
The Journal of pharmacology and experimental therapeutics, , Volume: 304, Issue:2 | 2003 |
Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
Pharmacology & toxicology, , Volume: 90, Issue:6 | 2002 |
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.
British journal of clinical pharmacology, , Volume: 53, Issue:5 | 2002 |
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
European journal of clinical pharmacology, , Volume: 56, Issue:11 | |
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
European journal of clinical pharmacology, , Volume: 55, Issue:6 | 1999 |
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
Clinical pharmacology and therapeutics, , Volume: 64, Issue:1 | 1998 |
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
Clinical neuropharmacology, , Volume: 19, Issue:4 | 1996 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Clinical neuropharmacology, , Volume: 19, Issue:3 | 1996 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
Clinical neuropharmacology, , Volume: 18, Issue:1 | 1995 |
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Clinical neuropharmacology, , Volume: 16, Issue:2 | 1993 |
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Neurology, , Volume: 44, Issue:5 | 1994 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
European journal of clinical pharmacology, , Volume: 45, Issue:5 | 1993 |
Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
European journal of clinical pharmacology, , Volume: 46, Issue:2 | 1994 |
The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
The Journal of pharmacology and experimental therapeutics, , Volume: 273, Issue:3 | 1995 |
Bioavailability (53)
| Article | Year |
|---|
Current and novel infusion therapies for patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 130, Issue:11 | 2023 |
Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.
International journal of pharmaceutics, , Dec-15, Volume: 629 | 2022 |
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Cells, , 04-30, Volume: 11, Issue:9 | 2022 |
[no title available]
Drug delivery, , Volume: 29, Issue:1 | 2022 |
Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking.
Cells, , 12-18, Volume: 9, Issue:12 | 2020 |
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Scientific reports, , 10-22, Volume: 10, Issue:1 | 2020 |
Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
Revista de neurologia, , Jun-12, Volume: 70, Issue:s01 | 2020 |
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46 | 2019 |
Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.
European journal of pharmacology, , Mar-15, Volume: 847 | 2019 |
Enhancing the Cancer Cell Growth Inhibitory Effects of Table Grape Anthocyanins.
Journal of food science, , Volume: 83, Issue:9 | 2018 |
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Neuromolecular medicine, , Volume: 20, Issue:2 | 2018 |
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Journal of Parkinson's disease, , Volume: 8, Issue:2 | 2018 |
Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone.
Neurology India, , Volume: 65, Issue:4 | |
Novel Levodopa Formulations for Parkinson's Disease.
CNS drugs, , Volume: 30, Issue:11 | 2016 |
Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
Biopharmaceutics & drug disposition, , Volume: 36, Issue:9 | 2015 |
Dopamine bioavailability in the mPFC modulates operant learning performance in rats: an experimental study with a computational interpretation.
Behavioural brain research, , Mar-01, Volume: 280 | 2015 |
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
British journal of pharmacology, , Volume: 172, Issue:7 | 2015 |
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Parkinsonism & related disorders, , Volume: 20, Issue:12 | 2014 |
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
European journal of clinical pharmacology, , Volume: 70, Issue:9 | 2014 |
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 121, Issue:11 | 2014 |
Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Carcinogenesis, , Volume: 35, Issue:2 | 2014 |
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Zhonghua yi xue za zhi, , Feb-19, Volume: 93, Issue:7 | 2013 |
Endothelial dysfunction in gestational hypertension induced by catechol-O-methyltransferase inhibition.
Experimental physiology, , Volume: 98, Issue:3 | 2013 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 383, Issue:6 | 2011 |
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Annals of neurology, , Volume: 69, Issue:1 | 2011 |
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
International journal of clinical pharmacology and therapeutics, , Volume: 48, Issue:11 | 2010 |
Entacapone.
Expert opinion on drug metabolism & toxicology, , Volume: 6, Issue:8 | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3 | 2010 |
Levodopa/carbidopa/entacapone in Parkinson's disease.
Expert review of neurotherapeutics, , Volume: 9, Issue:7 | 2009 |
The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.
Clinical neuropharmacology, , Volume: 31, Issue:5 | |
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.
Clinical neuropharmacology, , Volume: 29, Issue:2 | |
Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine.
Journal of mass spectrometry : JMS, , Volume: 40, Issue:12 | 2005 |
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Clinical neuropharmacology, , Volume: 28, Issue:3 | |
Entacapone in the treatment of Parkinson's disease.
The Lancet. Neurology, , Volume: 4, Issue:6 | 2005 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Experimental neurology, , Volume: 192, Issue:1 | 2005 |
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
European journal of neurology, , Volume: 11, Issue:9 | 2004 |
Clinical advantages of COMT inhibition with entacapone - a review.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:10-11 | 2004 |
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 25, Issue:2 | 2004 |
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:2 | 2004 |
Levodopa/carbidopa/entacapone (Stalevo).
Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1 | 2004 |
Safety and tolerability of COMT inhibitors.
Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1 | 2004 |
Absorption rate limit considerations for oral phosphate prodrugs.
Pharmaceutical research, , Volume: 20, Issue:6 | 2003 |
Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
Pharmacology & toxicology, , Volume: 90, Issue:6 | 2002 |
Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
The Journal of pharmacy and pharmacology, , Volume: 53, Issue:11 | 2001 |
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Clinical therapeutics, , Volume: 23, Issue:6 | 2001 |
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
European journal of clinical pharmacology, , Volume: 56, Issue:11 | |
Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.
Life sciences, , Volume: 67, Issue:2 | 2000 |
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry, , Volume: 68, Issue:5 | 2000 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Clinical neuropharmacology, , Volume: 19, Issue:3 | 1996 |
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.
Neurology, , Volume: 44, Issue:1 | 1994 |
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry, , Volume: 57, Issue:2 | 1994 |
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
General pharmacology, , Volume: 25, Issue:5 | 1994 |
Dosage (61)
| Article | Year |
|---|
Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.
International journal of pharmaceutics, , Dec-15, Volume: 629 | 2022 |
Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime.
Expert opinion on pharmacotherapy, , Volume: 21, Issue:18 | 2020 |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
Neuromolecular medicine, , Volume: 21, Issue:3 | 2019 |
Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers.
Journal of psychopharmacology (Oxford, England), , Volume: 30, Issue:4 | 2016 |
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
The Lancet. Neurology, , Volume: 15, Issue:2 | 2016 |
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Journal of Parkinson's disease, , Volume: 5, Issue:4 | 2015 |
Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Bioanalysis, , Volume: 7, Issue:2 | 2015 |
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Parkinsonism & related disorders, , Volume: 20, Issue:12 | 2014 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Mayo Clinic proceedings, , Volume: 89, Issue:7 | 2014 |
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
European journal of clinical pharmacology, , Volume: 70, Issue:9 | 2014 |
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Neuro endocrinology letters, , Volume: 33, Issue:7 | 2012 |
Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
Acta neurologica Scandinavica, , Volume: 127, Issue:2 | 2013 |
The liver toxicity biomarker study phase I: markers for the effects of tolcapone or entacapone.
Toxicologic pathology, , Volume: 40, Issue:6 | 2012 |
The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.
European journal of clinical pharmacology, , Volume: 68, Issue:3 | 2012 |
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Parkinsonism & related disorders, , Volume: 17, Issue:7 | 2011 |
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Current medical research and opinion, , Volume: 26, Issue:7 | 2010 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 117, Issue:3 | 2010 |
Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation.
Journal of AOAC International, , Volume: 92, Issue:2 | |
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
European journal of clinical pharmacology, , Volume: 65, Issue:5 | 2009 |
The effect of entacapone on levodopa rate of absorption and latency to motor response in patients with Parkinson disease.
Clinical neuropharmacology, , Volume: 31, Issue:5 | |
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
European journal of neurology, , Volume: 15, Issue:7 | 2008 |
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.
Clinical neuropharmacology, , Volume: 30, Issue:6 | |
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:11 | 2007 |
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.
Movement disorders : official journal of the Movement Disorder Society, , Aug-15, Volume: 22, Issue:11 | 2007 |
Entacapone improves complex movement performance in patients with Parkinson's disease.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 14, Issue:5 | 2007 |
Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.
Clinical neuropharmacology, , Volume: 29, Issue:2 | |
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 113, Issue:10 | 2006 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Acta neurologica Scandinavica, , Volume: 113, Issue:1 | 2006 |
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Movement disorders : official journal of the Movement Disorder Society, , Volume: 21, Issue:3 | 2006 |
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
The Cochrane database of systematic reviews, , Oct-18, Issue:4 | 2004 |
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Movement disorders : official journal of the Movement Disorder Society, , Volume: 20, Issue:3 | 2005 |
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 111, Issue:8 | 2004 |
Levodopa/carbidopa/entacapone (Stalevo).
Neurology, , Jan-13, Volume: 62, Issue:1 Suppl 1 | 2004 |
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Drugs in R&D, , Volume: 4, Issue:5 | 2003 |
Absorption rate limit considerations for oral phosphate prodrugs.
Pharmaceutical research, , Volume: 20, Issue:6 | 2003 |
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:3 | 2003 |
Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
The Journal of pharmacology and experimental therapeutics, , Volume: 304, Issue:2 | 2003 |
Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
Pharmacology & toxicology, , Volume: 90, Issue:6 | 2002 |
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
British journal of clinical pharmacology, , Volume: 54, Issue:4 | 2002 |
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Acta neurologica Scandinavica, , Volume: 105, Issue:4 | 2002 |
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.
Neurology, , Feb-26, Volume: 58, Issue:4 | 2002 |
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
European neurology, , Volume: 46, Issue:1 | 2001 |
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Clinical therapeutics, , Volume: 23, Issue:6 | 2001 |
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Clinical neuropharmacology, , Volume: 24, Issue:3 | |
Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
European journal of clinical pharmacology, , Volume: 56, Issue:11 | |
Practical issues with COMT inhibitors in Parkinson's disease.
Neurology, , Volume: 55, Issue:11 Suppl 4 | 2000 |
Issues important for rational COMT inhibition.
Neurology, , Volume: 55, Issue:11 Suppl 4 | 2000 |
Entacapone.
The Annals of pharmacotherapy, , Volume: 34, Issue:9 | 2000 |
[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
Neurologia (Barcelona, Spain), , Volume: 14, Issue:7 | |
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
Pharmacotherapy, , Volume: 19, Issue:11 Pt 2 | 1999 |
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
European journal of clinical pharmacology, , Volume: 55, Issue:6 | 1999 |
[Entacapone: is it useful as complimentary treatment with levodopa?].
Revista de neurologia, , Volume: 28, Issue:8 | |
New pharmacotherapy for Parkinson's disease.
The Annals of pharmacotherapy, , Volume: 31, Issue:10 | 1997 |
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
Clinical neuropharmacology, , Volume: 19, Issue:4 | 1996 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Clinical neuropharmacology, , Volume: 19, Issue:3 | 1996 |
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.
Journal of neurology, neurosurgery, and psychiatry, , Volume: 60, Issue:1 | 1996 |
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.
Neurology, , Volume: 44, Issue:1 | 1994 |
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Neurology, , Volume: 44, Issue:5 | 1994 |
COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise.
International journal of clinical pharmacology and therapeutics, , Volume: 32, Issue:11 | 1994 |
The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.
Clinical pharmacology and therapeutics, , Volume: 58, Issue:2 | 1995 |
Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 346, Issue:3 | 1992 |
Interactions (6)
| Article | Year |
|---|
Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Carcinogenesis, , Volume: 35, Issue:2 | 2014 |
L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
Medical hypotheses, , Volume: 80, Issue:2 | 2013 |
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
European journal of neurology, , Volume: 19, Issue:6 | 2012 |
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Parkinsonism & related disorders, , Volume: 17, Issue:7 | 2011 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Pharmacology & therapeutics, , Volume: 106, Issue:1 | 2005 |
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 109, Issue:1 | 2002 |